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Rectal cancer 
Cancer is a disease causing uncontrolled division of abnormal cells in a certain part of 
the body. When cells in the human body become old or damaged, they are replaced 
with new cells. However, DNA (genetic material) of a cell can become damaged or 
changed, producing mutations that affect normal cell growth and division. As a 
consequence superfluous cells may form a mass of tissue called a tumor. A tumor can 
be benign or malignant. Only malignant tumors are called cancerous and they are a 
threat to the patient’s health since they may invade other adjacent organs, are more 
prone to grow back after treatment (local recurrence) and their cells can spread to 
other parts of the body through the blood and lymph systems (metastasis).   
 
Malignant tumor growth in and from the inner wall of the distal part of the large 
intestine is called rectal cancer. Colorectal cancer (cancer of the colon and rectum 
combined) is in the modern western world the 3rd cancer, both with respect to 
incidence rate and mortality rate (about 9% of all cancer cases and cancer related 
mortalities).
1,2
 Only prostate and lung cancer for men and breast and lung cancer for 
women have a higher incidence, and lung cancer heads the list of mortality. In the 
Netherlands, colorectal cancer is even the 2nd cancer in men for both incidence and 
mortality and the 2nd in women for incidence.
1
 In the year 2011 a total of 21463 
patients were alive in the Netherlands with rectal cancer (http://www.iknl.nl/). Rectal 
cancer is more common in men and the incidence rates increased the last 20 years 
from 21.8 to 25.2 for men and from 13.4 to 14.2 for women (per 100.000 inhabitants 
standardized with the European standardized rate). Currently, 59% of the rectal cancer 
patients survive the first 5 years after diagnosis. This survival rate increased by 20% 
over the last 40 years due to improvements of the treatment, mainly related to 
changes and standardization of the surgical approach, better imaging and optimal use 
of chemo- and radiotherapy before and/or after surgery. Factors that affect the 
prognosis of rectal cancer are among others the degree of penetration of the tumor 
through the rectal wall, the possible involvement of the tumor into regional lymph 
nodes and the presence of distant metastasis.
3
 The circumferential margin (CRM) after 
surgery is also an important predictor of local and distant recurrence and patient 
survival.
4
 
 
In general, two classifications are often distinguished in rectal cancer: non-locally 
advanced rectal cancer (NLARC) and locally advanced rectal cancer (LARC). There are 
various clinical definitions for LARC and NLARC depending on the country of issue, but 
in general NLARC patients present a clear margin between tumor and mesorectal 
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Treatment of rectal cancer  
Surgery is the major component of the treatment for rectal cancer patients. However, 
until 10 years ago, without any other treatment, conventional surgery alone resulted in 
a high probability of local recurrence.
6
 Another surgical technique was introduced and 
standardized over the last 10 years called the total mesorectal excision (TME). 
Compared to conventional surgery, this technique resulted in a significant decrease in 
the number of local recurrences and consequently improved disease free survival.
7,8
 
The efficacy of TME is however also found to be highly dependent on the specific 
experience of the surgeon with the technique.
9,10
 Radiotherapy (RT) is a treatment 
modality that can be administered before surgery for rectal cancer to decrease the 
local recurrence rate. Patients undergoing RT receive ionizing radiation generated by a 
linear accelerator. The treatment beams are directed and shaped by dedicated 
treatment planning software in such a way that the tumor receives sufficient dose, 
while the dose to surrounding healthy tissue and organs is limited. Certain 
chemotherapy agents help sensitizing radiation in the neoadjuvant setting so that it 
works better. In order to kill rapid dividing cells, antineoplastic drugs are administered 
to the patient. These drugs are designed to impair the mitotic part of the cell cycle, 
required for cell division. The downside is that chemotherapy also affects the cell cycle 
of healthy rapidly dividing cells like cells in bone marrow, digestive tracts and hair 
follicles. 
 
In the Netherlands, patients diagnosed with NLARC are treated with either TME 
surgery alone or surgery after a RT scheme of 5 fractions of 5 Gy (Gray, units or RT 
dose). This short RT scheme was proven to further significantly reduce probabilities of 
local recurrence compared to TME alone.
11
 The group of patients diagnosed with LARC 
follows a protocol of long-course scheme of radiotherapy in 28 fractions of 1.8 Gy 
combined with the chemotherapeutic agent 5-fluorouracil (5FU). This agent is in these 
fascia (MRF) on magnetic resonance (MR) images. LARC on the other hand is referring 
to the status in which the tumor invaded the MRF or when the tumor is involved into 
regional lymph nodes. In other countries, T3 and/or N1 is a common definition for LARC 
(60-70% of rectal cancer patients), while in the Netherlands one of the definitions is 
positive margins and/or N2 status (about 15-20% of the tumors). Generally, LARC 
patients have a worse prognosis with 5-year survival rates of 28% to 59% than NLARC 
patients with 5-year survival rates of 67% to 74% after treatment.
5
 In this thesis only 
LARC patients have been studied. 
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cases administered as capecitabine (Xeloda), which is enzymatically converted into 
5FU. In Europe, variations in this long-course treatment schemes are present, for 
example the RT administration of 45 Gy with a 10 Gy boost and/or a combination of 
the chemotherapeutic agents capecitabine (a prodrug of 5FU) and oxaliplatin. 
However, in general it was found that a long-course chemoradiotherapy (CRT) scheme 
results in significant downstaging and downsizing of the primary tumor.
8,12
 In 15-30% 
of the LARC patients treated with CRT, the response to treatment is excellent, resulting 
in a complete response confirmed by pathology (pCR). For those patients a less 
invasive surgical approach or even a watchful waiting approach can be optional to 
avoid complications and/or a decrease in quality of life due to sphincter loss. In 
contrast, patients who are the least sensitive to the CRT might benefit from treatment 
intensification. Therefore it would be useful to identify groups of patients who respond 
differently to treatment as early as possible, to be able to adapt treatment in an early 
phase. This is an approach towards individualized medicine for rectal cancer, which will 
be the central theme in this thesis. 
Individualized treatment and decision tools 
In order to identify different risk groups accurately it is important to consider all the 
information available on a patient. Currently, treatment decisions are based on general 
guidelines and implicit experience, often only taking into account tumor stage and 
physical condition of the patient (http://oncoline.nl). This limited assessment leads to 
over-treatment for some patients and inadequate therapy for others, which results not 
only in a burden to the patient but also to healthcare expenses. However, the amount 
of available medical information has expanded rapidly over the last few years and will 
continue to increase due to the development of new (diagnostic) tools like genomic 
profiling and more advanced imaging techniques. Because of this information 
expansion, the opportunities for the physician to make a detailed assessment of risk 
and benefits associated with a specific combination of tumor, patient and treatment 
characteristics are limited. Computers, and more specifically dedicated decision tools, 
are better able to deal with these large amounts of information. Therefore, these tools 
are inevitable in the future with the aim to assist in treatment decision making for 
cancer.  
 
For locally advanced rectal cancer the treatment decisions will most likely be based on 
the probability of a patients’ response to CRT and the probability that the complete 
treatment cycle will reduce recurrence rates and therefore increase overall survival in 
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the long term. To assess individual response in rectal cancer, positron emission 
tomography (PET) is an important imaging technique. Making a PET scan involves 
injection of a positron emitting radionuclide into the bloodstream of the patient and 
the measurement of photons resulting from the interactions between these positrons 
and electrons within the patients’ body. The most commonly used radionuclide in 
oncology is 18F-fluorodeoxyglucose (FDG). This glucose analog is heavily consumed by 
brain, kidney and cancer cells. The PET scan reveals functional information and is 
usually made in combination with a computed tomography (CT) scan for the 
anatomical information. Many studies have been performed assessing treatment 
response using PETCT imaging, and it was shown that accurate predictions can be 
made, especially when assessing PET pre-treatment and during/after the treatment.
13
 
However, these studies rarely combined PETCT-imaging with clinical factors and they 
lack external validation. Previously, also blood biomarkers such as carcinoembryonic 
antigen (CEA), osteopontin (OPN) and interleukin-6 have been studied for rectal cancer 
and found to be prognostic for outcome.
14-16
 A holistic approach in which variables 
from different sources are combined is expected to generate the most accurate 
predictions for outcome, as for example has been shown for lung cancer, combining 
clinical variables with blood biomarkers to predict survival.
17
 If in rectal cancer 
accurate predictions for tumor response can be made by for example using clinical, 
imaging and biomarker information, treatment decisions can be guided with those 
predictions. For excellent responders there is an option to avoid surgery to maintain 
the quality of life for the patient. This decision requires a strong indication that tumor 
disappeared after treatment, which is mainly assessed using endoscopy. Excellent 
results have been reported for this wait-and-see approach.
18
 In the context of this 
decision, the prediction models can assist to administer for example a radiotherapy 
boost when it is predicted that the patient will only respond moderately to CRT. 
Predicting outcomes that occur later, such as local recurrences, distant metastases and 
survival, can also be very useful to tailor treatment, especially because these are often 
the primary outcomes of clinical trials. However, these predictions are hard to make 
because of the noisy nature of these outcomes, resulting in the requirement that the 
prediction data have to hold large numbers of patients.    
Objectives and outline of the thesis 
The main aim of this thesis is to study the prognostic and predictive value of clinical 
factors, imaging and blood biomarkers for pathologic complete response and follow-up 
outcome related to recurrences and survival of patients with locally advanced rectal 
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cancer. The focus of this work is on the development of multivariate prediction models 
which are able provide a prediction score for every individual patient. To provide 
sufficient confidence for these predictions all these models are based on large 
databases with high quality data, externally validated and based on state-of-the-art 
statistical models. Accurate prediction of response and follow-up outcome would allow 
treatment modifications in an early stage for certain risk groups, which is expected to 
reduce toxicity and mortality for these patients. This work is a first step towards 
computer assisted decision making for rectal cancer.  
 
In Chapter 2 a general overview of predicting outcome in radiotherapy is given. This 
involves an introductory section on methodological aspects of outcome prediction and 
a literature overview of published examples of clinical, treatment, imaging and 
molecular factors related to outcome. Furthermore, it is described how prediction 
models should be interpreted and how they can be used as a part of decision making 
tools in clinical practice. The following chapters are divided into two parts, related to 
the outcome of subject in rectal cancer. These chapters are put in context of the 
treatment schedule of LARC in Figure 1.1.   
Part 1: Tumor response prediction using PETCT-imaging and biomarkers  
The first part focusses on the prediction of pathological complete response in locally 
advanced rectal cancer patients. In Chapter 3, an externally validated prediction model 
is developed for pCR using clinical factors and sequential PETCT imaging just before 
radiochemotherapy and just before surgery. This would allow assistance in making the 
decision for a wait-and-see policy or reduced surgery for patients with a very high 
probability of complete response. With the same motivation pCR is also predicted in 
the prospective sequential PETCT imaging study described in Chapter 4 but in this case 
the second PETCT scan is already made after two weeks of radiochemotherapy. This 
early prediction with the developed model would allow for treatment modifications 
like radiotherapy boosts or chemotherapy intensification, to increase the number of 
responding patients. Chapter 5 describes a prospective study showing that blood 
biomarkers have an added value to clinical and imaging factors when predicting 
response. 
Part 2: Predicting long-term follow-up outcomes for decision support 
This part involves studies which focus on outcomes recorded in the follow-up time 
after surgery. These outcomes are important because they are considered as measures 
for effectiveness of the treatment in elongating patients’ lives, reducing the number of 
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recurrences and improving the quality of life for patients. Knowing which set of 
combined factors affect these outcomes allows decision making for additional 
treatment after surgery. Chapter 6 describes the development of prediction models 
for the risk of local and distant recurrences and the probability of survival for LARC 
based on a large clinical dataset containing pooled data from five European 
randomized clinical trials. This same cohort of patients was used in Chapter 7 to show 
the benefits of being two years free of disease and if this is of value to tailor treatment 
when combined with the knowledge of being a complete responder just after 
treatment.     
 
 
 
Chapter 8 includes a general discussion on the developed prediction models and 
places them into perspective with other related studies. An outlook is provided on how 
these decision tools may be implemented into daily clinical practice. 
Figure 1.1 Representation of the relationship between the thesis chapters and the treatment scheme of 
LARC patients. Red data represent evaluated or predicted outcomes. CH: chapter, FU: follow-up, pCR: 
pathological complete response, PETCT: positron emission tomography combined with computed 
tomography, pTN: pathological tumor and nodal staging, CRT: chemoradiotherapy, wk: weeks, yr: years  
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Abstract 
With the emergence of individualized medicine and the increasing amount and 
complexity of available medical data, a growing need exists for the development of 
clinical decision support systems based on prediction models of treatment outcome. In 
radiation oncology, these models combine both predictive and prognostic data factors 
from clinical, imaging, molecular and other sources to achieve the highest accuracy to 
predict tumor response and follow-up event rates. In this Review, we provide an 
overview of the factors that are correlated with outcome—including survival, 
recurrence patterns and toxicity—in radiation oncology and discuss the methodology 
behind the development of prediction models, which is a multistage process. Even 
after initial development and clinical introduction, a truly useful predictive model will 
be continuously re-evaluated on different patient datasets from different regions to 
ensure its population-specific strength. In the future, validated decision support 
systems will be fully integrated in the clinic, with data and knowledge being shared in a 
standardized, instant and global manner.  
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Introduction  
Over the past decade, we have witnessed advances in cancer care, with many new 
diagnostic methods and treatment modalities becoming available,
1
 including advances 
in radiation oncology.
2
 The abundance of new options and the progress in 
individualized medicine has, however, created new challenges. For example, achieving 
level I evidence is increasingly difficult given the numerous disease and patient 
parameters that have been discovered, resulting in an ever-diminishing number of 
‘homogeneous’ patients.
3
 This reality contrasts to a certain extent with classical 
evidence-based medicine, whereby randomized trials are designed for large 
populations of patients. Thus, new strategies are needed to find evidence for 
subpopulations on the basis of patient and disease characteristics.
4
  
 
For each patient, the clinician needs to consider state-of-the-art imaging, blood tests, 
new drugs, improved modalities for radiotherapy planning and, in the near future, 
genomic data. Medical decisions must also consider quality of life, patient preferences 
and, in many healthcare systems, cost efficiency. This combination of factors renders 
clinical decision making a dauntingly complex, and perhaps inhuman, task because 
human cognitive capacity is limited to approximately five factors per decision.
3
 
Furthermore, dramatic genetic,
5
 transcriptomic,
6
 histological
7
 and 
microenvironmental
8
 heterogeneity exists within individual tumors, and even greater 
heterogeneity exists between patients.
9
 Despite these complexities, individualized 
cancer treatment is inevitable. Indeed, intratumoral and intertumoral variability might 
be leveraged advantageously to maximize the therapeutic index by increasing the 
effects of radiotherapy on the tumor and decreasing those effects on normal tissues.
10-
12
  The central challenge, however, is how to integrate diverse, multimodal information 
(clinical, imaging and molecular data) in a quantitative manner to provide specific 
clinical predictions that accurately and robustly estimate patient outcomes as a 
function of the possible decisions. Currently, many prediction models are being 
published that consider factors related to disease and treatment, but without 
standardized assessments of their robustness, reproducibility or clinical utility.
13
 
Consequently, these prediction models might not be suitable for clinical decision 
support systems for routine care. 
 
In this Review, we highlight prognostic and predictive models in radiation oncology, 
with a focus on the methodological aspects of prediction model development. Some 
characteristic prognostic and predictive factors and their challenges are discussed in 
relation to clinical, treatment, imaging and molecular factors. We also enumerate the 
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steps that will be required to present these models to clinical professionals and to 
integrate them into clinical decision support systems (CDSS). 
Methodological aspects  
Factors for prediction 
The overall aim of developing a prediction model for a CDSS is to find a combination of 
factors that accurately anticipate an individual patient’s outcome (Figure 2.1).
14
 These 
factors include, but are not limited to, patient demographics as well the results of 
imaging, pathology, proteomic and genomic testing, the presence of key biomarkers 
and, crucially, the treatment undertaken. ‘Outcome’ can be defined as tumor response 
to radiotherapy, toxicity evolution during follow up, rates of local recurrence, 
evolution to metastatic disease, survival or a combination of these end points. 
Although predictive factors (that is, factors that influence the response to a specific 
treatment) are necessary for decision support, prognostic factors (that is, factors that 
influence response in the absence of treatment)
15
 are equally important in revealing 
the complex relationship with outcome. Herein, we refer to both of these terms 
generically as ‘features’ because, for a predictive model, correlation with outcome 
must be demonstrable. 
Model development stages 
The procedure for finding a combination of features correlated with outcome is 
analogous to the development of biomarker assays.
16
 In that framework, we can 
distinguish qualification and validation. Qualification demonstrates that the data are 
indicative or predictive of an end point, whereas validation is a formalized process 
used to demonstrate that a combination of features is both reliable and suitable for 
the intended purpose. That is, we need to identify features, test whether they are 
predictive in independent datasets and then determine whether treatment decisions 
made using these features improve outcome. The complete cycle of model 
development entails several stages (Figure 2.2). 
 
In the hypothesis-generation stage, one must consider the end point to predict, the 
timing of the treatment decision and the available data at these time points. In the 
data-selection step, a review of potential features is first conducted, ideally by an 
expert panel. A practical inventory of the available data and sample size calculations 
are recommended, especially for the validation phase.
17,18
 Data from both clinical trials 
Predicting outcomes in radiational oncology  19 
(high quality, low quantity, controlled, biased selection) and clinical practice (low 
quality, high quantity, unbiased selection) are useful, but selection biases must be 
identified in both cases and the inclusion criteria should be equivalent. For all features, 
including the characteristics of the treatment decision, data heterogeneity is a 
requirement to identify predictive features and to have the freedom to tailor 
treatment.  
 
 
Next, performance measures for models are determined, and include the area under 
the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity and 
c-index of censored data.
19
 AUC, which has values between 0 and 1 (with 1 denoting 
the best model and 0.5 randomness), is the most commonly used performance 
measure. However, for time-to-event models the c-index and hazard ratio are more 
appropriate because both can handle censored data. The preprocessing stage deals 
with missing data (imputation strategies; that is, replacing missing values by calculated 
estimates),
20
 identifying incorrectly measured or entered data
21
 as well as discretizing 
(if applicable) and normalizing data to avoid sensitivity for different orders of data 
Figure 2.1 Several data sources for the prediction of outcome after cancer treatment. It is believed that a 
combination of all the available data with a high variety of sources will predict outcome more accurately 
than data from individual sources. 
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scales.
22
 If an external, independent dataset is not available for validation, the 
available data must be split (in a separate stage) into a model training dataset and a 
validation set, the latter of which is used subsequently in the validation step. In the 
feature selection stage, the ratio of the number of evaluated features to number of 
outcome events must be kept as low as possible to avoid overfitting. When a model is 
overfitted, it is specifically and exclusively trained for the training data (including its 
data noise) and, as a result, performs poorly on new data. Data-driven preselection of 
features is, therefore, recommended.
23
 Univariate analyses are commonly used to 
prioritize the features—that is, testing each feature individually and ranking them on 
their strength of correlation with outcome. 
Predicting outcomes 
In the next stage, the input data are fed into a model that can classify all possible 
patient outcomes. Traditional statistical
24
 and machine-learning models
25
 can be 
considered. For two or more classes (for example, response versus no response), one 
might consider logistic regression, support vector machines, decision trees, Bayesian 
networks or Naive Bayes algorithms.
26,27
 For time-to-event outcomes, whether 
censored or not, Cox proportional hazards models
28
 or the Fine and Gray model
28
 of 
competing risks are most common. The choice of model depends on the type of 
outcome (for example, logistic regression for two or more outcomes, or Cox regression 
for survival-type data) and the type of input data (for example, Bayesian networks 
require categorized data, whereas support vector machines can easily deal with 
continuous data). In general, several models with similar properties can be tested to 
find the optimal model for the available data. A simple model is, however, preferred 
because it is expected to be robust to a wider range of data than a more complex 
model. 
 
Performance on the training dataset is upwards-biased because the features were 
selected. Thus, external validation data must be used, which can be derived from a 
separate institute or independent trial. When data are limited, internal validation can 
be considered using random split, temporal split or k-fold cross-validation 
techniques.
29
 The developed model should have a benefit over standard decision 
making, and must be assessed prospectively in the clinic in the penultimate stage of 
development. Models must be compared against predictions by clinicians
30,31
 and to 
standard prognostic and predictive factors.
32
 Critically, to demonstrate the 
improvement of patient outcome, quality of life and/or reduced toxicity,
33
 clinical trials 
must be conducted whereby the random assignment of patients is based on the 
prediction model output.  
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Figure 2.2 Schematic overview of methodological processes in decision support system development, 
describing model development, assessment of clinical usefulness and what ideally to publish. The colored, 
parallel lines represent heterogeneous data, which have been split early for independent validation (but 
without internal cross-validation). 
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Fulfilling this requirement will generate the final evidence that the model is improving 
healthcare by comparing, in a controlled way, the tailored treatments with standard 
treatments in the clinic.  
 
Finally, the prediction models and data can be published, enabling the wider 
oncological community to evaluate them. Full transparency on the data and 
methodology is the key towards global implementation of the model into CDSSs. This 
suggestion is similar to clinical ‘omics’ publications for which the raw data, the code 
used to derive the results from the raw data, evidence for data provenance (the 
process that led to a piece of data) and a written description of nonscriptable analysis 
steps are routinely made available.
34
 In practice, this cycle of development usually 
begins by identifying clinical parameters, because these are widely and instantly 
available in patient information systems and clinical trials. These clinical variables also 
form the basis for extending prediction models with imaging or molecular data. 
Clinical features 
Decision making in radiotherapy is mainly based on clinical features, such as the 
patient performance status, organ function and grade and extent of the tumor (for 
example, as defined by the TNM system). In almost all studies, such features have 
been found to be prognostic for survival and development of toxicity.
35-37
 
Consequently, these features should be evaluated in building robust and clinically 
acceptable radiotherapy prognostic and predictive models. Moreover, measurement 
of some clinical variables, such as performance status, can be captured with minimal 
effort. 
 
Even the simplest questionnaire, however, should be validated as is the case for 
laboratory measurements of organ function or parameters measured from blood.
38,39
 
Furthermore, a standardized protocol should be available to ensure that comparisons 
are possible between centers and questionnaires over time.
40
 Moreover, why specific 
features were chosen for measurement should be clearly explained. For example, if 
haemoglobin measurements were only taken in patients with fatigue, the resulting 
bias would demand caution when including and interpreting the measurements. Only 
when clinical parameters are recorded prospectively with the same scrutiny as 
laboratory measurements will observational studies become as reliable as randomized 
trials.
41,42
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Toxicity measurements and scoring should also build on validated scoring systems, 
such as the Common Terminology Criteria for Adverse Events (CTCAE), which can be 
scored by the physician or patient.
43,44
 Indeed, a meta-analysis showed that high-
quality toxicity assessments from observational trials are similar to those of 
randomized trials.
45,46
 However, a prospective protocol must clarify which scoring 
system was used and how changes in toxicity score were dealt with over time with 
respect to treatment.  
 
Finally, to ensure a standardized interpretation, the reporting of clinical and toxicity 
data and their analyses should be performed in line with the STROBE (Strengthening 
the Reporting of Observational Studies in Epidemiology) statement for observational 
studies and genetic association studies, which is represented as checklists of items that 
should be addressed in reports to facilitate the critical appraisal and interpretation of 
these type of studies.
47,48
  
Treatment features 
Currently, image-guided radiotherapy (IGRT) is a highly accurate cancer treatment 
modality in delivering its agent (radiation) to the tumor.
49
 Furthermore, very accurate 
knowledge of the effects of radiation on normal tissue has been obtained.
50
 With 
modern radiotherapy techniques, such as intensity-modulated radiotherapy, 
volumetric arc therapy or particle beam therapy, the treatment dose can be sculpted 
around the target volume with dosimetric accuracy of a few percentage points. IGRT 
ensures millimeter precision to spare the organs at risk as much as possible.
51
 
 
For prediction modeling, recording features that are derived from planned spatial and 
temporal distribution of the radiotherapy dose is crucial. Additionally, features must 
be recorded that describe the efforts undertaken during treatment to ensure that the 
dose is delivered as planned (that is, in vivo dosimetry); a delicate balance exists 
between tumor control and treatment-related toxicity.
52
 Additional therapies, such as 
(concurrent) chemotherapy, targeted agents and surgery, and their features must also 
be recorded because these have various effects on outcome.
32,53
 An example is the 
difference between concurrent versus sequential chemoradiation, which has a major 
influence on the occurrence of acute oesophagitis that induces dysphagia.
54
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With respect to the spatial dimension of radiotherapy, how to combine information 
about the spatially variable dose distribution for every subvolume of the target tumor 
(or organ) with the global effect to the tumor or adjacent normal tissue remains 
indeterminate. Dose-response relationships for tumor tissues are often reported in 
terms of mean (biologically equivalent) dose, although voxel-based measures have also 
been reported.
55
 Mean doses or doses to a prescription point inside the tumor are 
easily determined and reported and may suffice for many applications. However, 
spatial characteristics might be more relevant in personalized approaches to ensure 
radioresistant areas of the tumor receive higher doses.
55
 For normal tissue toxicity, 
dose features including the mean and maximum dosage, as well as the volume of the 
normal tissue receiving a certain dose, are important. For example, V20 <35% is a 
common threshold to prevent lung toxicity.
56
 
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-
small-cell lung cancer was first described in 1991.
57
 In 2010, a series of detailed 
reviews of all frequently irradiated organs (the QUANTEC project) was described,
50
 
showing that, as for the tumor, care must be taken when assessing dose at the organ 
level. For example, in some organs, the volume receiving a certain dose is important 
(such as the oesophagus or lung) because of their proximity to other vital structures, 
whereas the maximum dose to a small region of other organs might be most important 
(such as for the spinal cord) because preserving its post-treatment function is crucial. 
Predicting complications to normal tissue is an active research area in ongoing, large, 
prospective multicentric projects, including ALLEGRO
58
, and others.
59-61
 
 
Although important, in general one must be careful about relying completely on 
planned-radiotherapy dose-based predictions because patients display wide variability 
in toxicity development. The reasons for this variability include many known clinical 
and molecular-based features as well as the quality of the treatment execution. The 
focus on the planned radiotherapy dose distribution as the prime determinant of 
outcome is perhaps the most common pitfall in prediction models because deviations 
from the original plan during the time of treatment frequently occur.
62
 The accuracy of 
prediction models is expected to increase when measured dose is used, as this 
measure reflects the effect of radiotherapy most accurately. Figure 2.3 shows an 
example of these variations in a patient with prostate cancer. Dose reconstructions (2D 
and 3D), Gamma Index calculations and dose–volume histograms during treatment can 
help in identifying increasingly accurate dose-related features
63,64
 such as radiation 
pneumonitis
65
 and  oesophagitis
66
. 
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The temporal aspect of fractionated radiotherapy is also an active area of research. 
The fact that higher radiation doses are required to control a tumor when treatment is 
prolonged is well-known, and increasing evidence suggests that accelerated regimens 
giving the same physical dose can improve outcome.
67,68
  
 
 
A multicentric analysis of patients with head-and-neck cancer treated with 
radiotherapy alone showed that the potential doubling time of the tumor before 
Figure 2.3 The importance of considering measured dose for outcome prediction for a patient with prostate 
cancer. (A) Original planning CT scan that includes contours of the prostate (red), bladder (yellow), exterior 
wall of the rectum (blue) and seminal vesicles (green). (B) Contoured CT scan after 16 fractions of 
radiotherapy. (C) Reconstructed 3D dose after 16 fractions of radiotherapy. (D) Calculated dose differences 
(expressed as a 3D Gamma Index) after 16 fractions of radiotherapy. (E) Dose–volume histograms at 
fractions 1, 6, 11, 16, 21 and 26 (dashed lines) as well as pre-treatment histograms (solid lines). Clear 
deviations are visible from the planned dose–volume histogram for the rectum and bladder. 
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treatment was not a predictor for local control.
69
 Alongside the classic explanation of 
accelerated repopulation,
70
 changes in cell loss, hypoxia and selection of radioresistant 
stem cells have each been suggested as underlying causes of this observation, the 
possible implications of which include shorter overall treatment times with higher 
doses per fraction and the avoidance of breaks during treatment.
71,72
 Overall, 
treatment time is an accessible feature that is correlated with local failure in several 
tumor sites.
73,74
 
 
Ideally, the spatial and temporal dimensions of radiotherapy would be exploited by 
showing a fractional dose distribution in a tumor radioresistance (and normal-tissue 
radiosensitivity) map that is continuously updated during treatment. However, such an 
image of radioresistance does not yet exist. If it did, CDSSs would guide the planning 
and modification of the spatial and temporal distribution of radiation in such a way as 
to maintain or improve the balance between tumor control and the probability of 
normal tissue complications continuously during treatment, instead of the current 
approach that delivers radiation as planned with an identical dose to the tumor as a 
whole.   
 
Imaging features 
 
Medical imaging has a fundamental role in radiation oncology, particularly for 
treatment planning and response monitoring.
75,76
 Technological advances in 
noninvasive imaging—including improved temporal and spatial resolution, faster 
scanners and protocol standardization—have enabled the field to move towards the 
identification of quantitative noninvasive imaging biomarkers.
77-79
 
 
Metrics based on tumor size and volume are the most commonly used image-based 
predictors of tumor response to therapy and survival,
80-87
 and rely on CT and MRI 
technology for 3D measurement.
88-90
 Although used in clinical practice, tumor size and 
volume measurements are subject to interobserver variability that can be attributed to 
differences in tumor delineations.
91,92,85-87
 Moreover, the optimal measurement 
technique and definitions of appropriate response criteria, in terms of changes in 
tumor size, are unclear.
93
 Additionally, tumor motion and image artifacts are additional 
sources of variability.
94,95
 To overcome these issues, automated tumor delineation 
methods have been introduced,
96-99
 on the basis of, for example, the selection of 
ranges of Hounsfield units (which represent the linear attenuation coefficient of the X-
ray beam by the tissue) on CT that define a certain tissue type, or calculation of the 
gradient of an image (mathematical filter) to reveal the borders between tissue types. 
Predicting outcomes in radiational oncology  27 
Extensive evaluation, however, is needed before these methods can be used routinely 
in the clinic.
100-102
   
 
A commonly used probe for the metabolic uptake of the tumor is 
18
F-fluorodeoxyglucose (FDG) for PET imaging.
103,104
 The pre-treatment maximum 
standardized uptake value (SUV, which is the normalized 
18
F-deoxyglucose uptake for 
an injected dose according to the patient’s body weight) is strongly associated with 
overall survival and tumor recurrence in a range of tumor sites, including the lung, 
head and neck, rectum, oesophagus and cervix.
105-111
 Furthermore, several studies 
have shown that changes in SUV during and after treatment are early predictors of 
tumor recurrence.
112-115
 FDG-PET measurements, however, are dependent on a 
number of factors, including injected dose, baseline glucose concentration, FDG 
clearance, image reconstruction methods used and partial-volume effects.
116,117
 
Standardization of these factors across institutions is, therefore, fundamental to 
enable comparisons and validation of data from FDG–PET imaging.
118,119
 
 
Multiple studies have shown that diffusion-weighted MRI parameters, such as the 
apparent diffusion coefficient (ADC), which is a measure of water mobility in tissues, 
can accurately predict response and survival in multiple tumor sites.
120-124
 However, 
lack of reproducibility of ADC measurements, due to lack of standardization of 
instruments between vendors and to lack of internationally accepted calibration 
protocols, remains a bottleneck in these types of studies.
125
 Evaluations of different 
time points in dynamic contrast-enhanced MRI have also been used to describe tumor 
perfusion.
90,126-128
 Indeed, hypothesis-driven preclinical
129
 and xenograft studies 
support these clinical studies. For example, assessment of the correlation of features 
from imaging (such as lactate level and the extent of reoxygenation) with tumor 
control is possible.
130,131
 
 
Increasingly advanced image-based features are currently being investigated. For 
example, routine clinical imaging can capture both tumor heterogeneity and post-
treatment changes, which can be analyzed to identify functional biomarkers (Figure 
2.4). Changes in Hounsfield units in contrast-enhanced CT are directly proportional to 
the quantity of contrast agent present in the tissue and have been used as a surrogate 
for tumor perfusion.
132,133
 Indeed, reductions of Hounsfield units following treatment 
have been used to evaluate treatment response in rectal, hepatic and pulmonary 
cancers.
134,135
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Standardizing the extraction and quantification of a large number of traits derived 
from diagnostic imaging are now being considered in new imaging marker 
approaches.
79
 Through advanced image-analysis methods, we can quantify descriptors 
of tumor heterogeneity (such as variance or entropy of the voxel values) and the 
relationship of the tumor with adjacent tissues.
136-138
 These analytical methods enable 
high-throughput evaluation of imaging parameters that can be correlated with 
treatment outcome and, potentially, with biological data. Indeed, qualitative imaging 
parameters on CT and MRI scans have been used to predict mRNA abundance 
variation in hepatocellular carcinomas and brain tumors.
139-141
 Furthermore, a 
combination of anatomical, functional and metabolic imaging techniques might be 
used to capture pathophysiological and morphological tumor characteristics in a 
noninvasive manner, including apparent intratumoral heterogeneity.
142
 
Molecular features 
Biological markers are also valuable clinical decision support features; these include 
prognostic and predictive factors for outcomes, such as tumor response and normal-
tissue tolerance. Despite these strengths, trials of molecular biomarkers are prone to 
experimental variability; for this reason standardizing assay criteria, trial design and 
analysis are imperative if multiple molecular markers are to be used in predictive 
modeling.
16
 
Figure 2.4 Axial 18F-deoxyglucose–PET and CT images of two different patients with non-small-cell lung 
cancer. Tumor imaging biomarkers describing, for example, textural heterogeneity, FDG uptake and tumor 
size can be assessed noninvasively before, during and after radiotherapy and associated with treatment 
outcome. Abbreviations: FDG, 18F-fluorodeoxyglucose; NSCLC, non-small-cell lung cancer.  
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Tumor response 
Next to tumor size, tumor control after radiotherapy is largely determined by three 
criteria: intrinsic radiosensitivity, cell proliferation and the extent of hypoxia.
143
 In 
addition, large tumors intuitively require higher doses of radiation than small tumors 
because there are simply more cells to kill; this requirement is true even if intrinsic 
radiosensitivity, hypoxia and repopulation rates are equal. Several approaches have 
been developed to measure these additional three parameters to predict tumor 
response to radiotherapy. 
Intrinsic radiosensitivity 
Malignant tumors display wide variation in intrinsic radiosensitivity, even between 
tumors of similar origin and histological type.
144
 Attempts to assess the radiosensitivity 
of human tumors have relied on determining the ex vivo tumor survival fraction.
145
 
Those studies and others have shown that tumor cell radiosensitivity is a significant 
prognostic factor for radiotherapy outcome in both cervical
146
 and head-and-neck
147
 
carcinomas. However, these colony assays suffer from technical disadvantages, that 
include a low success rate (<70%) for human tumors and the time needed to produce 
data, which can be up to several weeks. 
 
Other studies have included assessments of chromosome damage, DNA damage, 
glutathione levels and apoptosis.
148
 Indeed, some clinical studies using such assays 
have shown correlations with radiotherapy outcome, whereas others have not.
149
 
However, these cell-based functional assays only have limited clinical utility as 
predictive assays, despite being useful in confirming a mechanism that underlies 
differences in the response of tumors to radiotherapy. For example, some studies have 
provided encouraging data showing that immunohistochemical staining for -histone 
H2AX, a marker of DNA damage, might be a useful way to assess intrinsic 
radiosensitivity very early after the start of treatment.
150,151
 Double-stranded breaks 
are generated when cells are exposed to ionizing radiation or DNA-damaging 
chemotherapeutic agents, which rapidly results in the phosphorylation of -histone 
H2AX. -histone H2AX is the most sensitive marker that can be used to examine the 
DNA damage and its subsequent repair, and it can be detected by immunoblotting and 
immunostaining using microscopic or flow cytometric detection. Clinically, two 
biopsies (one before and one after treatment) are needed to assess the -histone 
H2AX status, which is not always easy to implement in practice. 
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Hypoxia 
Tumor hypoxia is the key factor involved in determining resistance to treatment and 
malignant progression; it is a negative prognostic factor after treatment with 
radiotherapy, chemotherapy and surgery.
152,153
 Indeed, some data show that hypoxia 
promotes both angiogenesis and metastasis and, therefore, has a key role in tumor 
progression.
154
 Although a good correlation has been demonstrated between 
pimonidazole (a chemical probe of hypoxia) staining and outcome after radiotherapy 
in head-and-neck cancer,
155
 the same relationship has not been found in cervical 
cancer.
156
 In light of these contrasting results, one of the hypotheses put forward to 
explain this is that hypoxia tolerance is more important than hypoxia itself.
157
  
 
The use of fluorinated derivatives of such chemical probes also enables their detection 
by noninvasive PET.
158-160
 Although this approach requires administration of a drug, it 
does benefit from sampling the whole tumor and not just a small part of it. Another 
possible surrogate marker of hypoxia is tumor vasculature; the prognostic significance 
of tumor vascularity has been measured as both intercapillary distance (thought to 
reflect tumor oxygenation) and microvessel density (the ‘hotspot’ method that 
provides a histological assessment of tumor angiogenesis). Some studies have found 
positive correlations with outcome, mainly using microvessel density in cervical cancer, 
whereas others have shown negative correlations.
161
 Some concerns have been raised 
about the extent to which biopsies taken randomly truly represent the usually large, 
heterogeneous tumors. 
Proliferation 
If the overall radiotherapy treatment time is prolonged, for example, for technical 
reasons (breakdown of a linear particle accelerator) or because of poor tolerance by 
the patient to the treatment, higher doses of radiation are required for tumor control, 
clearly indicating that the influence of tumor proliferation is important.
162
 Although 
proliferation during fractionated radiotherapy is clearly an important factor in 
determining outcome, reliable measurement methods are not yet available. To 
understand why radiation leads to an accelerated repopulation response in some 
tumors and not in others, a greater understanding of the response at both the cellular 
and molecular level is required. 
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Normal-tissue tolerance 
Inherent differences in cellular radiosensitivity among patients dominate normal-tissue 
reactions more than other contributing factors.
163
 That is, the radiation doses given to 
most patients might in actuality be too low for an optimal cure because 5% of patients 
are very sensitive; these 5% of patients are so sensitive that they skew what is 
‘optimal’ radiotherapy to the lower end of the spectrum, to the detriment of the 
majority of patients who are not as sensitive. Future CDSSs should be able to 
distinguish such overly sensitive patients and classify them separately so they receive 
different treatments to the less-sensitive patients. 
 
Several small
164
 and large
165
 in vitro studies found a correlation between 
radiosensitivity and severity of late effects, namely radiation-induced fibrosis of the 
breast, but these findings were not consistent because no standardized quality 
assurance exists for radiotherapy in vivo.
166,167
 Similar discrepancies were later found 
using rapid assays that measure chromosomal damage,
168
 DNA damage
169
 and 
clonogenic cell survival.
170
 For example, the lymphocyte apoptosis assay has been used 
in a prospective trial as a stratification factor to assess late toxicity using letrozole as 
radiosensitizer in patients with breast cancer.
171
 Cytokines such as TGF- which 
influences fibroblast proliferation and differentiation are known to have a central role 
in fibrosis and senescence.
172,173
 Currently, the relationships between the lymphocytes 
predictive assay, TGF- and late complications are purely correlative and a clear 
molecular explanation is lacking. Genome-wide association studies (GWAS) and the 
analysis of single nucleotide polymorphisms (SNPs) in candidate genes have also 
shown promise in identifying normal-tissue tolerance,
174,175
 although these do not 
often validate results from independent studies.
176
 In general, the problem with all 
these studies has been the wide experimental variability rather than interindividual 
differences in radiosensitivity. Normal tissue tolerance is the dose-limiting factor for 
the administration of radiotherapy, and therefore any CDSS should be based on 
predictors of tumor control and the probability of complications. 
Representation of predictions 
Although the decisions made in the process of developing predictive models will 
determine the characteristics of a multivariate model (for example, which features are 
selected and the overall prediction accuracy), the success of the model depends on 
other factors, such as its availability and interactivity, which increases the 
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acceptability. Even models based on large patient populations, with proper external 
validation, can fail to be accepted within the healthcare community if the model and 
its output are not easily interpretable, if there is a lack of opportunity to apply the 
model or if the clinical usefulness is not proven or reported.
177
 
 
 
Although some models, such as decision trees, implicitly have a visual representation 
that is somewhat interpretable, most models do not. One highly interpretable 
representation of a set of features is the nomogram.
178
 The nomogram was originally 
used in the early 20
th
 century to make approximate graphical computations of 
mathematical equations. In medicine, nomograms have experienced a revival, 
reflected by the increasing number of studies reporting them.
179-183
 Figure 2.5 shows 
Figure 2.5 A published nomogram for local control in patients with cancer of the larynx treated with 
radiotherapy. Clinical and treatment variables are associated with local control status at follow-up durations 
of 2 and 5 years. The predictors are age of the patient (in years), haemoglobin level (in mmol/l), clinical 
tumor stage (T-stage), clinical nodal stage (N-stage), patient’s sex and equivalent dose (in Gy). A probability 
for local control can be calculated by drawing a vertical line from each predictor value to the score scale at 
the top—‘points’. After manually summing up the scores, the ‘total points’ correspond to the probability of 
local control, which are estimated by drawing a vertical line from this value to the bottom scales to estimate 
local control.180 
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an example of a published clinical nomogram of local control in larynx cancer in which 
values for the selected features directly relate to a prediction score. The sum of these 
scores corresponds to a probability of local control within 2 or 5 years.
180 
 
Another idea for increasing acceptability of computer-assisted personalized medicine 
is to make prediction models available on the internet. If interactive, peer-reviewed 
models are provided with sufficient background information, clinicians can test them 
using their own patient data. Such a system would provide retrospective validation of 
the multiple features by the wider community, as well as provide an indication on the 
clinical usefulness of the methodology. The best-known website with interactive 
clinical prediction tools is Adjuvant! Online.
184
 This website provides decision support 
for adjuvant therapy (for example, chemotherapy and hormone therapy) after surgery 
for patients with early-stage cancer. Many researchers have evaluated the models 
available on this prediction website, thereby refining them with additional predictors 
and updated external validations.
185,186
 A prediction website that focuses on decision 
support for radiotherapy was recently established.
187
  The aim of this website is to let 
users work with and validate the interactive models developed for patients with cancer 
treated with radiotherapy, which contributes to CDSS development in general by 
demonstrating the potential of these predictions and raising the awareness of their 
existence and limitations. 
 
Future prospects 
 
The major focus of this Review, thus far, has been model development, validation and 
presentation (including the features from different domains that might be considered 
as predictive and prognostic). Although an accurate outcome prediction model forms 
the basis of a CDSS, additional considerations must be made before a new CDSS can be 
used in daily radiation oncology practice.  
 
First, any decision a patient or physician makes is based on a balance between its 
benefits (survival, local control and quality of life) and harms (toxic effects, 
complications, quality of life and financial cost). For example, an increased radiation 
dose usually results in both a higher probability of tumor control, but a concomitant 
higher probability of normal-tissue complications. Identifying the right balance 
between harm and benefit is a deeply personal choice that can vary substantially 
among patients. Thus, a CDSS should simultaneously predict local control, survival, 
treatment toxicity, quality of life and cost. The system should represent these 
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predictions and the balance between them in a way that is not only clear to the 
physician, but also to the patient, to achieve shared decision making. 
 
Additionally, any prediction using a CDSS should be accompanied by a confidence 
interval. Accurately evaluating the confidence interval is an active and challenging area 
of research because uncertainties in the input features, missing features, size and 
quality of the training set and the intrinsic uncertainty of cancer must be incorporated 
to specify the uncertainty in the prediction for an individual patient. Without knowing 
if two possible decisions have a statistically significant and clinically meaningful 
difference in outcome, clinical decision support is difficult. Always sharing the data on 
which the model was based is a crucial prerequisite for this effort.  
Current prediction models for decision support can only assist in distinguishing very 
high-level decisions—such as palliative versus curative treatment, sequential versus 
concurrent chemoradiation, surgery versus a wait-and-see approach. The radiation 
oncology community, however, is probably more interested in decisions such as 
intensity-modulated radiotherapy versus 3D-conformal radiotherapy or accelerated 
versus non-accelerated treatment. The current prediction models are simply not 
trained on datasets with these detailed subgroups and are not, therefore, accurate 
enough to support these decisions. Whether learning from increasingly diverse patient 
groups and adding other features will sufficiently improve the current models is 
unclear. As a result, tightly controlled studies using evidence-based medicine 
approaches are still crucial to guide clinical practice. 
 
Finally, CDSSs should be seen as medical devices that require stringent acceptance, 
commissioning and quality assurance by the local institute. The key part of the 
commissioning and subsequent quality assurance is to validate the accuracy of the 
prediction model in the local patient population. Indeed, local patient data should be 
collected and the predicted outcomes compared with actual outcomes to convince 
local physicians that the support system works in their local setting. This ‘local 
validation’ should be done at the commissioning stage, but should be repeated to 
ensure the decision support remains valid, despite changes in local practice. Validation 
studies need to indicate what will be the required commission frequency.  
This required quality assurance also enables the improvement of the system as more 
patient data becomes available. Using routine patient data to extract knowledge and 
apply that knowledge immediately is called ‘rapid learning’.
3,188
 Rapid learning via 
continuously updated CDSSs offers a way to quickly learn from retrospective data and 
include new datasets (such as randomized controlled trial results) to adapt treatment 
protocols and deliver personalized decision support. 
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As a data-driven discipline with well-established standards, such as DICOM–RT (digital 
imaging and communications in medicine in radiotherapy), radiotherapy offers an 
excellent starting point for adopting these rapid-learning principles (Figure 2.6). Aside 
from the importance of local data capture, which is still often lacking for (patient-
reported) outcome and toxicity in particular, the quantity and heterogeneity of data 
that is necessary for rapid learning requires the pooling of data in a multi-institutional, 
international fashion.
189,190
 One method of pooling data is to replicate routine clinical 
data sources in a distributed de-identified data warehouse, such as what is done in an 
international Computer-Aided Theragnostics network.
191
 Examples of initiatives that 
create large centralized data and tissue infrastructures for routine radiation oncology 
patients are GENEPI,
192
 the Radiogenomics Consortium,
193
 ALLEGRO
58
 and ULICE
194
. 
These initiatives also facilitate studies for external validation, reproducibility and 
hypothesis generation (Figure 2.7).
189  
 
As datasets become larger (both in number of patients and in number of features per 
patient) high-throughput methods, both molecular
195-200
 and imaging-based,
79
 can 
produce large numbers of features that correlate with outcome.
68,70,201-203
 A limited 
Figure 2.6 Knowledge-driven health-care principles using a clinical decision support system in conjunction 
with standard evidence and regulations to choose the optimal treatment. In learning from follow-up data, 
knowledge is fed back to improve the clinical decision support system and adapt regulations. 
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application of these techniques has already transformed our understanding of 
radiotherapy response. For example, GWAS have associated SNPs with radiation 
toxicity.
204,205
 Similarly, mRNA-abundance microarrays have been used to predict 
tumor response and normal-tissue toxicity in both patient and in vitro studies,
206-210
 as 
well as to create markers that reflect biological phenotypes that are important for 
radiation response, such as hypoxia
211,212
 and proliferation.
213
 Both the data analysis 
and validation are important but challenging aspects of model development.
195,214
 For 
example, the studies described above suffer from the substantial multiple-testing 
problem (that is, a large number of measured features compared with the sample 
number), which renders their results preliminary.
206-213
 Human input and large, robust 
validation studies are, therefore, needed before features from high-throughput 
techniques can be included in CDSSs.
215-217
 
 
 
Although studies on a single feature can be informative, only its combination into 
multimodal, multivariate models can be expected to provide a more holistic view of 
the response to radiation.  
Figure 2.7 Illustration of the data handling paradigms. In the current paradigm the datasets are lost to the 
scientific community after collection, analysis and publication. In the future paradigm all the data will be 
shared in a standardized way and reused for e.g. reproducibility studies, validation studies, and studies 
testing new hypotheses. Pooling of multiple datasets may also improve accuracy of future predictions. This 
illustration is inspired on Deasy et al.189 
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By combining events at different levels using systems-biology-like approaches, creating 
tumor-specific and patient-specific models of the effects and implications of radiation 
therapy should become possible (Figure 2.8). 
Figure 2.8 A simplified schematic representation of systems biology applied to radiotherapy. (A) On the basis 
of in-vitro, in-vivo and patient data, modules representing the three biological categories (gene expression, 
immunohistochemical data and mutation data) important for radiotherapy response can be created. (B) For 
an individual patient, appropriate molecular data will be accumulated. (C) Combining the individual patient 
data with the modules will provide knowledge on specific module alterations (such as a deletion [X], 
upregulation [red] or downregulation [blue]), which can be translated to information on relative 
radioresistance and the molecular ‘weak’ spots of the tumor. This information will subsequently indicate 
whether dose escalation is necessary and which targeted drug is most effective for the patient. Part b used 
with permission from the National Academy of Sciences © Dubois, L. J. Proc. Natl Acad. Sci. USA 108, 14620–
14625 (2011). 
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Indeed, future studies will not only need to identify the individual components related 
to radiation response, but will also need to establish the interactions and relations 
amongst them.
218
 Although this approach has not yet been applied to model 
radiotherapy responses, at least one study has demonstrated that combining multiple 
high-throughput data types can be used to map molecular cancer characteristics.
219
 
Combining models at different levels (societal, patient, whole tumor or organ, local 
tumor or organ, and cellular) is expected to lead to an increasingly holistic and 
accurate CDSS for the individual patient. Evidence that longitudinal data have added 
value to predicting outcome in, for example, repeated PET-imaging
220
 and tumor 
perfusion
221
 studies is growing, implying that this data need to be taken into account 
as candidates for future CDSSs. 
Despite the challenges that remain, the vision of predictive models leading to CDSSs 
that are continuously updated via rapid learning on large datasets is clear, and 
numerous steps have already been taken. These include universal data-quality 
assurance programs and semantic interoperability issues.
222
 However, we believe that 
this truly innovative journey will lead to necessary improvement of healthcare 
effectiveness and efficiency. Indeed, investments are being made in research and 
innovation for health-informatics systems, with an emphasis on interoperability and 
standards for secured data transfer, which shows that ‘eHealth’ will be among the 
largest healthcare innovations of the coming decade.
222,223 
Conclusions 
Accurate, externally validated prediction models are being rapidly developed, whereby 
multiple features related to the patient’s disease are combined into an integrated 
prediction. The key, however, is standardization—mainly in data acquisition across all 
areas, including molecular-based and imaging-based assays, patient preferences and 
possible treatments. Standardization requires harmonized clinical guidelines, regulated 
image acquisition and analysis parameters, validated biomarker assay criteria and 
data-sharing methods that use identical ontologies. Assessing the clinical usefulness of 
any CDSS is just as important as standardizing the development of externally validated 
accurate prediction models with high-quality data, preferably by standardizing the 
design of clinical trials. These crucial steps are the basis of validating a CDSS, which, in 
turn, will stimulate developments in rapid-learning healthcare and will enable the next 
major advances in shared decision making. 
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Review criteria 
The PubMed and MEDLINE databases were searched for articles published in English 
(not restricted by date of publication) using a range of key phrases, including but not 
limited to: “PET imaging”, “heterogeneity in imaging”, “tumor response in 
radiotherapy”. 
      Chapter 2 
 
40
Reference List 
1. Vogelzang NJ, Benowitz SI, Adams S, et al. Clinical cancer advances 2011: Annual Report on Progress 
Against Cancer from the American Society of Clinical Oncology. J Clin Oncol 2012; 30:88-109 
2. Fraass BA, Moran JM. Quality, technology and outcomes: evolution and evaluation of new treatments 
and/or new technology. Semin Radiat Oncol 2012; 22:3-10 
3. Abernethy AP, Etheredge LM, Ganz PA, et al. Rapid-learning system for cancer care. J Clin Oncol 2010; 
28:4268-74 
4. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin 2011; 
61:365-81 
5. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed 
by multiregion sequencing. N Engl J Med 2012; 366:883-92 
6. Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of 
intratumor heterogeneity. Clin Cancer Res 2006; 12:5632-40 
7. Boyd CA, Benarroch-Gampel J, Sheffield KM, et al. 415 patients with adenosquamous carcinoma of the 
pancreas: a population-based analysis of prognosis and survival. J Surg Res 2012; 174:12-9 
8. Milosevic MF, Fyles AW, Wong R, et al. Interstitial fluid pressure in cervical carcinoma: within tumor 
heterogeneity, and relation to oxygen tension. Cancer 1998; 82:2418-26 
9. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours 
reveals novel subgroups. Nature 2012;  
10. Suit H, Skates S, Taghian A, et al. Clinical implications of heterogeneity of tumor response to radiation 
therapy. Radiother Oncol 1992; 25:251-60 
11. Aerts HJ, Bussink J, Oyen WJ, et al. Identification of residual metabolic-active areas within NSCLC 
tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 2012; 
75:73-6 
12. Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within 
individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother 
Oncol 2009; 91:386-92 
13. Vickers AJ. Prediction models: revolutionary in principle, but do they do more good than harm? J Clin 
Oncol 2011; 29:2951-2 
14. Bright TJ, Wong A, Dhurjati R, et al. Effect of Clinical Decision-Support Systems: A Systematic Review. 
Ann Intern Med 2012;  
15. Clark GM. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol 
Oncol 2008; 1:406-12 
16. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of 
biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16:1745-55 
17. Peek N, Arts DG, Bosman RJ, et al. External validation of prognostic models for critically ill patients 
required substantial sample sizes. J Clin Epidemiol 2007; 60:491-501 
18. Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Substantial effective sample sizes were required for 
external validation studies of predictive logistic regression models. J Clin Epidemiol 2005; 58:475-83 
19. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a 
framework for traditional and novel measures. Epidemiology 2010; 21:128-38 
20. Aittokallio T. Dealing with missing values in large-scale studies: microarray data imputation and 
beyond. Brief Bioinform 2010; 11:253-64 
Predicting outcomes in radiational oncology  41 
21. Ludbrook J. Outlying observations and missing values: how should they be handled? Clin Exp 
Pharmacol Physiol 2008; 35:670-8 
22. Jayalakshmi T, Santhakumaran A. Statistical Normalization and Back Propagation for Classification. 
International Journal of Computer Theory and Engineering 2011; 3:89-93 
23. Huan L, Motoda H: Feature Selection for Knowledge Discovery and Data Mining, 1998, Springer 
24. Harrell FEJ: Regression modeling strategies, 2001, Springer, New York 
25. Bishop CM: Pattern Recognition and Machine Learning, 1st ed, 2007, Springer 
26. Lee SM, Abbott PA. Bayesian networks for knowledge discovery in large datasets: basics for nurse 
researchers. J Biomed Inform 2003; 36:389-99 
27. Cruz JA, Wishart DS. Applications of machine learning in cancer prediction and prognosis. Cancer 
Inform 2007; 2:59-77 
28. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat 
Med 2007; 26:2389-430 
29. Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. External validation, model 
updating, and impact assessment. Heart 2012; 98:691-8 
30. Dehing-Oberije C, De Ruysscher D, Petit S, et al. Development, external validation and clinical 
usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. 
Radiother Oncol 2010; 97:455-61 
31. Specht MC, Kattan MW, Gonen M, et al. Predicting nonsentinel node status after positive sentinel 
lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005; 12:654-9 
32. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of 
positive lymph node stations is a more important prognostic factor than TNM stage for survival of 
non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 
2008; 70:1039-44 
33. Vickers AJ, Kramer BS, Baker SG. Selecting patients for randomized trials: a systematic approach based 
on risk group. Trials 2006; 7:30 
34. Baggerly KA, Coombes KR. What Information Should Be Required to Support Clinical "Omics" 
Publications? Clin Chem 2011;  
35. Klopp AH, Eifel PJ. Biological predictors of cervical cancer response to radiation therapy. Semin Radiat 
Oncol 2012; 22:143-50 
36. Kristiansen G. Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 
2012; 60:125-41 
37. Dehing-Oberije C, Yu S, De Ruysscher D, et al. Development and external validation of prognostic 
model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J 
Radiat Oncol Biol Phys 2009; 74:355-62 
38. Ang CS, Phung J, Nice EC. The discovery and validation of colorectal cancer biomarkers. Biomed 
Chromatogr 2011; 25:82-99 
39. Schmidt ME, Steindorf K. Statistical methods for the validation of questionnaires--discrepancy 
between theory and practice. Methods Inf Med 2006; 45:409-13 
40. Garrido-Laguna I, Janku F, Vaklavas C, et al. Validation of the Royal Marsden Hospital prognostic score 
in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer 
2012; 118:1422-8 
41. Shrier I, Boivin JF, Steele RJ, et al. Should meta-analyses of interventions include observational studies 
in addition to randomized controlled trials? A critical examination of underlying principles. Am J 
Epidemiol 2007; 166:1203-9 
      Chapter 2 
 
42
42. Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from 
observational studies versus randomised trials: meta-epidemiology study. BMJ 2011; 343:d6829 
43. Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event 
reporting in oncology. J Clin Oncol 2007; 25:5121-7 
44. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for 
the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-81 
45. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised 
controlled trials as compared to observational studies: methodological overview. PLoS Med 2011; 
8:e1001026 
46. Steg PG, Lopez-Sendon J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial 
infarction. Arch Intern Med 2007; 167:68-73 
47. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association studies 
(STREGA): an extension of the STROBE Statement. Ann Intern Med 2009; 150:206-15 
48. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 
370:1453-7 
49. Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol 
2006; 7:848-58 
50. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic 
(QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010; 76:S3-9 
51. Verellen D, De Ridder M, Linthout N, et al. Innovations in image-guided radiotherapy. Nat Rev Cancer 
2007; 7:949-60 
52. Holthusen H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen und deren 
Nutzanwendung zur Verhütung von Schäden. Strahlentherapie. 1936; 57:254-269 
53. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant 
metastases, and overall survival for patients with locally advanced rectal cancer on the basis of 
European randomized clinical trials. J Clin Oncol 2011; 29:3163-72 
54. Belderbos J, Uitterhoeve L, van Zandwijk N, et al. Randomised trial of sequential versus concurrent 
chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur 
J Cancer 2007; 43:114-21 
55. Lambin P, Petit SF, Aerts HJ, et al. The ESTRO Breur Lecture 2009. From population to voxel-based 
radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-
small cell lung cancer. Radiother Oncol 2010; 96:145-52 
56. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 
3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45:323-9 
57. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat 
Oncol Biol Phys 1991; 21:109-22 
58. Ottolenghi A, Smyth V, Trott KR. The risks to healthy tissues from the use of existing and emerging 
techniques for radiation therapy. Radiat Prot Dosimetry 2011; 143:533-5 
59. Beetz I, Schilstra C, van der Schaaf A, et al. NTCP models for patient-rated xerostomia and sticky saliva 
after treatment with intensity modulated radiotherapy for head and neck cancer: The role of 
dosimetric and clinical factors. Radiother Oncol 2012;  
60. van der Schaaf A, Xu CJ, van Luijk P, et al. Multivariate modeling of complications with data driven 
variable selection: Guarding against overfitting and effects of data set size. Radiother Oncol 2012;  
61. Xu CJ, van der Schaaf A, Van't Veld AA, et al. Statistical validation of normal tissue complication 
probability models. Int J Radiat Oncol Biol Phys 2012; 84:e123-9 
Predicting outcomes in radiational oncology  43 
62. Nijsten SM, Mijnheer BJ, Dekker AL, et al. Routine individualised patient dosimetry using electronic 
portal imaging devices. Radiother Oncol 2007; 83:65-75 
63. van Elmpt W, Petit S, De Ruysscher D, et al. 3D dose delivery verification using repeated cone-beam 
imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancer. 
Radiother Oncol 2010; 94:188-94 
64. van Elmpt W, Nijsten S, Petit S, et al. 3D in vivo dosimetry using megavoltage cone-beam CT and EPID 
dosimetry. Int J Radiat Oncol Biol Phys 2009; 73:1580-7 
65. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose - volume histogram 
parameters in lung cancer--a systematic review. Radiother Oncol 2004; 71:127-38 
66. Werner-Wasik M, Yorke E, Deasy J, et al. Radiation dose-volume effects in the esophagus. Int J Radiat 
Oncol Biol Phys 2010; 76:S86-93 
67. Saunders M, Rojas AM, Dische S. CHART revisited: a conservative approach for advanced head and 
neck cancer. Clin Oncol (R Coll Radiol) 2008; 20:127-33 
68. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast 
cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29:2013-23 
69. Begg AC, Haustermans K, Hart AA, et al. The value of pretreatment cell kinetic parameters as 
predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 
1999; 50:13-23 
70. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer 
patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase 
inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007; 99:838-46 
71. Hessel F, Petersen C, Zips D, et al. Impact of increased cell loss on the repopulation rate during 
fractionated irradiation in human FaDu squamous cell carcinoma growing in nude mice. Int J Radiat 
Biol 2003; 79:479-86 
72. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev 
Cancer 2008; 8:545-54 
73. Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control 
in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 
and 98-11. J Clin Oncol 2010; 28:5061-6 
74. Thames HD, Kuban D, Levy LB, et al. The role of overall treatment time in the outcome of radiotherapy 
of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. 
Radiother Oncol 2010; 96:6-12 
75. Leonard F. Imaging and cancer: A review. Molecular Oncology 2008; 2:115-152 
76. Torigian DA, Huang SS, Houseni M, et al. Functional imaging of cancer with emphasis on molecular 
techniques. CA Cancer J Clin 2007; 57:206-24 
77. Eadie LH, Taylor P, Gibson AP. A systematic review of computer-assisted diagnosis in diagnostic cancer 
imaging. European Journal of Radiology 2012; 81:e70-e76 
78. Gillies RJ, Anderson AR, Gatenby RA, et al. The biology underlying molecular imaging in oncology: from 
genome to anatome and back again. Clinical Radiology 2010; 65:517-521 
79. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: Extracting more information from medical 
images using advanced feature analysis. European Journal of Cancer 2012; 48:441-446 
80. Velazquez ER, Aerts HJ, Oberije C, et al. Prediction of residual metabolic activity after treatment in 
NSCLC patients. Acta Oncol 2010; 49:1033-9 
81. Cangir AK, Kutlay H, Akal M, et al. Prognostic value of tumor size in non-small cell lung cancer larger 
than five centimeters in diameter. Lung Cancer 2004; 46:325-331 
      Chapter 2 
 
44
82. Lam JS, Klatte T, Patard J-J, et al. Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A 
Multicentre Experience. European Urology 2007; 52:155-162 
83. Pitson G, Fyles A, Milosevic M, et al. Tumor size and oxygenation are independent predictors of nodal 
diseases in patients with cervix cancer. International Journal of Radiation Oncology*Biology*Physics 
2001; 51:699-703 
84. Thomas F, Arriagada R, Mouriesse H, et al. Radical radiotherapy alone in non-operable breast cancer: 
The major impact of tumor size and histological grade on prognosis. Radiotherapy and Oncology 1988; 
13:267-276 
85. Steenbakkers RJ, Duppen JC, Fitton I, et al. Observer variation in target volume delineation of lung 
cancer related to radiation oncologist-computer interaction: a 'Big Brother' evaluation. Radiother 
Oncol 2005; 77:182-90 
86. Greco C, Rosenzweig K, Cascini GL, et al. Current status of PET/CT for tumour volume definition in 
radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007; 57:125-34 
87. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients 
with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J 
Radiat Oncol Biol Phys 2001; 51:923-31 
88. Bowden P, Fisher R, Mac Manus M, et al. Measurement of lung tumor volumes using three-
dimensional computer planning software. Int J Radiat Oncol Biol Phys 2002; 53:566-73 
89. Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small-cell 
lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol 2011; 18:54-62 
90. Marcus CD, Ladam-Marcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment 
in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009; 72:217-38 
91. Schwartz LH, Mazumdar M, Brown W, et al. Variability in response assessment in solid tumors: effect 
of number of lesions chosen for measurement. Clin Cancer Res 2003; 9:4318-23 
92. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in 
measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor 
response. J Clin Oncol 2003; 21:2574-82 
93. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer 2002; 38:1817-23 
94. Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a 
review. Semin Nucl Med 2008; 38:167-76 
95. Sonke JJ, Belderbos J. Adaptive radiotherapy for lung cancer. Semin Radiat Oncol 2010; 20:94-106 
96. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung 
cancer correlates with pathology and reduces interobserver variability in the delineation of the 
primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007; 68:771-8 
97. Wu K, Ung YC, Hornby J, et al. PET CT thresholds for radiotherapy target definition in non-small-cell 
lung cancer: how close are we to the pathologic findings? Int J Radiat Oncol Biol Phys 2010; 77:699-
706 
98. Wanet M, Lee JA, Weynand B, et al. Gradient-based delineation of the primary GTV on FDG-PET in 
non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical 
specimens. Radiother Oncol 2011; 98:117-25 
99. Strassmann G, Abdellaoui S, Richter D, et al. Atlas-based semiautomatic target volume definition (CTV) 
for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2010; 78:1270-6 
100. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-
FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell 
lung cancer. J Nucl Med 2005; 46:1342-8 
Predicting outcomes in radiational oncology  45 
101. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: 
comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 
233:93-100 
102. van Loon J, van Baardwijk A, Boersma L, et al. Therapeutic implications of molecular imaging with PET 
in the combined modality treatment of lung cancer. Cancer Treat Rev 2011; 37:331-43 
103. Wood KA, Hoskin PJ, Saunders MI. Positron Emission Tomography in Oncology: A Review. Clinical 
Oncology 2007; 19:237-255 
104. O'Connor JPB, Jackson A, Asselin M-C, et al. Quantitative imaging biomarkers in the clinical 
development of targeted therapeutics: current and future perspectives. The Lancet Oncology 2008; 
9:766-776 
105. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan 
during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer 
(NSCLC) patients. Radiotherapy and Oncology 2007; 82:145-152 
106. Rodney J H. PET for Therapeutic Response Monitoring in Oncology. PET Clinics 2008; 3:89-99 
107. Chung HH, Kim JW, Han KH, et al. Prognostic value of metabolic tumor volume measured by FDG-
PET/CT in patients with cervical cancer. Gynecologic Oncology 2011; 120:270-274 
108. Borst GR, Belderbos JSA, Boellaard R, et al. Standardised FDG uptake: A prognostic factor for 
inoperable non-small cell lung cancer. European Journal of Cancer 2005; 41:1533-1541 
109. Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical 
radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. 
Lung Cancer 2005; 49:95-108 
110. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-
fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-
cell lung cancer. J Clin Oncol 2005; 23:8362-70 
111. Soto DE, Kessler ML, Piert M, et al. Correlation between pretreatment FDG-PET biological target 
volume and anatomical location of failure after radiation therapy for head and neck cancers. 
Radiother Oncol 2008; 89:13-8 
112. Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and diffusion-weighted magnetic 
resonance imaging for response prediction before, during and after preoperative chemoradiotherapy 
for rectal cancer. Acta Oncol 2010; 49:956-63 
113. Janssen MHM, Ã–llers MC, van Stiphout RGPM, et al. Evaluation of early metabolic responses in rectal 
cancer during combined radiochemotherapy or radiotherapy alone: Sequential FDG-PET-CT findings. 
Radiotherapy and Oncology 2010; 94:151-155 
114. Ceulemans Gt, Voordeckers M, Farrag A, et al. Can 18-FDG-PET During Radiotherapy Replace Post-
Therapy Scanning for Detection/Demonstration of Tumor Response in Head-and-Neck Cancer? 
International Journal of Radiation Oncology*Biology*Physics 2011; 81:938-942 
115. van Loon J, Offermann C, Ollers M, et al. Early CT and FDG-metabolic tumour volume changes show a 
significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. 
Radiother Oncol 2011; 99:172-5 
116. Bussink J, Kaanders JH, van der Graaf WT, et al. PET-CT for radiotherapy treatment planning and 
response monitoring in solid tumors. Nat Rev Clin Oncol 2011; 8:233-42 
117. Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl 
Med 2011; 52 Suppl 2:93S-100S 
118. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and 
quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008; 
35:2320-33 
      Chapter 2 
 
46
119. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for 
tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37:181-200 
120. Bayouth JE, Casavant TL, Graham MM, et al. Image-Based Biomarkers in Clinical Practice. Seminars in 
Radiation Oncology 2011; 21:157-166 
121. Harry VN, Semple SI, Parkin DE, et al. Use of new imaging techniques to predict tumour response to 
therapy. The Lancet Oncology 2010; 11:92-102 
122. Heijmen L, Verstappen MC, Ter Voert EE, et al. Tumour response prediction by diffusion-weighted MR 
imaging: Ready for clinical use? Crit Rev Oncol Hematol 2012;  
123. Lambrecht M, Vandecaveye V, Van Limbergen EJ, et al. The prognostic value of pretherapeutic 
diffusion-weighted MRI in oropharyngeal carcinoma treated with (chemo-)radiotherapy. Cancer 
Imaging 2011; 11 Spec No A:S112-3 
124. Vandecaveye V, Dirix P, De Keyzer F, et al. Diffusion-weighted magnetic resonance imaging early after 
chemoradiotherapy to monitor treatment response in head-and-neck squamous cell carcinoma. Int J 
Radiat Oncol Biol Phys 2012; 82:1098-107 
125. Kim SY, Lee SS, Byun JH, et al. Malignant hepatic tumors: short-term reproducibility of apparent 
diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. 
Radiology 2010; 255:815-23 
126. Sinkus R, Van Beers BE, Vilgrain V, et al. Apparent diffusion coefficient from magnetic resonance 
imaging as a biomarker in oncology drug development. Eur J Cancer 2012; 48:425-31 
127. Kierkels RGJ, Backes WH, Janssen MHM, et al. Comparison Between Perfusion Computed Tomography 
and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Rectal Cancer. International Journal 
of Radiation Oncology*Biology*Physics 2010; 77:400-408 
128. Shukla-Dave A, Lee NY, Jansen JFA, et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as 
a Predictor of Outcome in Head and Neck Squamous Cell Carcinoma Patients with Nodal Metastases. 
International Journal of Radiation Oncology*Biology*Physics 2012;  
129. Yaromina A, Quennet V, Zips D, et al. Co-localisation of hypoxia and perfusion markers with 
parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int J Radiat 
Biol 2009; 85:972-80 
130. Morchel P, Melkus G, Yaromina A, et al. Correlating quantitative MR measurements of standardized 
tumor lines with histological parameters and tumor control dose. Radiother Oncol 2010; 96:123-30 
131. Quennet V, Yaromina A, Zips D, et al. Tumor lactate content predicts for response to fractionated 
irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006; 81:130-5 
132. Kim YI, Chung JW, Park JH, et al. Multiphase contrast-enhanced CT imaging in hepatocellular 
carcinoma correlation with immunohistochemical angiogenic activities. Acad Radiol 2007; 14:1084-91 
133. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003; 76 
Spec No 1:S36-42 
134. Miles KA. Molecular imaging with dynamic contrast-enhanced computed tomography. Clinical 
Radiology 2010; 65:549-556 
135. Petralia G, Bonello L, Viotti S, et al. CT perfusion in oncology: how to do it. Cancer Imaging 2010; 10:8-
19 
136. Asselin MC, O'Connor JP, Boellaard R, et al. Quantifying heterogeneity in human tumours using MRI 
and PET. Eur J Cancer 2012; 48:447-55 
137. Eary JF, O'Sullivan F, O'Sullivan J, et al. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor 
of patient outcome. J Nucl Med 2008; 49:1973-9 
Predicting outcomes in radiational oncology  47 
138. Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by textural features on 
baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal 
cancer. J Nucl Med 2011; 52:369-78 
139. Diehn M, Nardini C, Wang DS, et al. Identification of noninvasive imaging surrogates for brain tumor 
gene-expression modules. Proc Natl Acad Sci U S A 2008; 105:5213-8 
140. Kuo MD, Gollub J, Sirlin CB, et al. Radiogenomic analysis to identify imaging phenotypes associated 
with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 2007; 
18:821-31 
141. Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive 
imaging. Nat Biotechnol 2007; 25:675-80 
142. Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic 
imaging. Eur J Radiol 2009; 70:232-41 
143. Lindegaard JC, Overgaard J, Bentzen SM, et al. Is there a radiobiologic basis for improving the 
treatment of advanced stage cervical cancer? J Natl Cancer Inst Monogr 1996:105-12 
144. Slonina D, Gasinska A. Intrinsic radiosensitivity of healthy donors and cancer patients as determined 
by the lymphocyte micronucleus assay. Int J Radiat Biol 1997; 72:693-701 
145. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness 
of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985; 
11:1699-707 
146. West CM, Davidson SE, Roberts SA, et al. The independence of intrinsic radiosensitivity as a prognostic 
factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997; 76:1184-90 
147. Bjork-Eriksson T, West C, Karlsson E, et al. Tumor radiosensitivity (SF2) is a prognostic factor for local 
control in head and neck cancers. Int J Radiat Oncol Biol Phys 2000; 46:13-9 
148. Bartelink H, Begg A, Martin JC, et al. Towards prediction and modulation of treatment response. 
Radiother Oncol 1999; 50:1-11 
149. Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol 2012; 
22:108-18 
150. Menegakis A, Yaromina A, Eicheler W, et al. Prediction of clonogenic cell survival curves based on the 
number of residual DNA double strand breaks measured by gammaH2AX staining. Int J Radiat Biol 
2009; 85:1032-41 
151. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat 
Oncol Biol Phys 2004; 58:331-5 
152. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in 
advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-15 
153. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis 
Rev 2007; 26:225-39 
154. Chouaib S, Messai Y, Couve S, et al. Hypoxia promotes tumor growth in linking angiogenesis to 
immune escape. Front Immunol 2012; 3:21 
155. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for 
treatment outcome in head and neck cancer. Cancer Res 2002; 62:7066-74 
156. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. The prognostic value of pimonidazole and tumour 
pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center 
study. Radiother Oncol 2006; 80:123-31 
157. Rouschop KM, van den Beucken T, Dubois L, et al. The unfolded protein response protects human 
tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin 
Invest 2010; 120:127-41 
      Chapter 2 
 
48
158. Krause BJ, Beck R, Souvatzoglou M, et al. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl 
Med Mol Imaging 2006; 50:28-43 
159. Dubois LJ, Lieuwes NG, Janssen MH, et al. Preclinical evaluation and validation of [18F]HX4, a 
promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011; 108:14620-5 
160. van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans 
in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; 
77:329-36 
161. West CM, Cooper RA, Loncaster JA, et al. Tumor vascularity: a histological measure of angiogenesis 
and hypoxia. Cancer Res 2001; 61:2907-10 
162. Maciejewski B, Withers HR, Taylor JM, et al. Dose fractionation and regeneration in radiotherapy for 
cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol 
Biol Phys 1989; 16:831-43 
163. Turesson I, Nyman J, Holmberg E, et al. Prognostic factors for acute and late skin reactions in 
radiotherapy patients. Int J Radiat Oncol Biol Phys 1996; 36:1065-75 
164. Johansen J, Bentzen SM, Overgaard J, et al. Evidence for a positive correlation between in vitro 
radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after 
radiotherapy. Int J Radiat Biol 1994; 66:407-12 
165. West CM, Davidson SE, Elyan SA, et al. Lymphocyte radiosensitivity is a significant prognostic factor for 
morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2001; 51:10-5 
166. Peacock J, Ashton A, Bliss J, et al. Cellular radiosensitivity and complication risk after curative 
radiotherapy. Radiother Oncol 2000; 55:173-8 
167. Russell NS, Grummels A, Hart AA, et al. Low predictive value of intrinsic fibroblast radiosensitivity for 
fibrosis development following radiotherapy for breast cancer. Int J Radiat Biol 1998; 73:661-70 
168. Russell NS, Arlett CF, Bartelink H, et al. Use of fluorescence in situ hybridization to determine the 
relationship between chromosome aberrations and cell survival in eight human fibroblast strains. Int J 
Radiat Biol 1995; 68:185-96 
169. Kiltie AE, Ryan AJ, Swindell R, et al. A correlation between residual radiation-induced DNA double-
strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. 
Radiother Oncol 1999; 51:55-65 
170. Dileto CL, Travis EL. Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: comparison between a 
fibrosis-prone and fibrosis-resistant mouse strain. Radiat Res 1996; 146:61-7 
171. Azria D, Belkacemi Y, Romieu G, et al. Concurrent or sequential adjuvant letrozole and radiotherapy 
after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. 
Lancet Oncol 2010; 11:258-65 
172. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets 
molecular pathology. Nat Rev Cancer 2006; 6:702-13 
173. Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother Oncol 1995; 35:83-
90 
174. Andreassen CN, Alsner J, Overgaard M, et al. Risk of radiation-induced subcutaneous fibrosis in 
relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM--a study 
based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 2006; 82:577-86 
175. Chang-Claude J, Popanda O, Tan XL, et al. Association between polymorphisms in the DNA repair 
genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin 
Cancer Res 2005; 11:4802-9 
176. Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported 
to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 2012; 13:65-77 
Predicting outcomes in radiational oncology  49 
177. Cammann H, Jung K, Meyer HA, et al. Avoiding pitfalls in applying prediction models, as illustrated by 
the example of prostate cancer diagnosis. Clin Chem 2011; 57:1490-8 
178. Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin 
Oncol 2008; 26:1364-70 
179. Dehing-Oberije C, Aerts H, Yu S, et al. Development and validation of a prognostic model using blood 
biomarker information for prediction of survival of non-small-cell lung cancer patients treated with 
combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and 
NCT00572325). Int J Radiat Oncol Biol Phys 2011; 81:360-8 
180. Egelmeer AG, Velazquez ER, de Jong JM, et al. Development and validation of a nomogram for 
prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy 
alone: a cohort study based on 994 patients. Radiother Oncol 2011; 100:108-15 
181. van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive 
model for pathological complete response of rectal cancer patients including sequential PET-CT 
imaging. Radiother Oncol 2011; 98:126-33 
182. Marko NF, Xu Z, Gao T, et al. Predicting survival in women with breast cancer and brain metastasis: A 
nomogram outperforms current survival prediction models. Cancer 2011;  
183. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after 
breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 2010; 28:3762-9 
184. http://www.adjuvantonline.com,  
185. Hajage D, de Rycke Y, Bollet M, et al. External validation of Adjuvant! Online breast cancer prognosis 
tool. Prioritising recommendations for improvement. PLoS One 2011; 6:e27446 
186. Kuo YL, Chen DR, Chang TW. Accuracy validation of adjuvant! online in Taiwanese breast cancer 
patients - a 10-year analysis. BMC Med Inform Decis Mak 2012; 12:108 
187. http://www.predictcancer.org,  
188. Ginsburg GS, Staples J, Abernethy AP. Academic medical centers: ripe for rapid-learning personalized 
health care. Sci Transl Med 2011; 3:101cm27 
189. Deasy JO, Bentzen SM, Jackson A, et al. Improving normal tissue complication probability models: the 
need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys 2010; 76:S151-4 
190. Roelofs E, Persoon L, Qamhiyeh S, et al. Design of and technical challenges involved in a framework 
for multicentric radiotherapy treatment planning studies. Radiother Oncol 2010; 97:567-71 
191. http://www.eurocat.info,  
192. De Ruysscher D, Severin D, Barnes E, et al. First report on the patient database for the identification of 
the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II. Radiother Oncol 
2010; 97:36-9 
193. West C, Rosenstein BS, Alsner J, et al. Establishment of a Radiogenomics Consortium. Int J Radiat 
Oncol Biol Phys 2010; 76:1295-6 
194. Kessel KA, Bougatf N, Bohn C, et al. Connection of European particle therapy centers and generation 
of a common particle database system within the European ULICE-framework. Radiat Oncol 2012; 
7:115 
195. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-
generation sequencing. Nat Rev Genet 2010; 11:685-96 
196. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev 
Cancer 2003; 3:267-75 
197. Pinkel D, Albertson DG. Array comparative genomic hybridization and its applications in cancer. Nat 
Genet 2005; 37 Suppl:S11-7 
198. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354:2463-72 
      Chapter 2 
 
50
199. Lu Y, Muller M, Smith D, et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating 
AKT signaling. Oncogene 2011; 30:4567-77 
200. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-
throughput screening. Cell 2009; 138:645-59 
201. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung 
adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14:822-7 
202. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis 
and prognosis. Cancer Cell 2006; 9:189-98 
203. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid 
leukaemia. Nature 2011; 478:524-8 
204. Best T, Li D, Skol AD, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced 
second malignancies after Hodgkin's lymphoma. Nat Med 2011; 17:941-3 
205. Kerns SL, Ostrer H, Stock R, et al. Genome-wide association study to identify single nucleotide 
polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American 
men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78:1292-300 
206. de Jong MC, Pramana J, van der Wal JE, et al. CD44 expression predicts local recurrence after 
radiotherapy in larynx cancer. Clin Cancer Res 2010; 16:5329-38 
207. Kitahara O, Katagiri T, Tsunoda T, et al. Classification of sensitivity or resistance of cervical cancers to 
ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. 
Neoplasia 2002; 4:295-303 
208. Torres-Roca JF, Eschrich S, Zhao H, et al. Prediction of radiation sensitivity using a gene expression 
classifier. Cancer Res 2005; 65:7169-76 
209. Wong YF, Sahota DS, Cheung TH, et al. Gene expression pattern associated with radiotherapy 
sensitivity in cervical cancer. Cancer J 2006; 12:189-93 
210. Yang S, Chen J, Guo Y, et al. Identification of prognostic biomarkers for response to radiotherapy by 
DNA microarray in nasopharyngeal carcinoma patients. Int J Oncol 2012; 40:1590-600 
211. Starmans MH, Chu KC, Haider S, et al. The prognostic value of temporal in vitro and in vivo derived 
hypoxia gene-expression signatures in breast cancer. Radiother Oncol 2012; 102:436-43 
212. Winter SC, Buffa FM, Silva P, et al. Relation of a hypoxia metagene derived from head and neck cancer 
to prognosis of multiple cancers. Cancer Res 2007; 67:3441-9 
213. Starmans MH, Krishnapuram B, Steck H, et al. Robust prognostic value of a knowledge-based 
proliferation signature across large patient microarray studies spanning different cancer types. Br J 
Cancer 2008; 99:1884-90 
214. Koboldt DC, Ding L, Mardis ER, et al. Challenges of sequencing human genomes. Brief Bioinform 2010; 
11:484-98 
215. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and 
guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007; 99:147-57 
216. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for 
predicting outcome in cancer. Proc Natl Acad Sci U S A 2006; 103:5923-8 
217. Teo YY. Common statistical issues in genome-wide association studies: a review on power, data 
quality control, genotype calling and population structure. Curr Opin Lipidol 2008; 19:133-43 
218. Kitano H. Systems biology: a brief overview. Science 2002; 295:1662-4 
219. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010; 
464:993-8 
Predicting outcomes in radiational oncology  51 
220. van Elmpt W, Ollers M, Dingemans AM, et al. Response Assessment Using 18F-FDG PET Early in the 
Course of Radiotherapy Correlates with Survival in Advanced-Stage Non-Small Cell Lung Cancer. J Nucl 
Med 2012;  
221. Mayr NA, Huang Z, Wang JZ, et al. Characterizing Tumor Heterogeneity with Functional Imaging and 
Quantifying High-Risk Tumor Volume for Early Prediction of Treatment Outcome: Cervical Cancer as a 
Model. International Journal of Radiation Oncology*Biology*Physics 2012;  
222. Digital Agenda for Europe [cited 2012 May 1]. Available from: 
http://ec.europa.eu/information_society/digital-agenda/index_en.htm  
223. Information Society - ICT for Health - home page [cited 2012 May 1]. Available from: 
http://ec.europa.eu/information_society/activities/health/index_en.htm,  
 
 
 
      Chapter 2 
 
52
 
Response prediction with sequential PET imaging  53 
 
 
Development and external validation of a 
predictive model for pathological complete 
response of rectal cancer patients including 
sequential PETCT imaging 
Chapter 3 
Response prediction with sequential PET imaging 
 
 
 
 
 
 
 
Ruud van Stiphout, Guido Lammering, Jeroen Buijsen, Marco Janssen, Maria 
Antonietta Gambacorta, Pieter Slagmolen, Maarten Lambrecht, Domenico Rubello, 
Marcello Gava, Alessandro Giordano, Eric O. Postma, Karin Haustermans, Carlo Capirci, 
Vincenzo Valentini, Philippe Lambin 
 
Published in: Radiotherapy and Oncology 2011; 98(1):126-33  
      Chapter 3 
 
54
Abstract 
Purpose 
To develop and validate an accurate predictive model and a nomogram for pathologic 
complete response (pCR) after chemoradiotherapy (CRT) for rectal cancer based on 
clinical and sequential PETCT data. Accurate prediction could enable more 
individualized surgical approaches, including less extensive resection or even a wait-
and-see policy.   
 
Methods and materials 
Population based databases from 953 patients were collected in four different 
institutes and divided into three groups: clinical factors (training: 677 patients, 
validation: 85 patients), pre-CRT PETCT (training: 114 patients, validation: 37 patients) 
and post-CRT PETCT (training: 107 patients, validation: 55 patients). A pCR was defined 
as ypT0N0 reported by pathology after surgery. The data were analyzed using a linear 
multivariate classification model (support vector machine), and the model’s 
performance was evaluated using the area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve.  
 
Results     
The occurrence rate of pCR in the datasets was between 15% and 31%. The model 
based on clinical variables (AUCtrain=0.61 ± 0.03, AUCvalidation=0.69 ± 0.08) resulted in the 
following predictors: cT- and cN-stage, and tumor length. Addition of pre-CRT PET data 
did not result in a significantly higher performance (AUCtrain=0.68 ± 0.08, 
AUCvalidation=0.68 ± 0.10) and revealed maximal radioactive isotope uptake (SUVmax) and 
tumor location as extra predictors. The best model achieved was based on the addition 
of post-CRT PET-data (AUCtrain=0.83 ± 0.05, AUCvalidation=0.86 ± 0.05) and included the 
following predictors: tumor length, post-CRT SUVmax and relative change of SUVmax. 
This model performed significantly better than the clinical model (ptrain<.001, 
pvalidation=.056). 
 
Conclusions  
The model and the nomogram developed based on clinical and sequential PETCT data 
can accurately predict pCR, and can be used as a decision support tool for surgery after 
prospective validation. 
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Introduction 
Over the past decades, treatment outcomes for rectal cancer have changed 
dramatically. A better surgical technique, total mesorectal excision (TME), and the 
introduction of neoadjuvant treatments in locally advanced rectal cancer (LARC) have 
significantly decreased the risk of locoregional relapse.
1,2
 In the last nine years at least 
seven published phase III trials have evaluated the role of adjuvant radiotherapy in 
rectal cancer.
3
 These have provided an evidence base demonstrating the efficacy of 
both preoperative radiotherapy and preoperative concurrent chemotherapy (CRT). 
CRT has been reported to induce significant tumor downsizing and downstaging,
4-6
 
with a pathologic complete response (pCR) after CRT observed in 10% - 30% of 
patients.
2,4-8
 Although some studies showed no correlation,
9
 many others reported 
that patients showing a pCR following preoperative CRT have improved long-term 
outcomes including excellent local control rates and disease-free survival, regardless of 
their initial clinical T- and N-stages.
10-13
  
However, despite the often phenomenal downsizing and sometimes even complete 
pathological responses after CRT, these patients are still operated with a standard 
extended surgical procedure due to the lack of reliable accurate preoperative 
diagnostic tools. However, it may be questioned whether a standard resection is still 
necessary, considering the good outcome of these patients reported with less invasive 
treatments.
14,15
 If accurately selected, patients with a complete response (no residual 
tumor) may undergo a less extensive resection or even a so called ‘wait-and-see’ 
policy. Compared to standard surgery, the benefits of these treatments are reduced 
morbidity and mortality (e.g., anastomotic leakage, relaparotomy, wound and pelvic 
infection, abscess, colostomy, chronic wound healing disturbances, faecal or urinary 
incontinence and sexual dysfunction), improved quality of life and reduced treatment 
costs.  
Thus, an accurate prediction of pCR can help in the selection of patients for more 
optimized treatment, sphincter-preserving surgery, less extensive resection, more 
intense radiation treatment, or even delayed surgery with a wait-and-see policy.
2,3,16
 
These considerations led to the overall goal of this study: to develop an accurate, data-
driven model to predict pathologic complete response for rectal cancer patients as 
decision support for more individualized treatment approaches in the future. 
 
The clinical variables associated with a better response to preoperative CRT include 
circumferential tumor extent, tumor differentiation, preoperative classification, 
carcinoembryonic antigen (CEA) level, distance from anal verge, and time to 
surgery.
6,17,18
 Recently, it has also been suggested that PET imaging might be correlated 
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with tumor response after CRT in locally advanced rectal cancer. However, the studies 
involved used only a small number of patients, which meant that contradictory results 
were found. Further, only semi-quantitative PET measurements were used and 
analyzed with univariate statistics.
4,5,7,19-26
 Multivariate analysis was performed in only 
one study, whose results lacked statistical significance.
27
 Notably, no studies verified 
and validated their results with external datasets, despite the fact that this represents 
an important prerequisite for the generalizability of prediction models for other 
institutes.  
In the current study, population based data from four different institutes were 
collected and used to train and validate predictive models for pCR. We hypothesized 
that the addition of PET imaging data to clinical variables significantly increases the 
performance of prediction models for pCR after CRT as compared to models based on 
clinical data alone.    
 
The study was performed within the framework of a decision support system based on 
centralized datasets. The increasing amount of available patient information requires 
automatic methods for model building and analysis. Machine learning methods can be 
used to update the models continuously by feeding them with information of new 
patients. The increasing complexity of prediction models, too, means that the 
representation and interpretation of the results also become more important. Tools to 
enhance interpretation for the clinic include visualization techniques such as 
nomograms and graphical networks. Nomograms are statistical tools that enable users 
to calculate the overall probability of a specific clinical outcome for an individual 
patient.
28
 In this study, the nomogram with the highest accuracy for the prediction of 
pCR is provided.    
Methods and materials 
Study population 
Six population based datasets were collected in four institutes: Maastro Clinic (GROW, 
MUMC, Maastricht, the Netherlands), Università Cattolica del S.Cuore (Rome, Italy), S. 
Maria della Misericordia Hospital (Rovigo, Italy) and University Hospital Gasthuisberg 
(Leuven, Belgium). In total, 953 patients met the criteria for inclusion: long-course RT 
with neoadjuvant chemotherapy and the availability of pathological outcome for pCR. 
Of these, 276 patients underwent a pre-CRT PET scan (one week before the start of 
CRT), and 169 patients had both pre- and post-CRT PET scans (one week before 
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surgery, and six to eight weeks after the end of CRT). The sequential PET data from 
Rovigo have already been published as a prospective study,
20
 the Leuven data were 
collected prospectively for the BioCare project (LSHC-CT-2204-505785) and the rest of 
the data were gathered for a population-based study registered in the Dutch Trial 
Register (NTR2166). All compositions of the cohorts were approved by the local IRB 
committees. The patient characteristics are reported in Table 3.1. The datasets were 
divided into three groups, based on PET data availability: 1. clinical variables only, 2. 
clinical variables with pre-CRT PET variables (PET-pre), 3. clinical variables with both 
pre- and post-CRT PET variables (PET-post). For each group, a training set and an 
external validation set were defined. The training sets were used to identify the pCR 
predictors, while the validation sets were used to test the performance of the models 
in other centers. Datasets from a single center with the highest number of patients 
were used for training. A dataset was deemed not useful for external validation if it 
originated from the same center as the corresponding training set. The definition of 
the different combined training and validation sets is explained in Table 3.2, based on 
the datasets in Table 3.1.  
 
The available clinical variables were age, gender (0: female, 1: male), clinical tumor (cT) 
and nodal (cN) stage, and two variables based on MRI (or endoscopy if MRI was 
unavailable): tumor location categorized in three levels (1: low, 0–5 cm from anal 
verge; 2: mid, 5–10 cm from anal verge; 3: high, >10 cm from anal verge) and tumor 
length (cm). For the patients who had PETCT scans, the tumors were semi-
automatically contoured at Maastro Clinic using dedicated software (TrueD, Siemens 
Medical, Erlangen, Germany). Standardized uptake-value (SUV) thresholding was 
based on the tumor-to-background signal ratio, with the gluteus muscle as reference 
background.
29,30
 From the resulting tumor contour, maximal tumor diameter (MaxD), 
gross tumor volume (GTV), and maximal and mean SUV values within the GTV were 
calculated. If the post-CRT PETCT scan was available, the same variables were scored, 
and a response index (RI) for each variable was calculated. For variable X, the response 
index is the relative percent difference between the value of the post-CRT and pre-CRT 
and it was defined as RI = (Xpre –Xpost) / Xpre x100%. Thus, six variables were evaluated 
for the clinical dataset, 10 for the PET-pre dataset and 18 for the PET-post dataset. 
From these sets, the models selected subgroups of variables with significant predictive 
value for pCR.      
 
All patients underwent surgery. Pathological complete response was defined as 
ypT0N0, extracted from the pathologic reports of surgical specimens. All other cases 
(ypT+ and/or ypN+) were considered non-responders, making the pCR a binary 
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outcome (0/1). The specimens were not re-evaluated centrally but the pathology 
protocols were very similar between institutes (3-5 mm slices of rectum tumor, 
intensified evaluation on several blocks of tissue at the tumor site, evaluation on 2-3 
sublevels when no tumor tissue was found in initial block).  
 
 
Table 3.1 Patient characteristics for six datasets from four different institutes. Clinical, PET-pre and PET-post 
groups are defined. Percentages of the total patient numbers are given for binary or ordinal variables. Mean 
and standard deviation (SD) are given for continuous variables. x denotes missing values. RT = Radiotherapy, 
PF = per fraction. 
Center Maastricht Rome Rovigo Leuven 
Dataset M1 M2 R1 R2 C1 L1 
Period 2004–2006 2004–2006 1984–2008 2007–2008 2003–2007 2005–2007 
# Patients 114 21 677 18 107 16 
Clinical  Validation - Training - - - 
PET-pre Training - - Validation - Validation 
PET-post - Validation - Validation Training Validation 
Gender (%)       
Male 63 67 63 83 74 81 
Female 37 33 37 17 26 19 
Age (years)       
Mean 65.6 66.1 61.3 60.4 66.3 58.6 
SD 10.0 10.6 10.2 7.1 10.8 10.1 
cT-stage (%)       
1 0 0 0 0 0 0 
2 1 0 3 11 0 0 
3 68 81 86 56 90 94 
4 30 14 11 33 10 6 
x 1 5 0 0 0 0 
cN-stage (%)       
0 25 38 23 17 51 0 
1 48 48 45 33 38 62 
2 26 10 30 50 10 38 
x 1 4 2 0 1 0 
cM-stage (%)       
0  73 71 100 94 100 100 
1 25 19 0 6 0 0 
x 2 10 0 0 0 0 
ypT0N0 (%)       
No 85 81 80 78 76 69 
Yes 15 19 20 22 24 31 
RT dose       
Mean 50.4 50.4 49.0 52.7 55.7 45.7 
SD 0 0 5.5 3.3 3.1 1.8 
RT dose PF        
(Gy) 1.8 1.8 1.8 1.8 2.2 1.8 
Chemo Types       
(number) 1 1 11 2 1 1 
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Statistical analysis 
Missing values in the dataset were substituted by the mean.
31
 This method performed 
similarly to other, more complex substitution methods for small percentages of 
missing values (e.g., expectation-maximization imputation, regression estimation). No 
variables in the datasets exceeded 5% of missing values. Patients who missed tumor 
location and length in the clinical datasets (Roma: n = 132 and Maastricht: n = 29) were 
excluded because of too large amounts of missing data for these variables. All patient 
numbers stated in this paper were extracted after the missing value procedure. To 
compare the weights of significance assigned to the variables by the model, all 
variables were normalized by subtracting the mean, and then divided by the standard 
deviation.   
 
To classify the complete responders and non-responders, a linear multivariate method 
suitable for binary classification from the machine learning field was used: the support 
vector machine (SVM).
32
 The SVM variant used (proximal SVM or pSVM) performs 
equally accurately but much faster than normal support vector machines.
33
 The 
different datasets’ performances in predicting pCR were evaluated by analyzing the 
area under the curve (AUC) of the receiver operating characteristic (ROC) curve.
34
 The 
maximum value of the AUC is 1.0, indicating a perfect prediction model; a value of 0.5 
indicates a random chance of correct prediction.          
To select the variables that contribute to pCR prediction, an exhaustive feature search 
was performed, with all possible variable combinations used as input for the pSVM 
model. The set of variables resulting in the highest AUC was selected as the final 
predictive set. To avoid over-fitting of the model through selection of the highest AUC, 
the variable sets resulting in AUCs that deviated less than 5% from the maximal AUC 
were compared to the final variable set. If conflicts occurred or if variables did not 
contribute significantly, selected variables were interchanged by considering their 
prevalence in the highly predictive sets, the factor analysis and the Spearman 
correlation coefficient (i.e., highly correlated and dependent variables are not present 
in the same predictive set). Furthermore, an extra univariate analysis was performed 
using the Wilcoxon rank sum test. 
 
Classification methods normally require at least several hundred cases. Because of the 
relatively small number of available patients, two extra evaluation methods were used. 
The first was leave-one-out (LOO) cross-validation, used to calculate an AUC for the 
training set. In LOO cross-validation, a single patient is selected from the original 
training dataset and used as the validation dataset, while the data from the remaining 
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patients are used to train the model. This is repeated until all patients have been 
selected once for validation. However, no LOO cross-validation was used for the 
external dataset. The second evaluation method was bootstrapping, which results in a 
more accurate approximation of the real dataset distribution.
35
 This means that 1000 
datasets are generated from the original dataset containing n patients by selecting 
these n patients, but with resampling (i.e., patients can be present in the dataset more 
than once). For every bootstrapped dataset, an AUC was calculated. The mean AUC 
with the corresponding standard deviation was then calculated with size 1000. This 
non-parametric method allows comparison of the confidence intervals of the AUCs of 
different datasets without making assumptions about the AUC distributions.
36
 The 
distribution of the difference in mean AUC (AUC) between the datasets was tested by 
calculating the two-sided p-value, i.e., the fraction of AUC samples smaller or larger 
than zero (depending on the dominant sign of AUC).  
 
Nomograms can reduce statistical predictive models to a single numerical estimate of 
the probability of an event, and visualize the effect of each selected variable on this 
probability.
37
 The model output of the pSVM models consists of assigned weights for 
each variable and an offset. The probability of a patient having a pCR can be calculated 
using logistic regression on the pSVM output.
38
 The complete procedure to convert 
SVM output to a nomogram is described in detail elsewhere.
39
 Developing a 
nomogram requires threshold selection in the ROC curve. For response prediction 
specificity is most important, because it is not preferred to predict non-responders as 
responders, which would result in under-treatment. Therefore, the threshold was 
selected in such a way that at least 90% of non-responders were correctly predicted. 
Partial ROC curve optimization has been tested but it had no gain for specificity 
compared to overall AUC maximization.
40
 Calibration of the nomogram, i.e., the 
agreement between predicted probability of complete response and true probability in 
the population, was performed by an assessment of the overall agreement and the 
Hosmer-Lemeshow statistic in four subgroups of patients in the validation data. The 
nomogram algorithm was implemented in MATLAB (version 7.1, MathWorks Inc., 
Natick, MA), as were all algorithms described in this section. 
Results 
The occurrence of pCR in the patient population varied between 15% and 31% (mean: 
21.8%, SD: 5.4%) depending on the dataset (Table 3.1). A first evaluation of CRT’s 
effect on the tumor demonstrated significant downsizing of the tumor in the PETCT, 
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and a significant decrease in metabolic activity within the tumor (Figure 3.1). Both 
gross tumor volume and maximal SUV decreased significantly between the pre- and 
post-CRT PETCT scans (p<.001).  
 
Table 3.2 shows the predictor selection results and the ROC curve analysis. For the 
clinical dataset, the univariate analysis reveals three variables significantly associated 
with pCR (95% confidence interval): tumor length (p<.001), cN-stage (p=.001), and cT-
Figure 3.1 (A) Tumour contour in a fused FDG-PETCT made pre-CRT. (B) Corresponding post-CRT FDG-PETCT 
scan with tumour contour. (C) Boxplot of SUVmax on PET-scans made pre-CRT and post-CRT; significant 
decrease: p<.001 (D) Boxplot of the GTV for the case of pre-CRT and post-CRT; significant decrease: p<.001. 
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stage (p=.001). These variables were also selected in the multivariate analysis. The 
normalized weights assigned to them by the pSVM model are tumor length (-0.085), 
cT-stage (-0.074), and cN-stage (-0.060). The selected variables were ranked in 
importance (i.e., weights). The sign of the weights can be interpreted by the effect on 
the probability of a pCR. For a negative sign, this probability decreases when the 
variable increases. For the clinical dataset, this means that the probability of a pCR 
increases for small tumor lengths and low cT- and cN-stages. The predictive 
performance of the clinical dataset for pCR, expressed by the AUC of the ROC curve, is 
0.61 ± 0.03 (mean ± SD) for the training set and 0.69 ± 0.08 for the external validation 
set.     
 
Table 3.2 Predictor selection and ROC analysis. Predictive variables are given with their corresponding 
assigned normalized weights from multivariate analysis (MVA). For each variable the p-value from univariate 
analysis (UVA) is given. Mean AUC and standard deviation (SD) are given for each variable set. RI = response 
index, SUV = standard uptake value, MaxD = maximal diameter (PETCT).  
Variable set 
 
Type Size Predictors (MVA) Weights 
(MVA) 
p-value 
(UVA) 
AUC SD 
Clinical 
 
  
  
  
Training 
(R1) 
677 Tumor length -0.085 <.001 0.61 0.03 
cT-stage -0.074 .001 
cN-stage -0.060 .001 
Validation 
(M1) 
85 - - - 0.69 0.08 
Clinical +  
PET-pre 
  
  
  
Training 
(M1) 
114 MaxDpre -0.12 .003 0.68 0.08 
cN-stage -0.12 .001 
Tumor location 0.094 .84 
SUVmax-pre -0.087 .29 
Validation 
(R2, L1) 
34 - - - 0.68 0.10 
Clinical +  
PET-pre + 
PET-post 
Training 
(C) 
107 RISUVmax 0.20 <.001 0.83 0.05 
Tumor length -0.20 <.001 
SUVmax-post -0.14 <.001 
Validation 
(M2, R2, L1) 
55 - - - 0.86 0.05 
 
For the dataset with pre-CRT PET data, the multivariate analysis selected these 
variables (ranked by weight): maximal diameter (-0.12), cN-stage (-0.12), tumor 
location (0.094), and SUVmax (-0.087). This resulted in a high probability of pCR for 
patients with small maximal tumor diameters, low cN-stage, high tumor locations, and 
small maximal metabolic activity. Maximal diameter (p=.003) and cN-stage (p=.001) 
were selected by univariate analysis, while the other two variables were not.  
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The AUCs for the training and validation set were both 0.68, but the SD differed (0.08 
and 0.10 respectively). The dataset including the post-CRT PET data resulted in the 
highest performance: AUCtrain = 0.83 ± 0.05 and AUCvalidation = 0.86 ± 0.05. The response 
index for SUVmax (0.20), tumor length (-0.20), and the post-CRT SUVmax were found to 
be predictive for pCR and significantly associated with pCR in the univariate analysis 
(p<.001).  
 
Figure 3.2 ROC curves of training and validation datasets for the clinical set (A), the PET pre-CRT set (C) and 
the PET post-CRT set (D). The straight dashed line represents a random prediction model. The bar plot (B) 
shows the corresponding mean AUC for each dataset and the standard deviation (error bars). There was a 
significant difference with clinical datasets of (*) p<.05 and (#) p<.06.    
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In evaluating the predictive value of the additional PET data to the clinical data, only 
the AUCs of the post-CRT PET data differed significantly from the clinical dataset AUC 
(Figure 3.2). The p-value for the AUC difference for the training set was <0.001, while 
that for the validation sets was 0.056 (just outside the 95% confidence interval). When 
only post-CRT PET data were used for the models (i.e., no clinical variables), the 
significant difference between the AUCs and the clinical dataset was no longer 
observed (training: p=.47, validation: p=.58). This indicated that a combination of both 
clinical and PET data was required to reach a significantly higher performance when 
using PET as a predictive imaging modality.      
 
 
 
The assigned weights for all the predictors formed the basis for the construction of the 
nomogram. The nomogram based on the post-CRT dataset is provided in Figure 3.3. 
The nomogram performs with a sensitivity of 0.62 and a specificity of 0.88 for the 
validation data. In the training phase these were respectively 0.65 and 0.90. The 
calibration of the nomogram (Figure 3.4) with the validation data reveals that the 
overall predicted and the actual probability are equal (23.6%, OR=1.0). If the validation 
data are divided into four equally numbered groups, the Hosmer-Lemeshow test 
results in a p-value of 0.78, which means a good calibration in this test (p>.05). The 
Figure 3.3 Nomogram for PET post-CRT dataset. A score for each predictor can be read out at the top scale 
(Score). All summed scores (Sum of scores scale) can be converted directly to the probability of responding 
with a pCR (ypT0N0). The probability scale is the only logarithmic scale.     
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linear fit through these probabilities results in a slope of 1.02 with R
2
 of 0.99, 
confirming a good balance between calibration and discrimination.  
 
 
Discussion 
We have developed predictive models based on clinical and PET-based data for 
pathologic complete response in patients diagnosed with rectal cancer. The 
performance of these models was externally validated using patient cohorts from 
different institutes treated with long-course preoperative chemoradiotherapy. The 
models showed that the accuracy of the predictions increased over time, i.e., when 
more information became available. Information from PETCT scans significantly 
improved the performance of the models.  
 
The significant difference in AUCs that we reported between the performance of the 
clinical model and the post-CRT PET data model reflects what others have found in 
Figure 3.4 Calibration of the nomogram for the validation data. For the four equally numbered subgroups 
(vertical lined intervals in figure), the predicted probability of a pCR and the actual fraction in the population 
were evaluated. The dashed line represents perfect calibration and the solid line is the linear fit of the 
calibration data. Pa: actual probability, Pp: predicted probability, R
2: coefficient of determination 
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their post-treatment PET analyses; like us, some have reported (significant) indications 
that the response index and post-treatment SUVmax are predictive for response, while 
the pre-treatment PET data do not provide enough predictive power.
12,19,27
 However, 
our PET-based models also contain clinical variables, which appeared to be necessary 
to obtain the high performance provided in Table 3.2. The most important clinical 
variables were tumor length and maximal diameter, which were selected in the models 
and are significantly correlated (spearman  = 0.55, p<.001). Overall, this means that 
the dominant tumor dimension in combination with (differences in) the maximal 
metabolic activity inside the tumor is the most predictive variable set for pCR, which 
was confirmed in the external datasets.  
Whether the corresponding AUC of 0.86 is accurate enough for clinical practice 
depends on the choice of the threshold in the ROC curve. A high specificity is preferred 
over a high sensitivity to avoid possible under-treatment (less surgery when surgery is 
required) rather than over-treatment (standard treatment when less surgery could 
have been considered). The provided nomogram focuses on specificity (training: 0.90, 
validation 0.88). Selecting higher specificities results in fast decreasing sensitivities. 
Careful follow-up is therefore necessary for the patients selected for a ‘wait-and-see’ 
policy to detect any possible local recurrences early on. To gain more specificity in the 
future, the addition of new variables and the other classification methods would have 
to be considered.  
 
The nomogram performs well, i.e., the distribution of the probability of a pCR provided 
by the nomogram represents the true distribution in the data, confirmed by overall 
calibration, calibration of the slope and Hosmer-Lemeshow test (Figure 3.4). Because 
of the number of events and the division of the patient cohorts into few probability 
intervals, the higher probabilities occur much less frequently and are thus the least 
accurate. Therefore, prospective validation of the model and the nomogram is 
required to ensure sufficient statistical power for clinical application of the models. 
Besides the number of patients to increase the models’ accuracy, more predictors 
could be added to increase the models’ performance, including biological variables 
such as gene signatures
41
 and blood biomarkers, and also more imaging variables from 
(perfusion) CT and (diffusion) MRI. The first indications have also appeared that PETCT 
data during CRT may be highly predictive for response.
25,26,42
 This time point is more 
favorable than post-CRT because of the possibility of earlier treatment changes and 
the decreased presence of inflammatory rectum cases, potentially causing impaired 
evaluation of fused PETCT scans. After prospective validation of the model, an 
intervention trial with less surgery for patients with a high probability for pCR will be 
performed.         
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The population based collected datasets date back five years, except for the clinical 
Roma database, which was collected from 1984 onward. Therefore, this dataset shows 
a higher variety in treatment schemes than the other datasets. This could explain the 
discrepancy of the higher prediction performance of the clinical validation set. On the 
other hand, the validation set is much smaller, implying that the distribution of data 
could not be representative of the true distribution. The consequence of population 
based data collection is that treatment protocols are not well tuned. This results in, for 
example, small differences in irradiation schemes and deviations in the evaluation of 
pathology outcome. Ideally, pathology is reviewed centrally to reduce the intra- and 
inter-observer variabilities for the outcome measure. However, in this study the 
quality of pathology is acceptable because of the prospective nature of most datasets 
and because the outcome was limited to only complete response evaluation. Also, 
glucose correction for SUV values was not applied to all datasets. However, minor 
variation in treatment schemes can be seen as an advantage because it leads to higher 
generalizability for other centers. In other words, the model still performs well, despite 
the disparities mentioned here.  
  
In conclusion, we have shown that sequential PETCT data in combination with clinical 
variables significantly increase the performance of prediction models for pathologic 
complete response. So far, this is the largest study of its kind and the only one that 
used external datasets for validation. The dominant tumor dimension and the maximal 
uptake of radioactive isotopes in the tumor as well as its relative difference between 
PET scans were found to be the best predictors for pCR resulting in very good overall 
performance AUC’s of 0.83 and 0.86 for training and validation, respectively. Including 
also biological and other imaging variables will probably further improve the 
performance. When prospectively validated, the model and the nomogram therefore 
provide a valuable decision support for more individualized treatment approaches in 
the future.  
  
Note: The predictive models in this paper are published on the website 
http://www.predictcancer.org 
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Abstract 
Purpose 
To develop and externally validate a predictive model for pathologic complete 
response (pCR) for locally advanced rectal cancer (LARC) based on clinical and early 
sequential 
18
F-FDG PETCT imaging.    
 
Methods and materials 
Prospective data (including the THUNDER trial) was used to train (N=112, Maastro 
clinic) and validate (N=78, Gemelli Hospital) the model for pCR (ypT0N0). All patients 
received long-term chemoradiotherapy (CRT) and surgery. Clinical parameters were 
age, gender, clinical tumor (cT) stage and clinical nodal (cN) stage. PET parameters 
were SUVmax, SUVmean, metabolic tumor volume (MTV) and maximal tumor diameter, 
for which response indices between pre-treatment and intermediate scan were 
calculated. Using multivariate logistic regression, three probability groups for pCR were 
defined.   
 
Results  
The pCR rates were 21.4% (training) and 23.1% (validation). The selected predictive 
features for pCR were cT-stage, cN-stage, response index of SUVmean and maximal 
tumor diameter during treatment. The models’ performances (AUC) were 0.78 
(training) and 0.70 (validation). The high probability group for pCR resulted in 100% 
correct predictions for training and 67% for validation.   
 
Conclusions 
The developed predictive model for pCR is accurate and externally validated. This 
model may assist in treatment decisions during CRT to select complete responders for 
a wait-and-see policy, good responders for extra RT boost and bad responders for 
additional chemotherapy. 
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Introduction 
An early prediction of pathologic complete response (pCR) for a locally advanced rectal 
cancer (LARC) patient is valuable because it allows for individualized treatment 
reorientation.
1,2
 The standard treatment for LARC patients is preoperative 
chemoradiotherapy (CRT) followed by surgery. The neo-adjuvant treatment, intended 
to control pelvic disease and improve the chance of sphincter preservation, results in a 
pathological complete response (pCR) in 15-30% of the patients.
3,4
 For these complete 
responders a wait-and-see policy after CRT is a possibility in order to reduce 
treatment-related morbidity and mortality, for which excellent results are reported.
5
 
This decision requires however a very accurate prediction and assessment of complete 
response. Other treatment options under consideration are a radiotherapy boost after 
CRT for good responding patients to achieve more pCRs
6
 and additional chemotherapy 
administration after CRT for the worst responding patients.
7
 Both these options 
require an early assessment of response even during CRT. Currently the leading 
candidate predictive marker for histopathological response prediction in LARC is 
18
F-
fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging. A meta-
analysis from 2012 confirmed the added value of PET imaging, especially for 
intermediate PET imaging (during CRT).
8
 However, most studies evaluated pre-CRT 
versus post-CRT PET imaging. Besides that an early prediction is preferred for 
treatment reorientation, later predictions may also be affected by CRT-induced 
inflammatory tissue, which presents tumor equivalent signal on FDG-PET scans.
9
 This 
recognition resulted in more early response assessment studies in the last few years 
(Table 4.1). The limitations of these studies were their small sample sizes (N=20-42), 
the main focus on good versus bad responders (not pCR), the univariate setting in 
which analyses were performed and the lack of validation. To increase the clinical 
applicability of these decision making tools, they need to be based on more evidence 
(i.e. larger number of patients and external validation), be trained on several data 
sources
10
 and they require focus on outcomes that are more relevant in terms of 
decisions, like pCR for a possible wait-and-see policy. We hypothesize that models with 
these requirements are the most suitable for decision making in clinical practice. The 
aim of this study is therefore to develop an externally validated multivariate predictive 
model for pCR combining clinical, pre-treatment and intermediate FDG-PETCT imaging 
parameters based on a prospective study. After development of a nomogram and the 
evaluation of its accuracy, risk group definition based on these predictions may 
provide decision support to clinicians for LARC patients (Figure 4.1). 
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Methods and materials 
Study population 
All data were prospectively collected (with written informed consent) between January 
2007 and March 2012 within two institutes: Maastro Clinic (GROW, MUMC, 
Maastricht, the Netherlands) and Università Cattolica del S.Cuore (Rome, Italy). The 
following prospective observational studies were involved: a study (2007-2009) 
involving 47 patients from Maastricht,
11,12
 a pilot study (2007-2009) with 19 patients 
from Rome and a multicentre study (2009-2012) involving one protocol for both 
institutes (Maastro: 65 patients, Rome: 59 patients) with acronym THUNDER 
(THeragnostic Utilities for Neoplastic DisEases of the Rectum, NCT00969657). All 
patients from Maastricht were pooled and used to train a prediction model for pCR 
(N=112). The pooled datasets from Rome were used for external validation of the 
model (N=78). The study inclusion criteria were: histological proven rectal cancer 
(primary tumors), UICC stage I-III, no recurrences, only concurrent chemoradiotherapy 
treatment, minimal age of 18 years, and no previous radiotherapy to the pelvis. The 
Figure 4.1 Schematic overview of prediction model development (top) and the proposed application of the 
model in clinical practice after it has been tested in a clinical trial with a control arm (bottom). 
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available clinical variables used as candidate prognostic and predictive factors were 
age, gender, clinical tumor (cT) and nodal (cN) stage. The criteria followed to consider 
tumor nodal involvement at MRI were related to border contour (sharply demarcated 
or irregular border) and signal intensity characteristics (homogeneous or 
inhomogeneous) or size >8 mm.
13,14
 All patients from Maastricht were treated 
preoperatively with radiotherapy (28 fractions of 1.8 Gy, 5 fractions/week) and 
concomitant chemotherapy (capecitabine, 825 mg/m2, twice daily), followed by a total 
mesorectal excision 6-8 weeks after the end of CRT. A minority of the thunder patients 
(N=11) with a clinical complete response (assessed using post-CRT MRI and endoscopy) 
were enrolled in a parallel study where a surgical wait-and-see policy was applied.
5
 
Some patients from Rome were also treated with 50.4Gy schedule, but 78.2% of the 
patients were treated with 25x1.8Gy schedule and a RT boost of 10Gy. The majority of 
the Rome patients (N=62) received a combination of capecitabine (1300 mg/m2 daily) 
and oxaliplatin (60 mg/m
2
 once a week for 5 weeks with 55.0Gy RT or 130 mg/m
2
 at 3 
time points with 50.4Gy RT), and the others capecitabine only (1650 mg/m
2
 daily with 
50.4Gy RT or 1300 mg/m
2
 daily with 55 Gy RT, N=14) or raltitrexed (3 mg/m
2 
at 3 time 
points, N=2). 
PETCT imaging 
All patients underwent a pre-CRT PET scan (one week before the start of CRT) and an 
intermediate PET scan (two weeks after the start of CRT). All Maastricht PETCT scans 
were performed by use of a dedicated Siemens Biograph 40 TruePoint PETCT simulator 
(Siemens Medical, Erlangen, Germany). Rome scans were performed with a 3D GEMINI 
GXL PETCT scanner with 16 channels CT (Philips Healthcare, Cleveland, OH). The PET 
acquisition settings were reported before and were calibrated for both institutes.
12
 
PET-based semi-automatically tumor contours were made by one observer using 
dedicated software (TrueD, Siemens Medical, Erlangen, Germany). Contours were 
defined by a threshold for the standardized uptake-value (SUV) based on the tumor-to-
background signal ratio, with the gluteus muscle as reference background.
15,16
 From 
the resulting tumor contour, maximal tumor diameter (MaxDiam), metabolic tumor 
volume (MTV), and maximal and mean SUV values within the MTV were calculated. 
SUV measures were corrected for blood glucose level.
17
 The same variables were 
scored for the intermediate CRT PETCT scan and for each variable a response index (RI) 
was calculated. The RI is the relative difference between the value of the intermediate 
scan and pre-CRT scan and defined as (Xpre – Xintermediate) / Xpre x100%.  
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Pathological assessment 
Pathological complete response was defined as ypT0N0, extracted from the pathologic 
reports of surgical specimens. All other cases (ypT+ and/or ypN+) were considered 
non-responders. The specimens were not re-evaluated centrally but the pathology 
protocols were very similar between institutes (3-5 mm slices of rectum tumor, 
intensified evaluation on several blocks of tissue at the tumor site, evaluation on 2-3 
sublevels when no tumor tissue was found in initial block).  For the 11 wait-and-see 
patients, a pCR was assigned if the patient was locally recurrence free after 12 months 
of follow-up.   
Statistical analysis 
All statistical analyses were implemented and performed in MATLAB (version 7.1, 
MathWorks Inc., Natick, MA). Any missing values (Maastricht: 1.1%, Rome: 1.9%) in the 
datasets were substituted using the Expectation-Maximization method.
18
 Datasets 
were pooled per institute on an individual patient level. Wilcoxon rank-sum tests were 
performed to test for association between a single variable and pCR. In the 
multivariate setting, logistic regression was applied to classify complete responders 
and non-responders, using the significant predictors from the univariate analysis as 
inputs. In the case of two very highly correlated input variables, only one was selected 
(using Spearman’s correlation matrix, p<.05). The model’s accuracy was evaluated with 
the area under the curve (AUC) of the receiver operating characteristic (ROC) curve.
19
 
The maximum value of the AUC is 1.0, indicating a perfect prediction model while a 
value of 0.5 indicates a random chance of correct prediction. Predictors were only 
selected if their addition resulted in a sufficient AUC change (>.01). For the final 
accuracy assessment, a bootstrapping scheme was applied (sampling with 
replacement, N=1000), resulting in 95% confidence intervals for AUC. A nomogram 
was generated to represent a visualization of the final predictive model in which three 
risk groups were defined by applying two thresholds for the estimated probability for 
pCR. To define the low probability group for pCR, first the (weighted) average rate of 
non-responders (TRG3-4) was calculated from literature and thereafter a threshold 
was selected that resulted in this percentage of non-responders.
12,20-24
 The threshold 
for the high estimated probability of pCR was calculated using decision curve 
analysis.
25
 This method optimizes the threshold by calculating the net benefit of 
applying such a model and comparing it to the situations in which none or all patients 
are treated with a wait-and-see policy.    
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Table 4.2 Patient characteristics of the training dataset (Maastricht) and the validation dataset (Rome). 
 
 
Maastricht Rome 
 N [%] N [%] 
Clinical Sex     
Female 2
9 
[25.9] 2
8 
[35.9] 
Male 8
3 
[74.1] 5
0 
[64.1] 
Age (years) 
    Median 65.0 66.3 
Range 44.0 – 81.1 27.0 - 82.7 
Clinical tumor stage 
    2  1
7 
[15.2] 5 [6.4] 
3 8
6 
[76.8] 4
9 
[62.8] 
4 9 [8.0] 2
4 
[30.8] 
Clinical nodal stage 
    0 1
5 
[13.4] 4 [5.1] 
+ 9
7 
[86.6] 7
4 
[94.9] 
PET imaging Time between PET scans (days) 
    Mean 21.9 28.5 
Standard deviation ± 2.5 ± 10.5 
Time 1st PET injection to acquisition (minutes) 
    Mean 82.6 80.2 
Standard deviation ± 18.1 ± 21.3 
Time 2nd PET injection to acquisition (minutes) 
    Mean 69.2 81.9 
Standard deviation ± 15.2 ± 23.0 
Treatment Total radiotherapy dose (Gy) 
    <50.4 5 [4.5] 2 [2.6] 
50.4 1
0
7 
[95.5] 1
5 
[19.2] 
55.0  [0.0] 6
1 
[78.2] 
Time last RT fraction to surgery (days) 
    Mean 73.6 72.9 
Standard deviation ± 18.8 ± 13.2 
Outcome 
 
Pathologic complete response 
    yes 2
4 
[21.4] 1
8 
[23.1] 
no 
 
 
8
8 
[78.6] 6
0 
[76.9] 
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Results 
Dataset characterization 
Pooling the clinical and PETCT imaging data per institute resulted in similar cohort 
characteristics (Table 4.2). The validation dataset from Rome had in general: less males 
(64.1% vs 74.1%, p=.187), higher clinical tumor stages (cT4: 30.8% vs 8.0%, p<.001), and 
more nodal involvement (94.9% vs 86.6%, p=.10). Almost all Maastricht patients 
received 50.4Gy of RT (95.5%) while the majority of the Rome patients received 55.0Gy 
(78.2%). There was also a small but non-significant difference in the number of 
pathologic complete responders (23.1% vs 21.4%, p=.927). The average time from last 
RT fraction to surgery was equal (73.6 ± 18.8 vs 72.9 ± 13.2 days, mean ± SD). Despite 
harmonization of the PET protocols in the THUNDER study, the time between the PET 
scans was on average lower for the Maastricht dataset (21.9 ± 2.5 vs 28.5 ± 10.5 days). 
Also the time between tracer injection and PET acquisition showed was lower for the 
intermediate PET scan in Maastricht (69.5 ± 15.2 vs 81.9 ± 23.0 minutes).    
Predictor selection 
Univariate analyses (Table 4.3) showed that age, pre-treatment SUV measures, 
intermediate SUVmean, and response index for maximal diameter have no significant 
predictive value for pCR (=.05). Negatively correlated significant predictors (i.e. 
increasing value results in lower pCR rate) were cT-stage, cN-stage, pre-treatment and 
intermediate metabolic tumor volume (MTV) and maximal diameter, and intermediate 
SUVmax. Positively correlated significant predictors (i.e. increasing value results in 
higher pCR rate) were the response indices for SUVmean, SUVmax and MTV. Female 
gender was also found to be significantly associated with high pCR rate.    
In multivariate logistic modeling only cT-stage was found significant in the total group 
of input predictors (p=.027*). However, highly correlated input variables increase p-
values in a multivariate setting (Figure 4.2). The following decisions were made based 
on the analyses to select the final set of predictors: 
 Gender was excluded: non-significant p-value and no other correlations with 
inputs 
 cN-stage was included: significance near decision boundary (p=.056) 
 The MTV measures were excluded: many outliers were detected (pre-
treatment: N=11 with MTV differences up to 4 times the average volume, 
intermediate: N=12 with MTV differences up to 10 times the average volume). 
These measures also didn’t have an added predictive value to the final 
selection.  
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 RI of SUVmean was included at the expense of RI of SUVmax: literature reported 
sufficient evidence for both of them (Table 4.1). However, these measures are 
highly correlated (Figure 4.2). Univariate RI of SUVmean had highest 
discriminative ability (p=.022* vs p=.030*) and was therefore selected.  
 From the other predictors, pre-treatment and intermediate maximal diameter 
and intermediate SUVmax, only intermediate maximal diameter was selected 
because it showed an AUC increase >0.02 when added to the final set (and 
significance < 0.1).    
Hence, the final selected predictors in the multivariate model were cT-stage (p=.007*), 
cN-stage (p=.032*), intermediate maximal diameter (p=.078) and RI of SUVmean 
(p=.025*).  
 
 
Figure 4.2 Spearman correlation matrix to identify significant (boxed + inner circle) correlations between 
model input variables. Red indicates positive correlation, blue indicates negative correlation.   
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Table 4.3 Prediction results. For each variable, the distributions are compared between training and 
validation dataset and a univariate analysis is performed (training set only). Multivariate analysis including 
feature selection are included.    
      Univariate  Multivariate Predictor selection 
    p pCR ↑  OR [95% CI]    p    OR [95% CI]   p 
Gender .048* Female  0.65 [0.19-2.23] .495    
Age .523 -        
cT-stage .002* ↓  0.20 [0.05-0.83] .027* 0.19 [0.06-0.64] .007* 
cN-stage .001* ↓  0.21 [0.04-1.04] .056 0.23 [0.06-0.88] .032* 
SUVmean0 .747 -        
SUVmax0 .617 -        
MTV0 .002* ↓  1.08 [1.00-1.17] .061    
MaxDiam0 .004* ↓  0.90 [0.42-1.90] .778    
SUVmean15 .067 -        
SUVmax15 .030* ↓  0.96 [0.83-1.10] .545    
MTV15 <.001* ↓  0.82 [0.67-1.02] .072    
MaxDiam15 .005* ↓  0.95 [0.58-1.56] .849 0.74 [0.53-1.03] .078 
RI_SUVmean .022* ↑  1.01 [0.90-1.13] .893 1.04 [1.00-1.07] .025* 
RI_SUVmax .030* ↑  1.01 [0.91-1.13] .839    
RI_MTV .017* ↑  0.99 [0.96-1.03] .757    
RI_MaxDiam .544 -        
 
Validation of the nomogram 
The multivariate model with the four selected predictors to estimate the probability of 
a pCR was visually represented by a nomogram (Figure 4.3A). Bootstrapped AUCs were 
0.78 (95% CI: 0.65-0.89) for the training dataset and 0.70 (95% CI: 0.55-0.84) for the 
validation dataset. With the aim of estimating three probability groups for pCR, two 
probability thresholds were defined to separate these groups. The 12.8% threshold 
(<12.8% low probability on pCR, >12.8% medium probability of pCR) was defined based 
on literature in which on average 49.2% of the patients are non-responders (weighted 
for number of patients). The other threshold was calculated at 53% based on decision 
curve analysis where the optimal net benefit of applying a wait-and-see policy was 
maximized (Figure 4.4). These three probability groups (low, medium, high) resulted in 
significantly increasing pCR rates (training data: respectively 7.3%, 21.3%, 100% pCR; 
validation data: 13.0%, 30.8% and 66.7% pCR). The highest probability groups 
contained 8.9% (training) and 7.7% (validation) of the total number of patients, while 
the lowest probability groups contained respectively 49.1% and 59.0% (Figure 4.3B).     
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Figure 4.3 (A) Nomogram of pathologic complete response based on the multivariate analysis. Three 
probability groups are defined and pCR rates of those groups are plotted. (B) Actual pCR rates in the training 
and validation set plotted for three probability groups from the model, which are defined by low: P <= 
12.8%, medium: 12.8% < P < 53%, high: P >= 53%. Relative number of patients in the group (%) is shown 
above the bars.  
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Discussion 
In this study a multivariate nomogram with clinical parameters and early sequential 
PETCT imaging markers predicting pCR in LARC was developed based on a large 
prospective study and validated prospectively within another institute. Good 
performances were measured for both training and validation dataset. After risk group 
identification a subgroup of just below 10% of the patients with high estimated 
probability for complete response was identified.       
Model predictors 
The selected predictive factors for pCR were cT-stage, cN-stage, SUVmean and 
intermediate maximal tumor diameter. A recent large analysis of 3105 patients found 
that cT-stage was predictive for pCR (p<.0001) but that cN-stage shows only a trend 
(p=.10).
4
 This study contained however also old cases where CT was used for cN-stage 
scoring. Another analysis of 677 patients associated both cT-stage (p<.001) and cN-
stage (p<.001) with pCR.
10
 The same study also found that pre-treatment (metabolic) 
tumor size was predictive (p=.003), but others show that only changes in metabolic 
volume in the pre-post treatment setting were significant for pCR and not the 
intermediate case (p=.010).
26
 In the presented study’s univariate analysis, it is clear 
that tumor size is important for pCR. The change in SUVmean at the intermediate time 
Figure 4.4 Clinical usefulness assessment for the model to determine the optimal threshold to define the 
high probability group. This group is a candidate for the wait-and-see policy. Net benefit of the model is 
compared to the situations in which all patients or no patients are treated with a wait-and-see policy (left). 
The threshold with the optimal benefit of the model is 53% (right).  
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point was found predictive in earlier studies for responders versus non-
responders,
12,20,21
 but SUVmax is stronger when predictions for pCR changes are 
made.
22,27
 In our study the response index of SUVmean was a stronger predictor than the 
RI of SUVmax. These two measures are also highly correlated, especially since our PET 
contouring was semi-automatic and calibrated for both institutes, resulting in less 
variation in SUVmean due to contouring.
28 
A variable selection scheme was chosen based on univariate analysis, correlation 
between input variables and contribution to multivariate prediction performance. 
Other strategies such as penalized feature selection are also common when dealing 
with highly correlated variables, but in general these results in interpretability issues 
for the (shrunken) coefficients.
29
        
Model performance  
The performance of the nomogram measured by AUC of 0.78 (95% CI: 0.65-0.89) for 
the training dataset and 0.70 (95% CI: 0.55-0.84) for the validation dataset are lower 
than the ones reported by single PET parameters in literature (0.70,
30
 0.83,
23
 0.87
12
). 
However, these studies predict response (TRG1-2) instead of pCR. Response prediction 
is in practice more accurate because the number of events for good response (45-55%) 
is much higher than those of pCR (15-30%). Identifying the complete responders in an 
early phase is useful to avoid additional treatments and related toxicity for these 
patients. Another possible reason for a lower overall performance can be the noisy 
pathology outcome (decentralized), but this is compensated by the high number of 
patients. The current studies reported in literature with low number of samples are 
sensitive to positive (or negative) findings by mere chance, and therefore it is reasoned 
that this large study’s performance is expected to reflect reality better.  
When stratifying the patients in three risk groups, the performance is acceptable: 
100% accuracy for high probability for pCR group for the training dataset (N=10) and 
67% for the validation dataset (N=6). The two misclassified patients in the validation 
set have TRG 2, ypT1N0 or ypT2N0 status and a clinical response on the PETCT scan two 
months after the end of CRT, thus they are considered as good responders.  
The difference in performance between training and validation dataset is likely to be 
based on differently distributed data with respect to the predictors. The validation set 
has lower model estimates for the probabilities of pCR due to significantly higher 
number pre-treatment cT-stages (p=.007), and significantly lower RIs of SUVmean 
(p<.001). The latter difference may be explained by the higher times between tracer 
injection and the intermediate PET acquisition in the validation institute in comparison 
to the training institute, resulting in higher intermediate SUVmean values (p<.001), 
despite PET protocol harmonization.       
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Model applicability  
As suggested, the developed model can be used to assist in decision making for LARC 
already during CRT (Figure 4.1). However, three notes have to be made. First, this 
model is only useful for decisions made during or immediately after CRT, like RT boost 
or additional chemotherapy. The decision for a wait-and-see approach can better be 
made just before surgery by using both specialized prediction models
10
 and careful 
assessment of imaging, endoscopies and biopsies.
5
 The advantages of an earlier 
estimate of pCR are avoidance of overtreatment of complete responders, a possible 
increase of the number of complete responders with a RT boost for good responders 
and perhaps a change in treatment strategy for non-responding patients. 
Secondly, any developed model requires prospective validation by means of a 
randomized trial, comparing an arm with standard treatment for all (CRT+surgery) to 
an arm receiving individualized treatment based on the prediction model. Such a study 
is currently being set up.    
And last, other predictors from different sources might be considered to further 
improve accuracy. Diffusion-weighted magnetic resonance imaging (DW-MRI) at 
different time points is reported as a promising candidate which increases the 
prediction accuracy significantly in combination with PETCT imaging.
27
 Blood 
biomarkers also can have additional value as for example has been reported for serum 
carcinoembryonic antigen (CEA).
31
 For all these additional sources however, cost-
benefit analyses are advised because saturation of the prediction accuracy can become 
an issue.   
Conclusions 
We have developed an externally validated and accurate prediction model for 
pathologic complete response in locally advanced rectal cancer based on large 
prospective studies. This nomogram can be used to distinguish three types of patients, 
i.e. complete responders, good responders and non-responders, for which respectively 
a wait-and-see policy, radiotherapy boost and additional chemotherapy can be 
administered. This personalized treatment approach is expected to promote more 
complete responders, reduce the number of surgeries and related complications, and 
to avoid unnecessary toxicity.     
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Abstract 
Purpose 
Chemoradiation (CRT) has been shown to lead to downsizing in an important part of 
rectal cancers. In order to tailor treatment at an earlier stage during treatment, 
predictive models are being developed. Adding blood biomarkers may be attractive for 
prediction, as they can be collected very easily and determined with excellent 
reproducibility in clinical practice. The hypothesis of this study was that blood 
biomarkers related to tumor load, hypoxia and inflammation can help to predict 
response to CRT in rectal cancer. 
 
Methods and materials 
295 patients with locally advanced rectal cancer who were planned to undergo CRT 
were prospectively entered into a biobank protocol (NCT01067872). Blood samples 
were drawn before start of CRT. Nine biomarkers were selected, based on a previously 
defined hypothesis, and measured in a standardized way by a certified lab: CEA, CA19-
9, LDH, CRP, IL-6, IL-8, CA IX, osteopontin and 25-OH-vit D. Outcome was analyzed in 
two ways: pCR vs. non-pCR and responders (defined as ypT0-2N0) vs. non-responders 
(all other ypTN stages).  
 
Results 
276 patients could be analyzed. 20.7% developed a pCR and 47.1% were classified as 
responder. In univariate analysis CEA (p=.001) and osteopontin (p=.012) were 
significant predictors for pCR. Taking response as outcome CEA (p<.001), IL-8 (p<.001) 
and osteopontin (p=.004) were significant predictors. In multivariate analysis CEA was 
the strongest predictor for pCR (OR 0.92, p=.019) and CEA and IL-8 predicted for 
response (OR 0.97, p=.029 and OR 0.94, p=.036). The model based on biomarkers only 
had an AUC of 0.65 for pCR and 0.68 for response; the strongest model included 
clinical data, PET-data and biomarkers and had an AUC of 0.81 for pCR and 0.78 for 
response. 
 
Conclusions 
CEA and IL-8 were identified as predictive biomarkers for tumor response and pCR 
after CRT in rectal cancer. Incorporation of these blood biomarkers lead to an 
additional accuracy of earlier developed prediction models using clinical variables and 
PET-information. The new model could help to an early adaptation of treatment in 
rectal cancer patients. 
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Introduction 
Combined treatment is the cornerstone of rectal cancer treatment. In case of locally 
advanced rectal cancer, defined as a tumor with a predicted positive circumferential 
resection margin (CRM) or four or more positive lymph nodes, chemoradiotherapy 
(CRT) has become standard of care.
1
 Pathological complete response (pCR) rates 
typically lie between 15 and 20% after CRT depending on the radiotherapy dose given 
and the interval between CRT and surgery.
2,3
 The group of patients that develop a pCR 
is of particular interest, because they have a better prognosis
2
 and may be offered less 
invasive surgery
4
 or surgery may be completely omitted
5,6
. Therefore it would be an 
advantage if the pCR rate could be increased. There are several possible strategies, of 
which early response prediction during CRT, leading to treatment adaptation, is very 
attractive. 
In the past, clinical parameters as well as information from PET-scans before and 
during treatment have been found to be predictive for treatment outcome.
7-9
 A 
prediction model based on tumor length, cT- and cN-stage had a predictive 
performance of of 0.61 as expressed by the area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve. A second model including maximal standardized 
uptake value (SUV) of the tumor derived from a PET-scan before the start of 
treatment, maximal tumor diameter as measured on PET-scan, tumor location and cN-
stage, resulted in an AUC of 0.68.
9
 PET-scan after 2 weeks of CRT has been shown to be 
very predictive for response (tumor regression grade (TRG) 1-2 vs TRG 3-5 according to 
Mandard).
8
  
It is attractive to consider the addition of blood biomarkers to these predictors, since 
samples can be collected easily, are relatively cheap to measure, and they contain 
information about different aspects of tumor biology.  Furthermore, they can be 
measured accurately and precisely using standardized methods. Reports on the 
predictive value of blood biomarkers are limited to studies mainly evaluating 1 or 2 
biomarkers.
7,10-13
 The most studied biomarker for response to CRT in rectal cancer is 
carcinoembryonic antigen (CEA) and one study analyzed the predictive value of 
osteopontin and interleukin-6. Based on these data combined with data of prognostic 
studies in colorectal cancer and our experience with a blood biomarker model in lung 
cancer,
14
 we decided to include 9 biomarkers. CEA and CA19-9 are related to tumor 
load, interleukin-6 and -8 (IL-6 and IL-8) and C-reactive protein (CRP) are markers of 
inflammation, lactate dehydrogenase (LDH) is a marker of cell death, carbonic 
anhydrase IX (CA IX) and osteopontin are hypoxia markers and 25-OH-vitamin D may 
induce growth arrest and apoptosis of tumor cells. 
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In this prospective study we tested the hypothesis that these biomarkers are helpful in 
the prediction of response to CRT in rectal cancer. 
Methods and materials 
Patient population 
We identified 295 patients who were treated with CRT with curative intent for locally 
advanced rectal cancer between January 2005 and December 2009.  All gave written 
informed consent to be included in a biobank protocol (NCT01067872). Nineteen 
patients were ineligible for different reasons (1 patient was treated with short course 
radiotherapy 5x5 Gy, 5 patients were not operated on and entered in a wait&see study 
so no ypTN stage could be determined, 2 patients underwent a TEM resection so no 
ypN-stage was available, 6 patients had metastases and were treated with palliative 
intent, 1 patient died during treatment, in 1 patient all biobank material was hemolytic 
and in 3 patients the PA report could not be retrieved), resulting in 276 patients for 
analysis. In 9 patients there were technical problems with the biomarker 
measurements, so that 267 patients were available for the biomarker analysis. Locally 
advanced disease was defined as a distal T3 tumor and/or N2 status and/or a mid- or 
upper-rectal tumor with a predicted circumferential resection margin <2 mm, or any T4 
tumor. Locoregional staging for clinical tumor and nodal stage was based on MRI. In 
198 patients for whom biomarkers were available a PETCT was made for radiotherapy 
planning. Treatment consisted of 28 fractions of 1.8 Gy on the primary tumor, 
mesorectum, presacral area and external iliac lymph nodes in combination with 
capecitabine 825 mg/m
2 
BID. Patients were operated on 8-10 weeks after the end of 
CRT. Pathology reports were collected from the referring hospitals.  
Blood samples 
Blood samples were collected before the start of treatment. Samples were processed 
and stored using a standard protocol. All biomarkers were measured in serum, except 
for osteopontin and CA IX, which were measured in EDTA plasma. Biomarker 
measurements were done in one single, certified laboratory, using commercially 
available kits. All samples were analyzed simultaneously. Measurements were 
performed using the following kits: CEA was measured using a solid-phase, two-site 
sequential chemoluminescent immunometric assay (Siemens Medical Solutions 
Diagnostics, LA, USA), IL-6 and IL-8 were determined with a solid phase, enzyme 
labeled, chemoluminescence sequential immunometric assay (Siemens Medical 
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Solutions Diagnostics, LA, USA).  (LDH (Beckman Coulter, Fullerton, CA), CRP (Beckman, 
Coulter Fullerton, CA) CA 19-9 has been determined on Brahms Kryptor (Brahms, 
ThermoFisher, Hennigsdorf, Germany) with a sandwich immuno-fluorescent assay.  25-
OH-Vitamine-D was measured with a commercially available radioimmunoassay (IDS, 
Frankfurt am Main, Germany). CA IX is measured by an enzyme-linked immunosorbent 
assay (Wilex (OncogenScience), Cambridge, MA, USA), and OPN was measured by an 
enzyme-linked immunosorbent assay (Quantikine Human Osteopontin Immuno assay; 
R&D Systems, Minneapolis, MN, USA). OPN, 25-OH-vitamin-D and CA IX were 
measured using manual methods in duplicate. All other biomarkers were measured in 
singletons. 
Statistical analysis 
Outcome after CRT was analyzed in 2 different ways: 1) pCR, defined as the absence of 
any tumor cells in the operative pathologic specimen, at the primary site, or in lymph 
node regions, versus non-pCR and 2) good responders, defined as ypT0-2N0, versus poor 
responders, defined as ypT3 and/or ypN1-2. Missing values were completed using 
expectation-maximization imputation. Correlations between biomarkers were 
analyzed by calculating Spearman’s rho. Because the biomarkers showed a skewed 
distribution, the Mann-Whitney U test was used to determine significant univariate 
predictors of response. Logistic regression analysis was used to identify the significant 
multivariate predictors of response. The next step was to combine blood biomarkers 
with clinical data and PET parameters. For this analysis clinical and PET-variables were 
selected manually, based on an earlier predictive model for pCR.
9
 The included clinical 
variables were tumor length, clinical T and N stage, all based on MRI. Included PET-
features were maximum SUV, pre-treatment metabolic volume and maximum 
diameter. The two latter variables were measured using a source-to-background ratio 
method as has been described earlier.
15
 ROC curves were constructed and the AUC 
was calculated. In order to approximate the true AUC and calculate confidence 
intervals bootstrapping (n=1000) was used. A perfect prediction model results in an 
AUC of 1.0, while an AUC of 0.5 indicates that response is predicted correctly in 50% of 
cases (i.e. as good as chance). Statistical analyses were performed using Matlab, 
release 2010b (The MathWorks, Natick, MA). 
Ethics 
The biobank study was conducted according to the Dutch law and approved by the 
local medical ethics committee. All patients gave written informed consent before 
collection of the blood samples. 
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Results 
The patient characteristics are shown in Table 5.1. The majority of patients had a 
tumor penetrating through the bowel wall and predicted positive lymph nodes on MR. 
In the total database 20.7% of patients developed a pCR and 47.1% of patients were 
classified as responder. Table 5.2 shows the results of the biomarker measurements 
for the different outcome groups, as well as the PET-parameters that were included in 
the model. In general lower serum levels for blood biomarkers were seen in the poor 
responding groups (except for 25-OH-vitamin-D).  Additional analysis (not shown in the 
table) revealed significant positive correlations between IL-6, IL-8, CRP and 
osteopontin and between CEA and CA19-9. 
 
Table 5.1 Patient characteristics (N = 276)  
Characteristic N [%] 
Age [years]   
median 65.8  
range 23.0 - 92.2  
Gender   
male 179 [64.9] 
female 97 [35.1] 
Clinical tumor stage (cT)   
2 26 [9.4] 
3 207 [75.0] 
4 43 [15.6] 
Clinical nodal stage (cN)   
0 47 [17.0] 
1 114 [41.3] 
2 115 [41.7] 
WHO performance index   
0 218 [79.0] 
1 53 [19.2] 
2 5 [1.8] 
Tumor length [cm]  
median 5.0  
range 2.0 - 13.0  
pCR (ypT0N0)   
no 219 [79.3] 
yes 57 [20.7] 
Good response (ypT012N0)   
no 146 [52.9] 
yes 130 [47.1] 
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Univariate analysis 
Univariate analysis indicated that CEA and osteopontin were significant predictors for 
pCR (p=.001, p=.012 respectively) and that CEA, IL-8 and osteopontin were significant 
predictors for response (p<.001, p<.001, p=.004 respectively) as shown in Table 5.3. 
Lower serum levels of these markers correlated with a higher chance of response to 
chemoradiation. Of the clinical parameters clinical N-stage was predictive for pCR 
(p=.026) and response (p=.001) in univariate analysis and tumor length (p=.02) and 
clinical T-stage (p=.004) for response only. The pre-treatment metabolic volume and 
maximum diameter based on PET were predictive for both outcome measures (p=.016 
and 0.009 for pCR and p=.006 and .005 for response respectively). 
 
Table 5.2 Biomarker levels and PET parameters (average ± standard deviation) compared for the 
subpopulations of pCR vs no pCR and good response vs no good response   
  pCR (ypT0N0) Good response (ypT012N0) 
  no yes no yes 
Biomarkers CEA 14.7 ± 28.4 8.7 ± 22.9 18.1 ± 33 8.5 ± 18.5 
(N = 267) IL-6 4.0 ± 8.4 2.9 ± 2.7 4.8 ± 10.1 2.7 ± 2.4 
 IL-8 15.8 ± 9 14.0 ± 7.4 17.3 ± 10 13.4 ± 6.4 
 LDH 181.3 ± 43.8 176.2 ± 33.9 181.9 ± 46.7 178.5 ± 36.1 
 CRP 11.5 ± 24.5 7.8 ± 8 13.8 ± 29.1 7.5 ± 9.2 
 CA 19-9 26.9 ± 29.1 25.1 ± 31.9 28.3 ± 28.8 24.6 ± 30.6 
 vitD-25 53.2 ± 20.9 55.5 ± 18.8 52.6 ± 22.4 54.8 ± 18.2 
 CA-9 282.5 ± 275 274.4 ± 302.9 282.0 ± 238.4 279.6 ± 320.9 
 OPN 79.2 ± 28.9 68.2 ± 16 81.6 ± 30.9 72 ± 21.3 
PET 
parameters 
SUVmax 15.3 ± 6.3 13.6 ± 5.2 14.3 ± 5.6 15.6 ± 6.7 
(N =198) SUVmean 8.2 ± 3.1 7.4 ± 2.7 7.8 ± 2.7 8.4 ± 3.3 
 MTV [cc] 33.8 ± 33.5 25 ± 20.2 37.6 ± 39.1 25.7 ± 17.6 
 Max diam [cm] 6.5 ± 1.9 5.8 ± 1.6 6.7 ± 2.1 5.9 ± 1.4 
 
Multivariate biomarker model 
Table 5.3 shows the results of the multivariate analysis for the total set of parameters 
as well as a selection of biomarkers and clinical and PET-parameters. In the complete 
set of parameters IL-8 was the only significant predictor for response (p=.05), while 
osteopontin was borderline significant for pCR prediction (p=.056). As a next step a 
manual selection of the most promising predictors was made. Blood biomarkers that 
had a significant predictive value in either univariate or multivariate analysis were 
included and IL-6, although not significant, was included because it had a predictive 
value in a prognostic model for lung cancer.
14
 In this selection of biomarkers consisting  
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Figure 5.1 ROC curves for prediction models for pCR and response including biomarkers and clinical variables 
(A and A*) and biomarkers, clinical variables and PET-data (B and B*) and resulting AUC for the different 
prediction models (C and C*).  
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of CEA, IL-6, IL-8 and osteopontin, CEA was the only significant predictor of pCR in 
multivariate analysis (p=.019) and CEA and IL-8 significantly predicted response 
(p=.029, p=.021 respectively). Including all biomarkers resulted in an AUC of 0.65 (95% 
CI 0.57-0.73) for pCR prediction and 0.68 (95% 0.61-0.75) for response prediction. 
Table 5.3 shows the odds ratios for all tested biomarkers as well as the clinical and 
PET-based parameters.  
Combination of blood biomarkers with clinical and PET data 
The biomarker selection was then added to the parameters that were predictive for 
response in an externally validated prediction model based on clinical and PET-scan 
data.
9
 The final model consisted of eight variables: tumor length, clinical T stage, 
clinical N stage, CEA, IL-6, IL-8, osteopontin, and maximal SUV on PET before start of 
treatment. In the current dataset tumor length was not a significant predictor for 
response to chemoradiation, but cT and cN were. Maximal SUV was only predictive for 
response, not for pCR. In Figure 5.1 the ROC curves for the combined models based on 
biomarkers and clinical data (Figure 5.1A and 5.1A*) and biomarkers, clinical data and 
PET information (Figure 5.1B and 5.1B*) are depicted, as well as the resulting AUCs 
Figure 5.1C and 5.1C*). The model based on biomarkers only resulted in an AUC that 
was more or less comparable to the clinical model.  
 
 
Figure 5.2 Nomogram for response prediction. A score for each predictor can be read out at the top scale 
(Score). All summed scores (Sum of scores scale) can be converted directly to the probability of response.  
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The AUC of the clinical model was 0.64 (95% CI 0.56-0.71) for pCR and 0.66 (95% CI 
0.60-0.72) for response. Combining clinical parameters and biomarkers (AUC 0.69 (95% 
CI 0.62-0.77) for pCR and 0.73 (95% CI 0.65-0.79) for response) made the model 
stronger than the model based on biomarkers only or clinical data only. This effect was 
most pronounced for prediction of response. Addition of information obtained from a 
PET-scan acquired before the start of treatment lead to strongest models for the 
prediction of both pCR and response, resulting in AUCs of 0.81 (95% CI 0.73 - 0.88) for 
pCR and 0.78 (95% CI 0.71-0.85) for response.  
The data of the combined prediction model were used to build a hypothesis generating 
nomogram, which is depicted in Figure 5.2. 
Discussion 
To the best of our knowledge this is the first prospective study evaluating the 
predictive value of a broad range of blood biomarkers analyzed in a standardized way 
for response prediction to CRT in rectal cancer. CEA turned out to be a significant 
predictor for pCR and CEA and IL-8 were predictive for response. Including these blood 
biomarkers in models based on clinical parameters and PET-based parameters resulted 
in an increased performance of the prediction models. 
Osteopontin is a glycophosphoprotein secreted by different cell types, that has been 
shown to be associated not only with malignancies but also with acute and chronic 
inflammatory processes. It influences adhesion, migration, invasion, chemotaxis and 
cell survival
16
 and is a marker of tumor aggressiveness and early progression
17
. 
Although the role of osteopontin as a prognostic factor has been studied extensively in 
a broad range of solid tumors, only one study looked at the predictive value of 
osteopontin levels and response to CRT in rectal cancer.  Debucquoy et al. found an 
association between lower osteopontin levels and better response in 30 rectal cancer 
patients, which is in line with our findings, but this did not reach statistical 
significance.
13
 In our patient group it was a significant predictor in univariate analysis, 
but it lost significance in multivariate analysis. This could be explained by the fact that 
osteopontin and IL-8 showed a positive correlation. 
CEA is an antigen produced by the normal fetus and only in very low concentrations by 
normal cells of the adult body. In the tumor environment it plays a role in intercellular 
recognition and attachment. It has been shown to be of prognostic value in colorectal 
cancer independent of clinical stage and differentiation grade.
18
 Although preoperative 
CEA levels cannot be used to make treatment decisions in colorectal cancer, they 
consistently have a prognostic value. Patients having a CEA level >5 μg/l have a 
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significant worse disease free and overall survival than patients with lower CEA levels. 
Three studies looked at the predictive value of CEA levels for response to CRT in rectal 
cancer. Das et al. studied a group of 562 rectal cancer patients treated with CRT.
7
 In 
their patient group CEA was only predictive for pCR in univariate analysis. However, 
they chose to dichotomize CEA levels (below and above 2.5 μg/l), while in our model 
CEA was incorporated as a continuous variable. Yoon et al. did an analysis in a group of 
351 rectal cancer patients.
12
 In multivariate analysis CEA levels ≤5 μg/l were predictive 
for downstaging and complete regression. Park et al. did a retrospective analysis in 352 
rectal cancer patients.
11
 CEA was analyzed as a continuous variable and had a 
significant predictive value for responders vs. non-responders. A higher CEA was an 
independent predictor of poor response to CRT and a worse disease free survival.  
IL-8 is a pro-inflammatory chemokine that plays a role in attracting neutrophils. 
Through the activation of phosphatidyl-inositol-3-kinase (PI3-K) and phospholipase C it 
can activate the Akt/mTOR and Raf/Mek/Erk pathways, leading to the promotion of 
angiogenesis, proliferation and survival and the migration of cancer cells.
19
 
Polymorphisms in IL-8 have been described to be related to an increased risk of 
recurrence in rectal cancer
20
 and the risk of nodal involvement,
21
 indicating a possible 
relationship with tumor biology of IL-8 in rectal cancer. However, until now there are 
no reports of a potential value of IL-8 in the prediction of response to CRT.   
In this study response was measured in two ways: pCR and ypT0-2N0. Of these 2 
endpoints pCR is the most robust, although the definition of pCR can be difficult. In this 
cohort routine pathological examination was performed and reported in a 
standardized way. A recent comparison between routine pathological examination and 
additional step sections in resection specimens showing no viable tumor cells at initial 
examination, showed no differences in outcome.
22
 Furthermore, pooled analysis of a 
large series of patients included in different studies, showed a clear prognostic value of 
pCR after CRT for long-term outcome, even if pooled from different studies, indicating 
that pCR as scored in routine pathology procedures is a valuable endpoint.
2
 The most 
frequently used method to distinguish responders from non-responders is by means of 
a tumor regression grade (TRG). However, for this cohort TRG was not scored routinely 
and we chose to use ypT0-2N0 as definition of response. It makes sense to predict the 
group of good responders, because they could be suitable for less invasive surgery, like 
transanal resection or TEM-surgery. 
Blood biomarkers give information about tumor biology in an indirect way. A more 
direct insight can be gained from genetic alterations within the tumor. An overview of 
these molecular biomarkers is given in the review of Kuremsky et al.
23
 A possible 
problem related to molecular biomarkers is the heterogeneity in tumors, making it 
necessary to collect a representative sampling of tumor material and the invasive 
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procedure needed to collect material. Blood biomarkers have the advantage that they 
are easy to collect and that they provide information about the “average” tumor. This 
makes blood biomarkers useful for daily practice. However translation of the results of 
this study should be done cautiously, because all biomarkers in this study were 
measured in a standardized way in one single laboratory, using the same kits. Less 
thorough and sensitive procedures might influence negatively the added value of 
biomarkers. 
Ideally response prediction takes place before the start of a treatment, so that a 
patient can be offered the treatment with the highest success rate. In the case of 
response prediction for rectal cancer, clinical factors and pre-treatment PET-scan have 
been shown to have predictive value before the start of treatment,
9
 but the 
performance of predictive models based exclusively on pre-treatment data typically 
lies between 0.65 and 0.70. The predictive value of biomarkers only is in the same 
range, but the combination of biomarkers and other pre-treatment data results in a 
stronger prediction model.  
The data presented here can be seen as a proof of principle that biomarkers contain 
predictive information for rectal cancer, but external validation of this prediction 
model is necessary for a better estimation of the performance and reproducibility of 
the model.
24
 For use in clinical practice a stronger performance is desirable. A 
possibility to strengthen the predictive model is to incorporate response data obtained 
early during CRT. If this time point lies early in the treatment course, it is still possible 
to modify treatment. For PETCT it has already been shown that changes in glucose 
metabolism after 2 weeks of CRT resulted in a stronger prediction model.
8
 An 
intriguing question is whether early changes in blood biomarker levels during CRT can 
further enhance the performance of this model. This question will be subject of future 
research. 
In conclusion, pre-treatment CEA levels help to predict pCR after CRT for rectal cancer 
and CEA and IL-8 levels are helpful in the prediction of response to CRT. These blood 
biomarkers have added value to earlier published prediction models based on pre-
treatment clinical- and PET-data and can be used in decision support systems for 
tailored therapy.
25
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Abstract 
Purpose 
The purpose of this study was to develop accurate models and nomograms to predict 
local recurrence, distant metastases and survival for patients with locally advanced 
rectal cancer treated with long-course chemoradiotherapy (CRT) followed by surgery 
and to allow for a selection of patients who may benefit most from postoperative 
adjuvant chemotherapy and close follow-up.  
 
Methods and materials 
All data (N = 2795) from the five major European clinical trials for rectal cancer were 
pooled and used to perform an extensive survival analysis and to develop multivariate 
nomograms based on Cox regression. Data from one trial was used as an external 
validation set. The variables used in the analysis were sex, age, clinical tumor stage, 
tumor location, radiotherapy dose, concurrent and adjuvant chemotherapy, surgery 
procedure and pTNM-stage. Model performance was evaluated by the concordance 
index (c-index). Risk group stratification was proposed for the nomograms.   
  
Results 
The nomograms are able to predict events with a c-index for external validation of 
local recurrence (LR; 0.68), distant metastases (DM; 0.73) and overall survival (OS; 
0.70). Pathological staging is essential for accurate prediction of long-term outcome. 
Both preoperative CRT and adjuvant chemotherapy have an added value when 
predicting LR, DM and OS rates. The stratification in risk groups allows significant 
distinction between Kaplan–Meier curves for outcome. 
 
Conclusions 
The easy-to-use nomograms can predict LR, DM and OS over a 5-year period after 
surgery. They may be used as decision support tools in future trials by using the three 
defined risk groups to select patients for post-operative chemotherapy and close 
follow-up (http://www.predictcancer.org). 
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Introduction  
The improvement in locoregional control reported in recent randomized studies 
resulting from the combination of preoperative chemoradiotherapy (CRT) and 
standardized surgical technique (total mesorectal excision, TME) in locally advanced 
resectable rectal cancer has not been associated with improved survival.
1-5
 In these 
trials, the incidence of distant metastases (DM) was 24%-28%, although local 
recurrence (LR) rates were only 7%-10%. New treatment strategies must therefore 
include focus on distant control.  
Randomized trials showed that certain patient subsets benefit from postoperative 
adjuvant chemotherapy after preoperative CRT, but the total patient group showed no 
reduction in DM or improvement in survival.
1,6
 A recent European Consensus 
Conference failed to reach consensus about the benefit of postoperative 
chemotherapy after CRT because of insufficient evidence.
7
 
To improve survival of patients with locally advanced rectal cancer (LARC), a reduction 
of the current 25% DM rate is needed. However, treating all patients with 
postoperative chemotherapy means potential exposure to unnecessary chemotherapy 
for the remaining 75%.
7
 An accurate predictive nomogram would therefore be greatly 
beneficial. Our primary goal was to develop a nomogram that would predict distant 
metastasis rate and survival for patients with LARC who are treated by neoadjuvant 
long-course CRT, and to help select patients who may benefit from the addition of 
postoperative adjuvant systemic treatment.   
The optimal follow-up recommendations after radical resection for colorectal cancer 
are still undefined, with little level 1 evidence.
7
 Many cohort and case-control studies 
have supported the effectiveness of follow-up, but few randomized controlled trials 
have correlated follow-up and cancer mortality.
8,9
 Identifying subgroups of patients at 
different risks for LR and DM can help identify the appropriate timing and imaging 
techniques in a more individualized fashion. Thus, our secondary goal is to develop a 
nomogram for local recurrence and distant metastases to aid selection of follow-up 
type and intensity based on an individual’s risk of both relapse types.  
There are many studies in the literature in which the development of nomograms 
leads to a successful application for oncology prognostics. Nomograms for predicting 
follow-up outcome for colorectal cancer are scarce.
10-12
 Providing nomograms based 
on five randomized trials, also allows classification of patients according to risk group 
to define treatment arms in future randomized trials. 
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Methods and materials 
Study population 
The mathematical models were developed by using data (N = 2795) from five large 
European randomized clinical trials for LARC (Table 6.1). These trials evaluated 
different treatment schemes with similar inclusion criteria and similar accrual times 
(1992-2003). All patients received preoperative radiotherapy (RT, 34–39 days of 
treatment time on average; 1.8 Gy per fraction) and surgery (36–47 days after the end 
of radiotherapy on average) and the fluorouracil (FU)-based adjuvant chemotherapy 
was the same in all patients who received it. There was heterogeneity for RT dose, 
surgery procedure and the use of preoperative and postoperative chemotherapy 
(chemo). Metastases at diagnosis were an exclusion criterion for all datasets. Patients 
with local excision were also excluded because the group was too small (24 patients) 
to include statistically.  
 
Table 6.1 Characteristics of the five European randomized trials (N = 3458) for training the prediction 
models. *: Only the pre-operative long-course radiotherapy arm was used for this study. Abbreviations: 
WHO: World Health Organization performance index, arv: anorectal verge.    
Name Study design Inclusion criteria Accrual Pts Ref 
EORTC  Preop. RT 
 Preop. CRT 
 Preop. RT + postop. chemo 
 Preop. CRT + postop. chemo 
 T3 or resect.T4M0 
 No history of cancer 
 Age <80 
 WHO 0–1 
 Tumor within 15cm arv  
‘93–‘03 
 
1011 1 
French   Preop. RT 
 Preop. CRT 
 T3,T4,M0 
 Age<75  
 WHO 0–1 
‘93–‘03 733 3 
German  Preop. CRT 
 Postop. CRT 
 cT3-4, or cN+ 
 No history of cancer 
 Age<75  
 Tumor within 16cm arv  
‘95–‘02 823* 18 
Polish  Preop. RT (5x5 Gy) 
 Preop. CRT (50.4 Gy) 
 cT3–4,resectable tumor 
 Age<75 
 WHO 0–2 
 No sphincter involvement 
‘99–‘02 312* 2,39 
Italian  Preop. CRT 
 Preop. CRT + postop. chemo 
 cT3–4 
 No history of cancer 
 Age<75  
 Tumor within 15cm arv 
‘92–‘01 579 38 
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The variables evaluated at diagnosis include sex, age at the date of random 
assignment, clinical tumor (cT) stage and tumor location. Location was categorized on 
the basis of the tumor distance measured from the anorectal verge (arv): low, less than 
5 cm; mid, 5 to 10 cm; high: more than 10 cm. Clinical nodal stage (cN) was not 
included in the multivariate models, because of its absence in certain datasets (69%) 
and the low reliability of the imaging-based nodal staging.
7
 Treatment factors included 
in the analysis were RT dose (<45 Gy, 45 Gy and >45 Gy), administration of concurrent 
chemotherapy (yes/no), the surgical procedure (low anterior resection [LAR] and 
abdominoperineal resection [APR]) and administration of adjuvant chemotherapy 
(yes/no). Data from pathology included tumor (ypT) and nodal (ypN) stages. Predicted 
outcomes were the presence of LR, DM and overall survival (OS), accompanied by 
corresponding time-to-event in months. LR was defined as tumor in the pelvis or 
perineum, or in the anastomosis as diagnosed by histology. DM was defined as 
evidence of a tumor in any other area given by at least two imaging exams. All causes 
of death were included.  
Statistical analysis 
To compare the contributions of the evaluated factors, all variables were standardized 
by subtracting the mean and dividing by the standard deviation. Any missing covariate 
values (for each covariate less than 10%) were imputed by expectation-maximization 
(EM) imputation.
13
 First, we provided pooled Kaplan-Meier estimates of 5- and 10-year 
event rates and compare curves for different variable values by using log-rank tests.
14
 
Secondly, the data were split into a training set and an external validation set. The 
Italian trial was used for external validation because it is the most recent trial reported. 
With the ratio of training (N=2242) and validation set size (N=553) it is expected that 
this split will provide balanced statistical power to find and evaluate the predictors.
15
  
An additional property of the Italian patient cohort is that all patients received long-
course RT and chemotherapy (with optional adjuvant chemotherapy) which is 
currently the standard treatment for LARC.  
The nomograms focus on 5-year event rates, as well as the reports of the pooled 
randomized trials, and the majority of the patients were followed during this period 
(54% to 74%). Multivariate analyses were performed by using the Cox proportional 
hazards model. Hazard ratios were calculated from the model coefficients. The model 
performance for predicting outcome was evaluated by calculating the concordance 
index (c-index), which is a generalization of the area under the curve (AUC) of the 
receiver operating characteristic (ROC) curve and can be applied to continuous 
outcome and censored data.
16
 The maximum value of the c-index is 1.0, indicating a 
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perfect discrimination, whereas 0.5 indicates a random chance to correctly 
discriminate outcome with the model.  
 
Significant predictors for outcome were selected by training the Cox model (training 
data) and selecting the variables that have a significant effect (p<.05). The models 
were trained again with the found predictors as input. In these reduced models, all 
predictors were still significantly contributing. All model performances were calculated 
by using bootstrapping, in which the evaluated dataset was tested 1000 times, and 
each time, the data were randomly resampled (patients can occur in the dataset more 
than once). The model output was converted into a nomogram.
17
  
Three risk groups were defined on the basis of the estimated probability for each event 
using thresholds on the basis of clinical expertise from literature. For LR, the thresholds 
chosen were 8%, representing the value of the LR rates in the CRT arms of European 
Organisation for Research and Treatment of Cancer (EORTC) 22921
1
, Fédération 
Francophone de Cancérologie Digestive (FFCD) 9203
3
 and CAO/ARO/AIO 94 [Working 
Group of Surgical Oncology/ Working Group of Radiation Oncology/Working Group of 
Medical Oncology of the Germany Cancer Society]
18
 studies and 20% in the surgery 
alone arm of the Dutch TME trial for stage III patients.
4
 For DM and OS, the probability 
thresholds were 15% and 25%, based on DM-free survival in a recent pathologic 
complete response (pCR) pooled analysis
19
 and in the CRT randomized studies
1,3,18
 
respectively. The model was calibrated using the Wald statistic for the calibration slope 
with the three risk groups as bins on the validation dataset and calibration-in-the-
large.
15
 The Cox model and nomogram algorithm were implemented by using Matlab 
version 7.1 (MathWorks, Natick MA) and Kaplan-Meier analyses were performed in 
SPSS version 15.0 (SPSS, Chicago IL). 
Results 
Follow-up analysis  
Of the 3458 patients accrued in the five randomized trials (Table 6.1), 2795 had pre-
operative long-course RT with or without chemotherapy and were eligible for analysis 
(clinical metastasis stage of 0; surgery; known follow-up time). Event rates at 5 years of 
follow-up were 12.9% for LR, 30.8% for DM and 30.4% for OS. Median follow-up times 
were 52.4 months for LR, 47.4 months for DM and 55.2 months for OS. Table 6.2 
(Kaplan–Meier analyses) shows that sex and age have a significant impact only on OS 
time, although tumor location affects both DM and OS. The variables clinical stage,  
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Table 6.2 Event free rates at 5- and 10-years for the complete randomized pooled dataset, stratified for each 
variable. Significant differences between the stratified Kaplan–Meier curves are indicated by the p-value. 
* Significant overall difference: p<.05 
 
   Local control Distant control Overall survival 
  N 5y 10y p 5y 10y 
yrs 
p 5y 10y p 
 Total 2795 87.1 85.7 - 69.2 65.8 - 69.6 57.3 - 
C
lin
ic
al
 d
ia
gn
o
si
s 
Sex           
Male 1961 87.4 85.1 
.466 
67.9 64.8 
.138 
67.6 54.1 
<.001* 
Female 843 88.7 87.0 72.1 68.1 74.1 64.9 
Age [years]           
<50 379 84.5 83.9 
.170 
68.0 64.5 
.191 
71.9 63.1 
<.001* 
50–60  751 86.9 85.9 70.1 66.6 72.9 65.2 
60–70 1135 88.7 85.4 67.3 64.5 67.0 54.6 
>70 539 89.8 87.4 72.8 68.3 68.8 46.9 
Tumor loc.           
Low 953 86.0 84.8 
.127 
64.3 60.1 
.001* 
64.7 52.6 
.001* Mid 1461 88.2 85.4 70.9 68.1 71.5 60.8 
High 369 90.8 88.6 75.4 72.5 74.3 55.6 
cT-stage           
2 18 94.4 94.4 
<.001* 
65.8 65.8 
.134 
83.0 83.0 
<.001* 3 2228 89.0 87.0 70.1 67.0 71.3 59.9 
4 275 77.5 77.5 64.3 62.0 56.7 39.2 
cN-stage           
0  309 93.2 92.6 
.776 
78.4 767 
.009* 
77.6 74.4 
.006* 
1+2 544 93.6 89.6 71.5 68.4 73.7 62.1 
cStage           
II 733 94.4 92.3 
.003* 
75.4 73.3 
.007* 
76.3 68.7 
.001* 
III 57 83.5 83.5 63.2 55.6 64.8 43.4 
Tr
e
at
m
e
n
ts
 
RT dose[Gy]           
<45 50 84.3 84.3 
.019* 
60.3 56.0 
.268 
53.1 39.2 
.001* 45  2205 86.7 85.4 68.9 65.7 68.3 56.6 
>45 547 92.2 87.6 70.8 66.8 75.3 61.5 
Conc.chemo           
No 868 81.1 80.2 
<.001* 
66.2 63.2 
.033* 
66.6 52.2 
.019* 
Yes 1933 90.7 88.2 70.5 67.0 70.8 59.2 
Surg. proc.           
LAR 1600 91.6 89.1 
<.001* 
74.0 70.9 
<.001* 
76.2 65.0 
<.001* 
APR 1071 84.6 83.2 63.3 59.8 63.2 49.0 
Adj. chemo           
No 1209 85.9 84.9 
.020* 
68.3 65.5 
.404 
66.1 53.1 
<.001* 
Yes 1572 89.2 86.6 70.0 66.3 72.3 60.4 
P
at
h
o
lo
gy
 
ypT stage           
0  299 96.7 94.5 
<.001* 
85.1 80.4 
<.001* 
82.2 71.5 
<.001* 
1+2 1008 93.7 92.0 81.4 78.6 80.6 69.8 
3 1329 83.0 80.8 57.9 54.7 62.1 48.0 
4 74 66.2 66.2 50.7 46.1 40.2 35.9 
ypN stage           
0  1879 91.3 89.6 
<.001* 
79.0 75.9 
<.001* 
77.9 65.7 
<.001* 
1+2 833 80.6 76.8 47.6 44.2 53.1 40.2 
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concurrent chemotherapy, surgical procedure, ypT-stage and ypN-stage have 
significant impact on all outcomes in this analysis. The clinical tumor (cT) stage, RT 
dose and adjuvant chemotherapy have the same impact, although not for DM. 
Pathologic staging seems essential in further nomogram development (p<.001 for all 
outcomes). The effects of all four different treatments on outcome (Figure 6.1) are 
significant, but RT dose and adjuvant chemotherapy do not have a significant effect on 
distant metastasis rates.  
Nomograms 
For the development of the nomograms, all patients in the training dataset were 
included (N = 2242). Some predictive variables in the Kaplan-Meier analysis (Table 6.2) 
were not significant anymore in the multivariate models (Table 6.3). Local recurrence 
prediction performed with a c-index of 0.68, with a 95% confidence interval (CI) for 
external validation of 0.59–0.76. For distant metastasis, the final model’s c-index was 
0.73 (95% CI: 0.68-0.77). The nomogram for OS had a c-index of 0.70 (95% CI: 0.65-
0.74). These validation performances are not significantly lower than the performances 
on the training dataset, which makes overfitting by the model less evident. 
The resulting nomograms (Figure 6.2) are able to estimate outcome probability by 
assigning a score (upper scale “Score”) to each predictor value. The sum of these 
scores corresponds to an event probability (bottom two scales). In all nomograms, 
pathologic staging (ypT and ypN) is the most important factor. Kaplan-Meier estimates 
of the event rates over time for the validation dataset showed statistically different 
outcomes for the three proposed risk groups (Figure 6.3); p=.010 for LR, p<.001 for DM 
and p<.001 for OS. Model calibration was good when applied to the training data, but 
never significant. In the calibration for external validation it appeared that probabilities 
were slightly overestimated by the model (LR, 6.4%; DM, 5.7%; OS, 3.7%). Calibration-
in-the-large (total average probability) was acceptable for external validation (3.0% - 
5.5% probability differences). 
Long-term follow-up outcome prediction  113 
 
Figure 6.1 Kaplan–Meier curves stratified for the treatment factors: radiotherapy dose, concurrent 
chemotherapy, surgery procedure and adjuvant chemotherapy. Exact event rates and p-values are listed in 
Table 6.2. Dashed line indicates 60 months of follow-up. 
      Chapter 6 
 
114
Table 6.3 Model development of five-year outcome: multivariate analyses (Cox proportional hazards 
regression, hazard ratio HR with confidence intervals and p-value), to determine the final predictors for the 
nomograms. The c-index (mean and confidence interval) for the training and external validation dataset are 
given for the derived nomograms as a performance measure.  
$ Hazard ratios are calculated in the following framework: sex (female vs male), cT-stage (cT4 cT12), tumor 
location (high  low), radiotherapy dose (>45 Gy  < 45 Gy), concurrent chemotherapy (yes vs no), surgery 
procedure (APR vs LAR), pT-stage (pT4 pT0), pN-stage (pN2 pN0), adjuvant chemotherapy (yes vs no). 
Age is continuous. 
* p-value < .05, selected as predictor for nomogram   
 
  Cox regression Nomogram 
 Variable Hazard ratio (C.I.) $ p-value Performance (c-index) 
Lo
ca
l r
e
cu
rr
e
n
ce
s 
Sex 0.98 (0.87 - 1.10) .703 
Training: 0.71 
95% CI: 0.67– 0.74 
  
Validation: 0.68 
95% CI: 0.59 – 0.76  
Age 0.87 (0.78 - 0.97) .016* 
cT-stage 1.18 (1.06 - 1.31) .002* 
Tumor location 0.97 (0.84 - 1.12) .644 
RT dose 0.98 (0.85 - 1.12) .732 
Conc. chemo 0.81 (0.72 - 0.91) .001* 
Surgery procedure 1.15 (1.00 - 1.33) .057 
pT-stage 1.64 (1.38 - 1.95) <.001* 
pN-stage 1.26 (1.13 - 1.40) <.001* 
Adj. chemo 0.81 (0.72 - 0.92) .001* 
D
is
ta
n
t 
m
e
ta
st
as
es
  
Sex 0.94 (0.87 - 1.01) .100 
Training: 0.71 
95% CI: 0.69 - 0.74 
  
Validation: 0.73 
95% CI: 0.68 - 0.77 
Age 1.00 (0.93 - 1.08) .941 
cT-stage 0.99 (0.91 - 1.06) .723 
Tumor location 0.92 (0.84 - 1.00) .062 
RT dose 0.95 (0.88 - 1.03) .193 
Conc. chemo 1.05 (0.97 - 1.13) .238 
Surgery procedure 1.12 (1.03 - 1.23) .010* 
pT-stage 1.42 (1.28 - 1.57) <.001* 
pN-stage 1.54 (1.44 - 1.64) <.001* 
Adj. chemo 0.90 (0.83 - 0.97) .006* 
O
ve
ra
ll 
su
rv
iv
al
 
Sex 0.87 (0.81 - 0.94) .001* 
Training: 0.68 
95% CI: 0.66 – 0.71 
  
Validation: 0.70 
95% CI: 0.65 – 0.74 
Age 1.13 (1.05 - 1.22) .001* 
cT-stage 1.13 (1.06 - 1.21) <.001* 
Tumor location 0.98 (0.90 - 1.07) .710 
RT dose 0.91 (0.85 - 0.98) .016* 
Conc. chemo 1.04 (0.97 - 1.12) .302 
Surgery procedure 1.18 (1.08 - 1.28) <.001* 
pT-stage 1.33 (1.21 - 1.46) <.001* 
pN-stage 1.35 (1.26 - 1.44) <.001* 
Adj. chemo 0.82 (0.76 - 0.88) <.001* 
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Figure 6.2 Nomograms developed for five year prediction of (A) local recurrence, (B) distant metastases, (C) 
overall survival. Each variable value is assigned a score, and the sum of scores is converted to a probability in 
the lowest scale. Calculated probabilities are assigned to a risk group (low, medium, high).  
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Discussion 
We have developed prediction models for LR, DM and OS for LARC patients based on 
clinical, treatment and pathological data. Our analysis is based on individual patient 
data accrued in five European randomized trials that tested preoperative CRT against 
preoperative RT or postoperative CRT and adjuvant chemotherapy. By pooling the 
long-course preoperative CRT/RT arms, heterogeneity in the data allowed the models 
to support decision making in daily practice. However, further external validation of 
our nomograms by using contemporary patient series is needed.    
Distant metastases prediction 
Our primary goal was to develop a nomogram to predict metastasis rates and select 
patients for postoperative adjuvant chemotherapy. Adding adjuvant chemotherapy to 
our pooled analysis improved the DM figures in the metastasis nomogram, but the 
benefit is small. The best model for DM resulted in the following predictors: ypN-stage, 
ypT-stage, surgery procedure, and adjuvant chemotherapy (in order of relevance).  
 
According to many studies, patients who achieve a pathologic complete response 
(ypT0N0) after preoperative CRT have improved local control rates and improved 
metastases-free survival rates.
19-21
 However, single randomized trials fail to confirm 
this, possibly because of lack of statistical power.
1,2
 Our analysis shows that responding 
patients had a lower risk of developing metastases. 
Pathological studies of the circumferential resection margins (CRMs) at the level of the 
anorectal junction and anal canal show a high risk of tumor involvement. The quality of 
surgery in the levator/anal canal area below the mesorectum varies between 
surgeons, because they may operate in different surgical planes.
22
 The higher risk of a 
residual tumor after an APR related to the more distal location of these cancers could 
partly explain the impact of the surgical procedure and tumor location in our 
nomogram. Prospective studies on the reliability of the levator plane (cylindrical APR) 
in reducing positive CRMs are currently under clinical evaluation.
23-25
 
Although the estimated probabilities by the nomograms are on a continuous scale, we 
proposed three risk groups of DM. Different treatment strategies could be followed for 
each of these categories (wait and see, 5FU-based regimens and combination of more 
drugs), and tailored schedule could be randomly tested for any category to test the 
value of multidrug schedules.  
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Figure 6.3 Kaplan–Meier curves of risk group stratification for A. Local control, B. distant control and C. 
overall survival for validation dataset (N=793). All curves are statistically different (pooled log-rank test,   = 
0.05). 
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Overall survival prediction  
Survival is more dependent on the incidence of DM (24% - 28%) than LR rates (7% - 
10%). The most predictive model for survival was based on predictors similar of those 
for LR and DM: ypT-stage and ypN-stage were most relevant, followed by cT-stage, 
age, adjuvant chemo, surgery procedure, RT dose and sex. Although 50% - 90% of cT4 
patients will be able to undergo a resection with negative margins, depending on the 
degree of tumor fixation, many still develop a LR as was observed in the univariate 
analysis and in different phase II studies.
26-28
 The selected randomized trials did not 
report the CRMs and the mesorectal fascia involvement before treatment, so the cT3 
stage could not be stratified. The few cT1-2 patients were accrued in the randomized 
trials for the evidence of involved nodes at the staging work-up. 
Biologic responses and compliance to cancer treatment seem to change with age: 
elderly patients showed a worse survival than younger patients, even if the LR 
nomogram supported less aggressive presentation, with lower LR rates.
29
 In any case, 
even if the randomized studies did not primarily select elderly patients, they 
demonstrated less favorable compliance with respect to survival when compared with 
patients in good physical and mental condition, as was also confirmed recently (short-
course preoperative RT and TME).
30
  
The RT dose affected survival and was related to a better local control (Table 6.2). The 
association between higher RT dose and better local control and worse sphincter 
function has been well recognized, although the combination of different radiation 
doses with concomitant chemotherapy means this topic continues to be debated.
31
  
Better survival in females was observed in a postoperative trial of the National Surgical 
Adjuvant Breast and Bowel Project (NSABP) group
32
 some time ago, but it barely 
reached significance in any subsequent randomized preoperative and postoperative 
randomized trials. In this analysis, survival associated more favorably with the female 
gender. Understanding of this difference is worthy of further investigation.  
Local recurrence prediction  
Our secondary goal was to develop a nomogram for LR to aid selection of follow-up 
type and intensity. A recent consensus conference recommended the selection of 
patients for individualized intensified follow-up, on the basis of age and tumor stage.
7
 
The best predictive model for LR was based on ypT-stage, cT-stage, age, ypN-stage, 
concomitant and adjuvant chemotherapy.  
Pathological downstaging remains the most relevant predictor of a low risk of LR. 
Concomitant chemotherapy has confirmed its contribution to ameliorating local 
control rates as shown in the EORTC 22921
1
 and FFCD 9203
3
 randomized trials. 
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Pending the long-term outcome of oxaliplatin-based randomized trials
33,34
 at present, 
infusional 5FU and oral fluoropyrimidines remain the standard agents to combine with 
preoperative RT.
7
 
5FU-based adjuvant chemotherapy reduced the risk of LR in the randomized dataset. 
To improve survival, the effect of this modality on LR incidence seems to be more 
important than for DM (Figure 6.1). This observation was also reported by a recent 
multicenter retrospective analysis.
35
 Thus, the nomograms can help clinicians 
recommend adjuvant chemotherapy according to the improvement in local control 
rather than for DM prevention.  
 
The nomograms allow identification of the contribution of adjuvant chemotherapy to 
the estimated outcome risk for any patient. When a responder patient (ypT0N0) of age 
65 years after LAR is compared with a non-responder patient (ypT3N1) after APR, the 
nomogram shows the small contribution of adjuvant chemotherapy for responders: 
For LR, the risk decreases from 3% to 2% for responders and from 20% to 12% for non-
responders. For DM, the risk decrease is 11% to 9% for responders and 51% to 36% for 
non-responders. For OS, the risk decreases from 11.5% to 9.5% for responders and 
68% to 57% for non-responders.  
 
Comparing our nomograms to the nomogram for recurrence in colon cancer from the 
Memorial Sloan-Kettering Institute,
10
 reveals that the number of nodes ratio is found 
as the most important factor in the colon nomogram, which was only recently 
proposed for rectal cancer.
36
 The addition of preoperative carcinoembryonic antigen 
(CEA) level is predictive, as reported earlier for rectal cancer.
37
 Despite the fact that 
the colon nomogram is based on retrospective data and is not validated, sample size is 
significant, and the model’s performance of 0.76 shows that these factors may be 
useful for further model development. The other nomogram by Massacesi et al
12
 
predicting survival, also confirms the importance of tumor response and, in addition, 
has CEA levels, number of metastatic sites and overall performance status.  
Statistical analysis  
The proposed nomograms have reliable c-indices for external validation (LR, 0.68; DM, 
0.73; OS, 0.70). This performance is good for clinical assistance, but is still not optimal. 
Adding other knowledge domains to the prediction model, such as traditional and 
molecular imaging, tumor biology and patient immune competence, is expected to 
increase model accuracy. Access to population-based registries for further validation 
will also increase model reliability. At present, the models represent a way to manage 
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subgroup-level evidence from the available randomized trials by number and to 
support the design of tailored studies according to different risk categories. 
This analysis did not overcome all uncertainties related to surgical quality control, 
treatment heterogeneity, missing values, unknown treatment compliance, and the 
unknown salvage treatment required for any pooled analysis. The trial effect was 
present for adjuvant chemotherapy; studies
1,38
 randomized for adjuvant 
chemotherapy showed no adjuvant chemotherapy effect on outcome, although the 
pooled dataset did. However, this may have been caused partly by the increase in 
number of patients. Future meta-analyses may provide more insight on the trial effect, 
but to achieve data heterogeneity, pooled data were preferred. The current statistical 
design does not account for competing risk of death for LR and DM prediction. 
Therefore, small overestimation of LR and DM risk is expected. However, 
interpretability and comparability with prognostic literature were motivations to use 
the framework of Kaplan-Meier method and the Cox proportional hazards model. 
 
In conclusion, our analyses suggest that a set of clinical, treatment and pathological 
variables after preoperative CRT or RT and surgery allows the development of 
nomograms to predict LR, DM and OS in patients with LARC. We propose a 
stratification in three risk groups that facilitates the selection of patients for clinical 
trials with different treatment approaches. Therefore, the nomograms provide 
decision support for the delivery of postoperative adjuvant chemotherapy for patients 
with a predicted risk of DM, LR, and OS and a rationale for more individualized follow-
up for patients based on the risk of LR and DM. 
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Abstract 
Purpose 
Personalized treatments require early characterization of a rectal cancer patient’s 
sensitivity to treatment. This study has two aims: (1) identify the main patterns of 
recurrence and response to the treatments (2) evaluate pathologic complete response 
(pCR) and two-year disease-free survival (2yDFS) as intermediate endpoints for 
predictive modeling. 
 
Methods and materials 
Pooled and treatment subgroup analyses were performed on five large European 
rectal cancer trials (2795 patients), who all received long-course radiotherapy with or 
without concomitant and/or adjuvant chemotherapy. The ratio of distant metastasis 
(DM) and local recurrence (LR) rates was used to identify patient characteristics that 
increase the risk of recurrences.  
 
Results 
The DM/LR ratio decreased to a plateau in the first two years, revealing it to be a 
critical follow-up period. Three patient groups were identified: 5%-15% had pCR and 
were disease free after 2 years (good prognosis), 65%-75% had no pCR but were 
disease free (medium prognosis) and 15%-30% had neither pCR nor 2yDFS (bad 
prognosis).  
 
Conclusions 
Compared with pCR, 2yDFS is a stronger predictor of overall survival. To adapt 
treatment most efficiently, accurate prediction models should be developed for pCR to 
select patients for organ preservation and for 2yDFS to select patients for more 
intensified treatment strategies. 
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Introduction  
To improve cancer treatment, new hypotheses need to be tested faster in a suitable 
cohort of patients to avoid diluting treatment for insensible patients. Common 
methods include the use of large databases
1
 and development of reliable surrogate 
endpoints. A typical example of such an endpoint is the finding that two-year disease-
free survival (DFS) is correlated with six-year overall survival (OS) for stage III colon 
cancer patients treated with adjuvant chemotherapy.
2
 Such surrogate endpoints can 
be identified early and have a high predictive value for survival. By treating them not 
as prognostic factors but as intermediate outcomes that can be predicted by statistical 
models, future clinical trials could evaluate individualized treatment strategies, with 
treatment randomization differentiated according to these predictions. An example of 
this strategy is model based decision making by using imaging based tumor response 
predictions, which has potential for radiotherapy boost decisions.
3
    
Patients with rectal cancer exhibit heterogeneous responses to treatment; Studies 
identified a subpopulation of patients who have a medically inoperable disease or who 
refused surgery but were cured with a low dose of radiotherapy.
4
 This subpopulation is 
characterized by slow growth and long regression time of rectal cancer. Patients who 
achieved a pCR are considered to be a more favorable subpopulation with less LR and 
DM as well as better OS.
5,6
 While the prediction of early intermediate endpoints (e.g. 
pCR) is less prone to uncertainties and may therefore be more accurate for 
individualizing treatment, these endpoints may be weaker prognosticators of long-
term outcome. 
 
In this study the value of both DFS and pCR is reported as intermediate endpoints for 
overall survival in locally advanced rectal cancer patients. The first aim of this study is 
to identify the optimal time point to assess DFS to best separate the population 
response-wise. A combination of treatment heterogeneity and a large number of 
patients in the pooled trial dataset allowed for sub group analyses of recurrence and 
response patterns. Inspired by Gelman et al.,
7
 patterns of recurrence are analyzed by 
calculating the ratio of DM rate and LR rate (which are competing risks)  over time to 
identify a subset of patients with more versus less aggressive disease.  
The second aim of the study was to evaluate pathologic complete response (pCR) and 
two-year disease-free survival (2yDFS) as intermediate endpoints in order to build 
predictive models which are able to identify patient subgroups before and during 
treatment. The rate of pCR may be a suitable endpoint to identify a subset of patients 
who could be successfully treated with more conservative surgery or a non-operative 
approach. In this setting, prediction of 2yDFS status may be useful to identify 
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subpopulations with the most aggressive tumors. The two-year timeframe was chosen 
based on initial inspection of the data, and may allow for selection of different 
chemotherapeutic regimens to reduce DM rates for this subpopulation by using an 
accurate prediction for 2yDFS status. If these two intermediate endpoints are able to 
separate the rectal cancer population in several risk groups accurate models predicting 
these endpoints may allow for better selection of personalized treatments along the 
treatment scheme (Figure 7.S1). It is beyond the scope of this paper to deliver accurate 
prediction models for pCR and 2yDFS, but the focus is on exploration of their role as 
intermediate endpoints in order to assist future prediction model generation.  
 
 
Methods and materials 
Study population 
The analyses were performed on data from five large European randomized clinical 
trials for locally advanced rectal cancer (N=2795) which were pooled on an individual 
patient level. This included the EORTC trial
8
 comparing preoperative radiotherapy with 
preoperative chemoradiation and observation with postoperative chemotherapy in a 
2x2 factorial design, the French trial
9
 comparing preoperative radiotherapy with 
preoperative chemoradiation, the German trial
10
 comparing preoperative 
chemoradiation with postoperative chemoradiation, the Polish trial
11
 comparing 
preoperative short-course radiation with chemoradiation, and the Italian trial
12
 
comparing observation with postoperative chemotherapy. The study designs, inclusion 
criteria, number of patients per trial, and accrual times of the pooled dataset were 
described in Valentini et al.
13
 All patients in the pooled dataset received preoperative 
radiotherapy (RT) with an average total treatment time of 34-39 days at 1.8 Gy per  
Figure 7.S1 Schematic overview of proposed time points along the treatment to predict pCR and 2yDFS 
(blue) and their possible corresponding treatment decision (red). 
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Table 7.1 Clinical and treatment characteristics of the pooled database and the four chemotherapy 
subgroups: no chemotherapy at all (i.e. only radiotherapy, RT), additional concomitant chemotherapy only, 
additional adjuvant chemotherapy only and both of these additional chemotherapies. Characteristics are 
given in number of patients N and as a percentage of the total number of patients in the selected group. 
Dataset Pooled RT only RT+Conc.chemo RT+Adj.chemo RT+both chemo 
 N [%] N [%] N [%] N [%] N [%] 
Patients 2795 [100] 366 [100] 839 [100] 501 [100] 1067 [100] 
Sex           
Male 1952 [69.8] 268 [73.2] 584 [69.6] 343 [68.5] 740 [69.4] 
Female 843 [30.2] 98 [26.8] 255 [30.4] 158 [31.5] 327 [30.6] 
Age           
Median 62.5  63.0  62.9  62.6  62.0  
Range 22.0 - 81.5 23.0 – 79.0 28.4 – 79.0 27.0 - 78.4 22.0 - 81.5 
cT-stage           
1+2 18 [0.6] - - 6 [0.7] 1 [0.2] 11 [1.0] 
3 2224 [79.6] 309 [84.4] 628 [74.9] 434 [86.6] 841 [78.8] 
4 274 [9.8] 41 [11.2] 90 [10.7] 51 [10.2] 92 [8.6] 
no data 279 [10.0] 16 [4.4] 115 [13.7] 15 [3.0] 123 [11.5] 
cN-stage           
0 311 [11.1] 1 [0.3] 230 [27.4] - - 80 [7.5] 
+ 551 [19.7] 3 [0.8] 154 [18.3] - - 377 [35.4] 
no data 1933 [69.2] 362 [98.9] 455 [54.2] 501 [100] 610 [57.2] 
RTdose           
<45 Gy 115 [4.1] 18 [4.9] 39 [4.6] 18 [3.6] 40 [3.7] 
45-47 Gy 2135 [76.4] 342 [93.4] 645 [76.9] 477 [95.2] 670 [62.8] 
>47 Gy 543 [19.4] 6 [1.6] 154 [18.4] 5 [1.0] 357 [33.5] 
no data 2 [0.1] - - 1 [0.1] 1 [0.2] - - 
Conc.chemo           
no 867 [31.0] 366 [100] - - 501 [100] - - 
yes 1925 [68.9] - - 839 [100] - - 1067 [100] 
no data 3 [0.1] - - - - - - - - 
Localization           
Proximal 1598 [57.2] 184 [50.3] 491 [58.5] 261 [52.1] 645 [60.4] 
Distal 1068 [38.2] 150 [41.0] 319 [38.0] 205 [40.9] 389 [36.5] 
no data 129 [4.6] 32 [8.7] 29 [3.5] 35 [7.0] 33 [3.1] 
pT-stage           
0 299 [10.7] 21 [5.7] 140 [16.7] 18 [3.6] 120 [11.2] 
1 191 [6.8] 25 [6.8] 64 [7.6] 37 [7.4] 64 [6.0] 
2 816 [29.2] 99 [27.0] 266 [31.7] 133 [26.5] 312 [29.2] 
3 1324 [47.4] 185 [50.5] 319 [38.0] 289 [57.7] 520 [48.7] 
4 74 [2.6] 15 [4.1] 25 [3.0] 11 [2.2] 22 [2.1] 
no data 91 [3.3] 21 [5.7] 25 [3.0] 13 [2.6] 29 [2.7] 
pN-stage           
0 1879 [67.2] 233 [63.7] 617 [73.5] 309 [61.7] 707 [66.3] 
+ 827 [29.6] 116 [31.7] 201 [24] 176 [35.1] 328 [30.7] 
no data 89 [3.2] 17 [4.6] 21 [2.5] 16 [3.2] 32 [3.0] 
Adj.chemo           
no 1206 [43.1] 366 [100] 839 [100] - - - - 
yes 1568 [56.1] - - - - 501 [100] 1067 [100] 
no data 21 [0.8] - - - - - - - - 
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fraction, followed by surgery 36–47 days after the end of RT. RT dose and the possible 
addition of preoperative and postoperative chemotherapy (chemo) introduced 
treatment heterogeneity into the database. No patients had metastatic disease at the 
beginning of treatment. A total of 24 patients who underwent a local excision were 
excluded in advance.  
Although many variables were collected in individual clinical trials, this analysis was 
restricted to assessing the long-term outcome of four subpopulations: 1) those who 
achieved a pCR and were disease free after 2 years (N=246, 9.2%), 2) those with pCR 
but also a recurrence (N = 21, 0.8%), 3) no pCR but disease free after 2 years (N = 1868, 
70,1%) and 4) no pCR and also a recurrence (N = 528, 19,8%). Additional variables 
included RT dose (<45 Gy, 45 Gy and >45 Gy), administration of concurrent and/or 
adjuvant chemotherapy (yes/no), the post-RT tumor localization used to determine the 
surgery strategy (proximal or distal, depending on the tumor’s location from the anal 
verge with 10 cm cut-off), and the interval between the last fraction of RT and surgery 
(<28 days, 28-42 days and >42 days).   
PCR was defined as the absence of tumor cells in the resected specimen (ypT0N0). LR 
was defined as tumor presence in the pelvis or perineum, or in the anastomosis as 
confirmed by histology. DM was defined as evidence of extrapelvic tumor tissue 
confirmed by at least two imaging exams. The cumulative incidence of both of these 
outcomes was reported separately. The absence of both LR and DM within two years 
was defined as disease free. Patients with less than two years of follow-up time and 
without occurrence of an event (death or recurrence) were excluded from the DFS 
analysis (excluded: N=301).  
Statistical analysis 
Treatment heterogeneity was accounted for by performing subgroup analyses for the 
patients receiving different chemotherapy regimens in addition to RT: no chemo, 
concomitant or adjuvant chemo, or a combination of both chemotherapies. The 
analyses:   
  
1. The risk ratio at time t was defined as the ratio of cumulative rate of DM at time t 
divided by the cumulative rate of LR at time t. By calculating the risk ratio for each year 
during the follow-up period, a time trend of the risk ratio was characterized. 
Confidence intervals were calculated by bootstrapping the ratio of the two rates from 
the estimated and normal assumed distributions to arrive at the ratio distribution.  
2. The long-term outcome between the non-pCR and pCR populations and between 
non-2yDFS and 2yDFS, as well as five- and ten-year rates for the cumulative incidence 
of LR, DM, and OS, were reported
14
 and confidence intervals were based on the log-log 
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transform.
15
 All time intervals were measured from the date of randomization, except 
for the analyses presented in analysis 4 described below. 
3. Logistic regression was used to study the impact of characteristics such as sex, age, 
tumor localization, cT-stage, RT dose, and time to surgery on the odds ratios for the 
three clinical outcomes of interest: pCR, 2yDFS, and five-year overall survival status 
(5yOS).  
4. The long-term outcomes of the subpopulations defined by their pCR and two-year 
disease-free status were compared by log-rank test, including the four chemotherapy 
group stratification. The landmark approach
16
 was used to avoid the bias of death 
within two years affecting the outcome of investigation (2yDFS).  
The analyses were conducted in line with the intention-to-treat principle, and 
performed using SPSS (version 15.0) and MATLAB (version R2010b, MathWorks Inc.).   
Results 
The database characteristics (Table 7.1) are similar in the four subgroups, with the 
exception of roughly 4% more males in the RT-only subgroup, a higher RT dose in the 
subgroups with concurrent chemo and both chemotherapies, more pT0 in the 
concurrent chemo subgroups compared to the RT-only groups (16.7% and 11.2% vs 
5.7% and 3.6%, respectively), and roughly 8% more pN0 for the concurrent chemo 
subgroup.  
Risk ratio  
The overall risk ratio between the rates of DM and LR (Figure 7.1A) revealed that, at 1-
year follow-up, six times more patients had developed DM than LR (between 4.2 and 
7.5, taking 95% confidence intervals into account). This number decreases to 
approximately 2.5 at two years and remains relatively constant thereafter, with a slight 
negative slope. Figure 7.1B shows that approximately 80% of the recurrences occur 
within the first four years, while deaths occur later. For the risk ratios of different 
chemo treatment schemes (neoadjuvant vs adjuvant), similar curves as in Figure 7.1 
are observed (Figure 7.2). These plots show that adding concomitant chemo to RT 
results in a higher DM/LR risk ratio over time compared to no concomitant chemo, 
suggesting that concomitant chemo may result in LR reduction without affecting DM 
incidence (after 2 years concomitant chemo reduces DM by 14.2% and LR by 49.0% 
compared to the non-concomitant chemo population).  
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Figure 7.1 Risk ratio, cumulative rate of distant metastases / cumulative rate of local recurrences, for A. All 
the patients including 95% confidence interval, and B. Histograms for the percentages of local recurrence 
and distant metastases occurrences (100%=event occurrence at 10 years) for the total population (N=2795) 
for each year of follow-up.  
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In addition, the population given chemo both adjuvant and neoadjuvant show 
different behavior on those curves than the other chemo schemes, with the ratio 
staying relatively constant and decreasing slowly over time. These differences before 
and after two years are confirmed by the results shown in Figure 7.S2, indicating that 
aggressiveness of disease is increased for early recurrences, resulting in poor survival, 
mainly associated with administration of adjuvant chemo. For this reason we consider 
2yDFS a reliable intermediate endpoint to stratify the population.  
Figure 7.2 Risk ratio, cumulative rate of distant metastases / cumulative rate of local recurrences, for 
different combinations of given concomitant and adjuvant chemotherapy, including 95% confidence 
intervals over 10 years of follow-up. 
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Characterization of populations according to pCR and 2yDFS status 
The pCR status was known for 2682 patients; of these, 11.1% had a pCR (N=298). There 
were significant differences in long-term outcome between the pCR and non-pCR 
populations (Table 7.2). After ten years, the non-pCR population had a 10.7% higher LR 
incidence than the pCR population (14.8% vs 4.1%). DM was more frequent in the non-
pCR group by 17.1% after ten years (35.2% vs 18.1%). The pCR population had 73.3% 
overall survivors versus 57% in the non-pCR population (16.6% difference). All 
differences were significant (log-rank p-values <.001). In the non-2yDFS population 
43.1% had LR and 94.8% had DM at five years, and only 12.9% survived. These 
numbers are far more favorable for the 2yDFS population (6.1%, 16.5%, and 85.3%, 
respectively). 
 
Table 7.2 Event rates for pathologic complete response (pCR) vs non-pCR populations and disease free 
survival at 2 years (2yDFS) vs non-2yDFS at 5 and 10 years of follow-up, including confidence intervals (CI) 
and p-values for the log-rank test to test if these two populations are significantly different (= .05).    
   5 years 10 years    
Outcome  N Rate [95% CI](%) Rate  [95% CI] (%)    p  HR [95% CI] 
LR rate          
Non-pCR  2415 12.8 [11.5-14.2] 14.8 [12.9-16.9] <.001 0.32 [0.15-0.68] 
pCR  267 1.6 [0.6-4.2] 4.1 [1.9-8.7]    
          
Non-2yDFS  611 43.1 [37.6-49.0] 46.0 [39.1-53.5] <.001 10.9 [8.5-14.0] 
2yDFS  2184 6.1 [5.0-7.4] 8.3 [6.9-10.0]    
DM rate          
Non-pCR  2415 32.3 [30.4-34.3] 35.2 [33.1-37.4] <.001 0.59 [0.42-0.83] 
pCR  267 13.0 [9.3-18.0] 18.1 [12.2-26.5]    
          
Non-2yDFS  611 94.8 [90.8-97.5] 94.8 [90.8-97.5] <.001 21.7 [18.3-25.6] 
2yDFS  2184 16.5 [14.8-18.4] 20.5 [18.4-22.8]    
OS rate          
Non-pCR  2415 69.5 [71.4-67.5] 57.0 [59.5-54.4] <.001 0.73 [0.54-0.98] 
pCR  267 84.3 [88.4-78.9] 73.3 [80.5-64.0]    
          
Non-2yDFS  611 12.9 [10.0-16.2] 6.5 [4.1-9.6] <.001 14.1 [12.2-16.4] 
2yDFS  2184 85.3 [83.7-86.8] 71.3 [68.5-73.9]    
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Multivariate analyses  
When considering the odds ratios for several predictors (Figure 7.3), 2yDFS better 
resembles OS than pCR as an outcome, which is significant for sex in the pooled 
population and for tumor localization in the adjuvant chemo populations. Longer 
delays between RT and surgery have an increasing effect on pCR rate but not on 
survival rate.  
 
 
Figure 7.S2 Overall survival for recurred patients for two groups with different time periods of the 
occurrence of first recurrence: within 2 years (N=681) and after 2 years (N=277). Starting point for 
measuring overall survival is the date of first recurrence. 
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Figure 7.3 Odds ratio’s (OR) based on the early multivariate prediction of pathologic complete response 
(pCR), disease free survival at 2 years (2yDFS) and overall survival at 5 years of follow-up (5yOS) with 
corresponding 95% confidence interval represented by the vertical lines. OR axes are on the same scale for 
all variables. Six pre-surgical factors were evaluated for their OR: Sex, age, tumor localization, cT-stage, 
radiotherapy dose and time from last RT fraction to surgery. Beside the pooled database, the four 
chemotherapy subgroups described in Table 7.1 are also evaluated. Dashed lines describe OR of 1. The 
direction of the OR is indicated in italic; the direction of the OR indicated a positive effect on outcome (more 
pCR, more 2yDFS, more 5yOS). White markers represent non-significant difference from 1 and black markers 
represent a significant different OR from 1.     
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pCR vs 2yDFS 
Figure 7.4 shows that disease-free status at two years appears to be a better predictor 
of OS than pCR. The landmark analysis shows that achieving a pCR is significantly 
beneficial when there is no recurrence within two years of follow-up. In the case of 
early recurrence, pCR status appears to be statistically irrelevant for OS. The greater 
effect for OS of achieving 2yDFS than pCR holds for all chemo subgroups. Due to the 
low number of patients in the subgroup pCR + recurrence within 2 years and the 
similarity in OS curve development with the no pCR + recurrence group these are 
considered as one group in the results. This results in three risk groups: 1) pCR + 2yDFS 
in 246 patients (9.3%, with an interval of 2.7-14.9% depending on treatment group), 2) 
no PCR + 2yDFS in 1868 patients (70.7% with interval 64.2-76.6%) and 3) no 2yDFS in 
528 patients (20% with interval 17.5-29.3%).    
Discussion 
This study identified different subpopulations of locally advanced rectal cancer based 
on their intermediate outcomes in a pooled database of five large European 
randomized trials. We identified three broad clinical patient subgroups:  
 Excellent (~10% with interval 5-15%): curable patients, highly treatable, organ 
preservation to be pursued, identified by a pCR and 2yDFS.  
 Good (~70% with interval 65-75%): curable patients, require effective local 
treatment, identified by no pCR- and 2yDFS; for some, the role of combined 
treatment is questionable.   
 Poor (~20% with an interval of 17.5-30%): ongoing treatment strategies do not 
lead to cure or patients having an early and late-occurring recurrent disease; 
They are identified by having no pCR and no DFS within 2 years.  
The overall longer-term aim of the identification of these three identified groups is to 
develop accurate prediction models for the two intermediate outcomes pCR and 
2yDFS with data before and along the treatment. Combined predictions of pCR and 
2yDFS (3 risk groups) using clinical, imaging and biomarkers would allow for 
personalizing treatment. 
    
Variables related to pathological staging after treatment (pT stage and pN stage) were 
recently found to be the main clinical predictors of LR, DM, and OS,
13
 with patients 
achieving a pCR having an OS benefit of 14.7% at five years and 16.3% at ten years. 
This is consistent with previous analyses suggesting better outcomes for patients with  
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Figure 7.4 Overall survival plots for population stratified for their combined status of pCR and 2yDFS. The 
time is measured from the chosen landmark of 2 years of follow-up to avoid bias of already deceased 
patients before that time. The five plots represent the pooled database and the subgroups based on 
administered concomitant and/or adjuvant chemotherapy. Encircled letters A, B, C and D indicate the 
represented subgroup. Letters with an asterisk indicate which curves are significantly different from the 
indicated one with =.05.  
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a pCR.
5,6
 These studies reported higher five-year survival rates of 91.6% and 87.6% 
respectively for patients who achieve a pCR, compared with 84.3% in the present 
study. However, Maas et al.
6
 reported a lower survival benefit of 11.2% at five years 
for patients achieving a pCR. In contrast to our pooled database, both studies used 
prospective and retrospective results, and almost all patients received concomitant 
chemo. Therefore, higher absolute rates for the pCR and non-pCR populations are 
expected. Also, the studies in Maas et al. were more recent, and the results may 
reflect improved treatment regimens and pathology assessment. In this regard, our 
study shows the long-term benefits of a pCR. In the current study we did not explore 
formal analyses of surrogacy, as there were too few trials and the treatments were too 
heterogeneous to perform a valid meta-analysis. Previously, the EORTC 22921 and the 
FFCD 9203 rectal cancer trials, which are both included in the current pooled dataset, 
explored the surrogacy of pCR and progression-free survival (PFS),
17
 finding that pCR 
was not a qualified surrogate endpoint for PFS and OS, while PFS was a surrogate 
endpoint for OS.  
For the pCR subgroup with favorable outcomes, lower RT doses or more conservative 
surgical strategies might be applied to improve their quality of life. To individualize 
these treatment decisions, reliable prediction models need to be developed to 
distinguish between these pCR subgroups. 
In the pCR group, 61% of the LR cases are reported after five years post treatment (5y 
LR: 1.6%, 10y LR: 4.1%). To our knowledge, this has not yet been reported in the 
literature, though it supports Habr-Gama et al.
18
 These findings indicate that patients 
with pCR require prolonged observation. 
Two-year disease-free status was associated with an OS benefit of 45.5% and 64.8% at 
five and ten years respectively, compared to patients with recurrence within two 
years. This supports the identification of a population of patients with aggressive 
disease that recurs early and leads to poor survival rates, regardless of treatment.
8
 
While not being the aim of this study, we identified some prognostic factors, such as 
sex, cT-stage, and tumor localization (Figure 7.3), but more imaging and biological 
markers should be explored to predict 2yDFS reliably. pCR status is a plausible 
candidate for 2yDFS based on the studies described above. The comparison between 
OS according to pCR and 2yDFS showed that the latter had a stronger prognostic 
impact (Table 7.2, Figure 7.4). A similar result was seen for patients who received 
either chemoradiotherapy alone or who received both chemoradiotherapy and 
adjuvant chemo (Figure 7.4).  
DFS is superior at predicting survival and should be used as an intermediate endpoint 
for new prediction models, with the added benefit that the outcome is clear at only 
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two years follow-up. Accurate prediction of 2yDFS is recommended to select patients 
for adjuvant chemo regimens. 
To decide on more or less aggressive treatments and/or more QoL-oriented 
treatments, it is important to identify the subgroup of patients with early recurrence, 
because inclusion in prospective randomized trials may negatively affect the findings. 
Also, the recurrence analysis of the DM/LR ratios (Figure 7.1) showed a prevalence of 
metastases in the first two years, indicating a patient group with aggressive disease in 
whom 5FU based treatment does not appear to reduce the metastasis rate. The not 
previously reported finding that the DM/LR ratio remained flat after two years, 
identifies a second group of patients with tumors which can become active after a long 
follow-up time and have a very slow growth rate. This may be due to an immunological 
response, and suggests that patients should be followed up for an extended period of 
time. It appears that for patients receiving concomitant chemo the DM/LR ratio is 
higher than for the patients without, mainly as a result of the overall reduction of LR 
induced by concomitant chemo, resulting in improved local effectiveness without 
corresponding reduction of DM (Figure 7.2). This effect is seen to a lesser extent for 
DM.  
It should be emphasized that, in three trials (N=1244), adjuvant chemo was not 
randomized or mandated; 73% did receive adjuvant chemo, and the percentage of 
these patients with pN+ stage was significantly higher than in the group without 
adjuvant chemo. While this introduces a possible bias, it is likely to be small given the 
patient numbers involved (14% of the total population had pN+ combined with 
adjuvant chemo). 
Conclusions 
This study identified different populations of rectal cancer patients: highly responsive 
patients (pCR and disease free after 2 years), good responsive curable patients (no pCR 
but disease free thereafter), and patients with early and late recurrence regardless of 
pCR status (poor prognosis). While both intermediate outcomes are prognostic 
(confirming our hypotheses), 2yDFS is stronger than pCR for OS. pCR predictions may 
identify a minority of highly responsive patients for whom surgery can be tailored, 
organ preservation promoted, and quality of life or other patient-reported outcomes 
improved, whereas 2yDFS predictions identify less responsive patients who may 
benefit from more aggressive chemo. Therefore, 2yDFS should also be considered as 
an intermediate endpoint in future trials, focusing on identifying and evaluating early 
predictors for pCR and 2yDFS in order to adapt treatment most efficiently. 
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The main goal of this thesis was to study the prognostic and predictive value of clinical 
factors, imaging and blood biomarkers for pathologic complete response and follow-up 
outcome related to recurrences and survival of patients with locally advanced rectal 
cancer (LARC). Multivariate prediction models were developed, i.e. trained and 
validated on large databases. These models can be used as clinical tools that allow for 
treatment modifications in an early stage based on individual predictions. This 
assistance in decision support requires predictions with high accuracy, which can be 
only achieved by a holistic approach in which various data sources, multiple time-
points and validated statistical methods are used. This chapter summarizes the studies 
and findings in this thesis and discusses them in a broad perspective and with respect 
to relevant literature. Furthermore, the implications of this work for the future of 
individualized medicine are presented.     
Response prediction 
The main motivation to assess tumor response to treatment in locally advanced rectal 
cancer is the ability to tailor treatment for certain risk groups. For example, an early 
prediction during chemoradiotherapy (CRT) would allow for tumor response 
improvement by giving a radiotherapy (RT) boost to patients for which a good but not 
complete response is predicted.
1
 For patients with a high chance of a complete 
response no additional treatment would be required, reducing also unnecessary 
toxicity. For these complete responder candidates a wait-and-see policy after CRT is a 
possibility in order to reduce treatment-related morbidity and mortality, for which 
excellent results are reported.
2
 Alternatively, reduced surgery with for example a 
transanal excision is an option if there is still evidence for a small remaining lesion. 
These organ sparing approaches increase the quality of life for patients because 
possible consequences of surgery, like permanent stomas, faecal incontinence and 
sexual dysfunction, can be avoided. For patients undergoing a wait-and-see approach 
or reduced surgery an intensified follow-up is however required to track down possible 
local recurrences as early as possible. Because of the focus on identifying patients with 
high probability of a complete response, pathologic complete response (pCR) was used 
as the predicted outcome in all presented response prediction studies. Three sources 
of data were used for tumor response assessment and prediction in this thesis: pre-
treatment clinical data like demographics and tumor stage, 
18
F-fluorodeoxyglucose 
(FDG) positron emission tomography (PET) imaging and blood biomarker data.  
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Clinical predictors 
When assessing clinical data for response assessment TNM-staging is often firstly 
considered because of its availability and dominance in making treatment decisions. All 
patients included in the response prediction studies in this thesis were metastasis free 
(M0). Clinical tumor (cT) stage and clinical nodal (cN) stage were found to be associated 
with pCR in all three studies (chapter 3-5) when evaluating only pre-treatment data. A 
recent analysis with large amount of patients found that cT-stage was predictive for 
pCR but that cN-stage shows only a trend.
3
 This study contained however also old 
cases where computed tomography (CT) imaging was used for cN-stage scoring. The 
cT-stage and cN-stage stayed significantly associated with pCR when PET-imaging data 
before and during treatment was added, but dropped out of the equation when PET 
information just before surgery was added. It is expected from prediction theory that 
data measured at this late time point have more impact than the data measured pre-
treatment (like cT- and cN-stage). Another finding was that the tumor dimensions are 
associated with pCR. In all the models the tumor length, assessed by mainly MRI 
imaging at diagnosis, or the maximum diameter in the metabolic tumor volume (MTV) 
were predictive for pCR in a multivariate setting. Although tumor length shows a high 
correlation with tumor volume, the latter was never selected by the models. Others 
have found that changes in metabolic volume in the pre-post treatment setting were 
significant for pCR but not the intermediate case (between pre-treatment and during 
treatment, two weeks after start of CRT).
4
 Changes in tumor volume or length over 
time were however not found to be significant in the presence of PET activity data. 
This can be explained by the high correlation between this tumor dimension change 
and reduction in PET activity (chapter 4). However, clinical data pre-treatment alone 
has low prediction accuracy; area under the curve (AUC) of the receiver operating 
characteristic (ROC) curve was only 0.61 (N=677, chapter 3) or 0.63 (N=267, chapter 5). 
For that reason, other sources of data were taken into account.  
PET imaging 
Currently, the leading candidate predictive marker for histopathological response 
prediction in LARC is FDG-PET
 
imaging. A meta-analysis confirmed the added value of 
PET imaging, especially for intermediate PET imaging (during CRT).
5
 The majority of the 
included studies evaluated pre-CRT versus post-CRT PET imaging and only some assess 
pre-CRT PET versus intermediate-CRT PET. Both analyses are important for different 
reasons, as explained above. During CRT, additional treatment decisions like a RT boost 
can be made based on the available information. Predictions made after CRT are more 
useful to tailor surgery (reduction or wait-and-see). The decision for a wait-and-see 
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approach can better be made as late as possible by using both specialized prediction 
models like the one in chapter 3 and careful assessment of imaging, endoscopies and 
biopsies.
2
 The limitations of the PET studies in the literature are their small sample 
sizes (numbers of patients are 20-42 for early PET, with a maximal number of patients 
of 78 for the pre-post setting), the main focus on good versus bad responders (not 
pCR), the univariate setting in which analyses were performed and the lack of 
validation. This thesis presented two studies assessing PET imaging in the pre-post 
setting (chapter 3) and during CRT (chapter 4). These studies aim to increase the 
clinical applicability of the developed decision making tools by using larger numbers of 
patients, external validation datasets, and multiple sources of data and focusing on 
pCR. 
 
For the first model taking into account clinical and PET data pre-CRT and post-CRT, the 
response index of the pre-treatment tumor length, the relative difference (response 
index, RI) of maximal standard uptake value (SUV) and the SUVmax value in the tumor 
just before surgery were predictive. Others have also reported (significant) indications 
that the response index and post-treatment SUVmax are predictive for response, 
whereas pre-treatment PET data do not provide sufficient predictive power.
6-8
 The 
second model (pre-CRT + intermediate-CRT) shows similarity in predictor choice for 
SUV and tumor dimensions: cT-stage, cN-stage, SUVmean and intermediate maximal 
tumor diameter. The change in SUVmean at the intermediate time point was found 
predictive in earlier studies for responders versus non-responders,
9-11
 but SUVmax was 
usually stronger when predictions for pCR changes are made.
12,13
 In our study the 
response index of SUVmean was a stronger predictor than the RI of SUVmax. These two 
measures are also highly correlated, especially since our PET contouring was semi-
automatic and calibrated for both institutes, resulting in less variation in SUVmean due 
to contouring.
14
 
 
The significant difference in performances that we reported between the performance 
of the clinical model and the post-CRT PET data model reflects what others have found 
in their post-treatment PET analyses. Addition of pre-treatment PET only increases 
AUC from ~0.6 to ~0.7, whereas addition of repeated PET increases performances to 
acceptable levels; AUC was 0.83 for training and 0.86 for validation for the pre-post 
model and respectively 1.0 and 0.78 for the pre-intermediate model. The studies that 
report AUC in general predict good versus no response instead of pCR, which has often 
higher accuracy.
11,13
 Response prediction is in practice more accurate because the 
number of events for good response (45-55%) is much higher than those of pCR (15-
30%). Furthermore, small studies, although very controlled, might be biased towards a 
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positive outcome by chance. One might also expect that the accuracy of predictions at 
a later stage (post-CRT) should be more accurate than during CRT, but this is not 
always the case.
11
 The first reason for this can be that the radiotherapy leads in some 
cases to peritumoral inflammatory tissue, which also avidly consumes FDG.
15
 This can 
result in underestimation of the metabolic response in the post-CRT scan. Measuring 
inflammation requires for example dynamic FDG-PET imaging, which is discomforting 
for the patient and more complex and more time-consuming to analyze.  Another 
reason for unreliable assessment of post-CRT PET scans is the partial volume effect 
(PVE).
16
 The PVE could lead to an underestimation of FDG uptake levels, in particular in 
small tumor volumes. Because CRT shrinks tumors, PVE will affect assessment of post-
CRT scans more than early repetitive scans.    
 
There are diverse factors influencing the quantification of PET imaging, like for 
example the used equipment, scanning protocol, uptake time of the radioactive tracer, 
the patient blood glucose level (BGL) and the time of scan acquisition (relative to the 
time of tracer injection). Several factors have been corrected for in the presented 
studies. Correcting SUV measures for the measured blood glucose level was previously 
shown to have a positive effect on response prediction.
17
 In the presented studies SUV 
measures were corrected for blood glucose, but most studies do not correct for it, 
even when it is known that glucose is in competition with FDG in metabolically active 
tissues.
18
 The time between tracer injection and acquisition is also an important factor 
because after 60 minutes, which is the guideline in most protocols, FDG is still 
accumulating in the tumor at fast rates. This means that large variations of SUV 
measures are present for deviations in acquisition time. Scanning after 90 minutes 
would be better but that will reduce patient throughput on the scanner.
19
 In the 
prospective THUNDER trial (chapter 4) it was difficult to harmonize protocols for e.g. 
acquisition time and reconstruction algorithms, also because different scanner types in 
different countries were involved. However, the semi-automatic contouring of the 
tumor on PETCT was standardized by performing phantom studies in the involved 
institutes, thereby calibrating the background corrected SUV thresholds.
20
 When 
interpreting multicentric PET studies one is advised to take the above described 
differences into account and to acknowledge any standardization.      
Blood biomarkers 
Blood biomarkers as additional predictors are attractive because the measurements 
are accurate, standardized, cost-effective and not discomforting for the patient. 
Previous studies on the predictive value of blood biomarkers are limited to studies 
mainly evaluating one or two biomarkers. The most studied biomarker for response to 
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CRT in rectal cancer is carcinoembryonic antigen (CEA).
21-23
 Only one other study 
analyzed the predictive value of osteopontin and interleukin-6.
24
 This thesis presented 
a study in which the added predictive value of 9 pre-treatment blood biomarkers for 
response was evaluated (chapter 5). The most significant predictor for pCR was CEA, 
because it remained significant after adding the biomarkers to PET related and clinical 
data. In this study also good response was predicted (ypT0-2N0) for which CEA and IL-8 
were predictive in the multivariate setting. For CEA its association with response to 
CRT is reported in LARC, but for IL-8 it is not.
21-23
 Including these blood biomarkers in 
models based on clinical parameters and pre-treatment PET-based parameters 
resulted in an increased AUC of 0.5 on average, however this increase was not 
significant. The presented data provided a proof of principle that biomarkers contain 
predictive information for rectal cancer, however extra time points for PET imaging in 
combination with (repeated) blood biomarker measurements and external validation 
of the prediction models are required to substantiate this additive value.    
 
The limitation of the presented response prediction studies is the lack of centralized 
pathology scoring to determine the predicted outcome ypTN-staging. However, a 
recent comparison between routine pathological examination and additional step 
sections in resection specimens showing no viable tumor cells at initial examination, 
showed no differences in outcome.
25
 Furthermore, pooled analysis of a large series of 
patients included in different studies, showed a clear prognostic value of pCR after CRT 
for long-term outcome, even if pooled from different studies, indicating that pCR as 
scored in routine pathology procedures is a valuable endpoint.
3
  
As suggested, the developed models for pCR can be used for either additional 
treatment when predictions are made during CRT or to tailor surgery for predictions 
made post-CRT. Whether the found AUCs between 0.8 and 0.9 are accurate enough for 
clinical practice depends on the cut-off values for the risk groups. In post-CRT response 
prediction specifically, the focus should be on high specificity to avoid possible under-
treatment (less surgery when surgery is required) rather than overtreatment (standard 
treatment when less surgery could have been considered). In chapter 4 this was 
considered for the threshold determination to avoid false positives for pCR. To 
conclude the discussion on response prediction in this thesis, it was found that 
repeated PET in combination with clinical factors resulted in the highest accuracy and 
blood biomarkers are a promising addition for response prediction. To our knowledge 
these are the first studies for rectal cancer showing that a holistic approach for 
response prediction is required.    
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Predicting long-term follow-up outcomes  
Five years of follow-up 
In recent trials it was found that locoregional control alone is not sufficient to improve 
survival and therefore distant control must also be taken into account for new 
treatment strategies.
26-30
 Administration of postoperative chemotherapy for all 
patients is hazardous for the 75% of the patients that do not require additional 
chemotherapy to improve survival. Therefore, prediction models for distant 
metastases (DM) and overall survival (OS) are useful to select patients who may 
benefit from the addition of postoperative adjuvant systemic treatment. The reason to 
predict local recurrences (LR) on the other hand, might be very helpful in deciding the 
appropriate intensity of follow-up. High risk patients require intense follow-up in order 
to reduce mortality rates.
31,32
 Chapter 6 of this thesis presented a high-impact study in 
which LR, DM and OS after 5 years of follow-up were predicted for a large group of 
patients who were pooled from 5 large European trials. As described in the response 
prediction section, variables scored later in the treatment scheme were more 
predictive as is found also in the follow-up models. The found DM predictors were the 
yielded pathological nodal-stage (ypN), yielded pathological tumor-stage (ypT), surgery 
procedure, and adjuvant chemotherapy. This means that response (ypTN), as 
predicted outcome in chapter 3-5, is now one of the main predictors for further 
prognosis of the patient. The reason why adjuvant chemotherapy was added as 
candidate predictor is the ability to calculate its effect for a specific patient. The higher 
risk of a residual tumor after an abdominoperineal resection (APR) related to the more 
distal location of these cancers could partly explain the impact of the surgical 
procedure and tumor location in our nomogram. Prospective studies on the reliability 
of resecting in different surgical planes for reducing positive CRMs are currently under 
clinical evaluation.
33-35
 The same predictors were found for overall survival but with the 
addition of cT-stage, age, RT dose and sex. Literature confirmed also these predictors 
for age
36
 and sex
37
, but even though the effect of RT on local control is recognized, the 
effect of different RT doses (in combination with chemotherapy) remains debated.
38
 
The nomogram for LR contains the predictors ypT-stage, cT-stage, age, ypN-stage, 
concomitant and adjuvant chemo. It was also found that a recommendation of 
adjuvant chemo is even more motivated by improvement in local control rather than 
for DM prevention, implying that all three nomograms need to be considered when 
making treatment decisions. In another published nomogram
39
 nodal involvement was 
the most important factor for recurrence, which was only recently proposed for rectal 
cancer.
40
 This nomogram and another one for survival
41
, also included 
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carcinoembryonic antigen (CEA) levels, resulting in nomogram accuracies of 0.76, 
which confirms the importance of blood biomarkers once more. In the referred 
survival model, tumor response was equally dominant for further prognosis as was the 
case in the presented nomograms.     
The proposed nomograms have reliable but suboptimal c-indices for external 
validation (LR, 0.68; DM, 0.73; OS, 0.70). Uncertainties related to surgical quality 
control, treatment heterogeneity, missing values, unknown treatment compliance 
might be contributing to these suboptimal performances. Although the estimated 
probabilities by the nomograms are on a continuous scale, we proposed three risk 
groups for the outcomes. These predicted risk groups may assist clinicians in selecting 
different treatment strategies, especially for the combination of more 
chemotherapeutic drugs and tailored follow-up schedule. 
Two years of follow-up 
By choosing earlier clinical endpoints than 5 or 10 years, new hypotheses can be tested 
faster which is beneficial for improving cancer treatment. Patients who achieved a pCR 
are considered to be a more favorable subpopulation with less LR and DM as well as 
better OS. pCR is expected to be more accurate for individualizing treatment, however 
this endpoint was found to be a weak prognostic factor of OS. Two-year disease-free 
survival (2yDFS) is an alternative endpoint having a high correlation with five year 
survival. In this thesis (chapter 7) this surrogate endpoint was not treated as a 
prognostic factor for survival but as an intermediate outcome that could potentially be 
predicted by a statistical model. This chapter explored the role of 2yDFS and pCR as 
intermediate endpoints in order to assist future prediction model generation. Three 
subgroups of patients were identified: 1. curable patients with a pCR and 2yDFS (5%-
10%, highly treatable, organ preservation to be pursued), 2. curable patients with no 
pCR but a 2yDFS (65%-75%, requiring effective local treatment), and 3. insensitive 
patients with no pCR or 2yDFS (17.5%-30%). 
Better outcomes for patients with a pCR are reported already in chapter 6 and in 
recent studies.
3,7
 However, pCR did not qualify to be a surrogate endpoint for 
progression-free survival and overall survival.
42
 An interesting and never reported 
finding (although supported by Habr-Gama et al.
43
) is that of the patients in the pCR 
group with a recurrence, 61% of the recurrences occur after five years of follow-up. 
This implies that even patients with pCR require prolonged observation. The status of 
being alive and disease-free after 2 years showed a clear benefit in overall survival and 
was also a stronger prognostic factor than pCR, even in subanalyses on different 
chemotherapy schemes. The risk ratio (DM rate/LR rate) over time shows also the 
clear cut-off point at 2 years of follow-up. In the first two years this ratio was high and 
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decreasing, implying the occurrence of relatively more metastases, which corresponds 
to the worst responding group of patients. After two years this risk ratio was 
approximately flat, which identifies a second group of patients with recurring tumors 
with a very slow growth rate. In conclusion of this study, pCR predictions may identify 
a minority of highly responsive patients for whom surgery can be tailored, organ 
preservation promoted, and quality of life or other patient-reported outcomes 
improved, whereas 2yDFS predictions identify less responsive patients who may 
benefit from more aggressive chemo. Therefore, 2yDFS should also be considered as 
an intermediate endpoint in future trials, focusing on identifying and evaluating early 
predictors for pCR and 2yDFS in order to adapt treatment most efficiently.    
Clinical impact of prediction models 
Despite the high regulation in the oncology field, both treatment and technology are 
surrounded by uncertain factors. Evidence is primarily generated by the outcomes of 
randomized clinical trials. This evidence is however often unavailable, inconclusive, 
valid for only a subgroup of patients, outdated or of insufficient quality. Furthermore, 
there still exists a translational gap between scientific discoveries and clinical practice. 
Personalized medicine can exist alongside evidence-based medicine and would allow 
for fast and efficient testing of new treatment strategies. The presented nomograms in 
this thesis are incremental steps towards the clinical application of this personalized 
medicine framework. 
 
In general and also in this thesis, the performance of the developed prediction models 
is evaluated by discrimination measures, like AUC and c-index, and calibration (i.e. 
predicted outcome probabilities vs real outcome probabilities). However, when 
assessing the potential impact of these models in clinical practice, these measures 
alone are not sufficient. Decision curve analysis can reveal the consequences of using a 
model in terms of net benefit.
44
 To do this, it is required to quantify the harms and 
benefits of a decision, which is tedious because of the lack of data. Another issue 
which arises is the selection of the weights for false-positives and false-negatives, 
which are dependent on the hypothesis and they may even differ from patient to 
patient. As a first step it is advised to carefully design clinical trials with the purpose of 
validating the prediction models and assessing their impact. In chapter 4 such a trial 
was already proposed in which one arm with standard treatment for all (CRT+surgery) 
is compared to an arm receiving individualized treatment based on the prediction 
model. 
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In the meantime, the use of the currently published prediction models can and should 
be promoted among medical professionals. They are the end-users and they will 
decide if a prediction model provides sufficient assistance in decision making. The 
success of the model depends on multiple factors, such as its availability and 
interactivity, which are expected to increase the acceptability. Even models based on 
large patient populations, with proper external validation, can fail to be accepted 
within the healthcare community if the model and its output are not easily 
interpretable, if there is a lack of opportunity to apply the model or if the clinical 
usefulness is not assessed. The reason the studies presented in this thesis focused on 
the nomogram representation of the models, is its high degree of interpretation. 
However, most insight of the model usefulness is gained by frequent application of 
models, which can be promoted by making them available on the internet. The most 
well-known online website with interactive prediction tools is Adjuvant!Online 
(http://www.adjuvantonline.com). This website aims to provide decision support for 
adjuvant therapy (chemotherapy, hormone therapy, etc.) after surgery for early cancer 
patients. A prediction website which focuses more on decision support for 
radiotherapy was previously set up by Maastro clinic (http://www.predictcancer.org).  
The last issue with the acceptance of these models is the statistical methodology 
barrier. In traditional statistics there is a subset of methods which are used most 
frequently for cancer related prognostic and predictive studies. In general, alternative 
methods are not easily accepted in the medical community, as for example methods 
from machine learning. These methods, like support vector machines, Bayesian 
networks and random forests, have the potential to predict the classification of clinical 
outcomes very accurately, as discussed in chapter 2. It is the responsibility of the 
medical community to consider these methods in clinical publications, but it is also a 
responsibility of the model developers to clearly explain the motivation for using a 
particular method, what inputs are required and how to interpret the output of these 
methods.  
Future perspectives 
The future of clinical decision making for rectal cancer using prediction models is 
dependent on a few crucial developments. The first step is to improve existing models 
by mining more sources of data, making more data available for training, validating 
and updating the models, and achieving higher data quality. Next, the assessment of 
the models’ clinical impact is required, with methods like the decision curve analysis 
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but certainly also with prediction model based clinical trials, as discussed in the 
previous section. Third, integration of the prediction models within the hospital IT 
systems is important for daily use in clinical practice. These aspects will be highlighted 
for this future outlook; the improvement of models using additional data and the 
implementation of prediction models within the emerging rapid learning healthcare 
framework.        
Data enrichment for model improvement 
Besides PET-imaging, other functional imaging techniques have shown to be helpful in 
assessing tumor response. Pre-treatment tumor perfusion or changes in tumor 
perfusion have been correlated before with pathological tumor response.
13,45
 Dynamic 
contrast enhanced magnetic resonance imaging (DCE-MRI) is most frequently used to 
measure tumor perfusion, but perfusion-CT (pCT) shows comparable results for 
perfusion quantification for rectal cancer.
46
 Quantifying the compactness, or cellularity 
of the tumor, to assess the diffusion process within the tumor, can be measured by 
diffusion-weighted imaging (DWI).
47
 Also diffusion-related parameters show high 
correlation with tumor response after treatment.
48
 In combination with PET measures, 
DWI even reached very high accuracies for a small group of patients.
13
 This finding 
indicates the potential of combining different (functional) imaging techniques. 
Although DWI is non-invasive, which is an advantage over PET-imaging, the protocols 
for calibration of DWI measures are not standardized to the same degree as for PET. 
When extra scans (generated outside the current treatment protocol) from different 
image modalities are suggested by a certain decision support system, cost-
effectiveness studies are required to assess if the benefits in model accuracy outweigh 
the costs. A less expensive and also promising imaging analysis development is the 
application of radiomics: the high-throughput extraction of large amounts of image 
features from radiographic images.
49
 Radiomics can be applied to scans from clinical 
routine like diagnostic and treatment-planning scans, which would increase the 
amount of extracted data, and thereby evidence.   
 
Alongside imaging, outcome prediction will gain more and more from biological 
markers in either the blood or in (tumor)-tissues, because of reducing measurement 
and analysis costs. In chapter 5, initial results of pre-treatment blood biomarkers were 
presented, but it was argued that measurements at multiple time-points would be 
more predictive, based on the analogy with the repeated PET findings. A more direct 
insight can be gained from genetic alterations within the tumor tissue collected with 
biopsies. A possible problem related to molecular biomarkers is the heterogeneity in 
tumors, making it necessary to collect a representative sample of tumor material, 
      Chapter 8 
 
152
requiring an invasive procedure to do so. An overview of these molecular biomarkers 
for rectal cancer is given in the review of Kuremsky et al.
50
 Gene expression analyses 
and genomic profiling through sequencing have also a promising prognostic and 
predictive value for (colo)rectal cancer. Although several validated prognostic gene 
expression signatures have been successfully developed, there is little overlap 
between them.
51
 Methodological and technical variances may explain this 
inconsistency, but it also seems evident that colorectal cancer is an extremely 
heterogeneous disease at the molecular level. Next-generation sequencing further 
improves our understanding of the biological mechanisms underlying rectal cancer and 
may provide additional prognostic information in the near future.
52
 
Clinical infrastructure  
The current development of a rapid learning healthcare system may be very effective 
to achieve clinical decision support in daily practice.
53
 In such a system, data is 
routinely generated through patient care and clinical research and fed into an ever-
growing databank or set of coordinated databases. High quality data should be 
available in real time, simultaneously used to improve clinical care, yield quality 
measures, and focus on research. This system would also expand the pace and 
magnitude of evidence generation. Developing a rapid learning healthcare system 
requires transformation of IT infrastructure, standardization of electronic health 
records and semantic interoperability between data sharing systems (the ability of any 
communicating system to share unambiguous meaning). Technical changes are 
however not sufficient for a successful implementation of the system. First of all, 
several cultural changes should be induced, like commitment across organizations, 
community participation for infrastructure development, persuasion of stakeholders to 
open up information silos, leadership, data governance, patient privacy and lastly that 
top research journals and grant funding bodies will request open source data sharing. 
Also, by promoting patient activation and empowerment, patient participation in both 
decision making and care delivery will be increased.  
 
Clinical decision making using prediction models would benefit greatly from such a 
rapid learning system. Not only will there be more variety in the data and are higher 
numbers of patients available to train the classifiers, the classifiers can also be 
validated across different institutes in a more automated and standardized manner. 
Also, the frequency of updating the models will increase due to constant monitoring of 
new data. Because of these promising developments, the medical doctor in the 21
st
 
century will be assisted by up-to-date tools that can predict multiple patient outcomes 
with high accuracy with just a single click on a button.    
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Biology 
CA IX Carbonic anhydrase 9 
CA19-9 Carbohydrate antigen 19-9 
CEA Carcinoembryonic antigen 
CRP C-reactive protein  
DNA Deoxyribonucleic acid 
GWAS Genome-wide association studies  
IL-6 Interleukin-6  
IL-8 Interleukin-8 
LDH Lactate dehydrogenase  
mRNA Messenger ribonucleic acid 
OPN Osteopontin 
SNP Single nucleotide polymorphism  
Clinical 
DFS Disease free survival 
DM Distant metastasis 
LARC Locally advanced rectal cancer 
LR Local recurrence  
NLARC Non-locally advanced rectal cancer 
OS Overall survival 
pCR Pathological complete response 
TRG Tumor regression grade 
Imaging  
5FU 5-fluorouracil  
ADC Apparent diffusion coefficient 
CT Computed tomography 
DICOM Digital imaging and communications in medicine 
DW-MRI Diffusion-weighted magnetic resonance imaging 
FDG 18F-fluorodeoxyglucose  
MRI Magnetic resonance imaging 
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MTV Metabolic tumor volume 
PET Positron emission tomography  
SUV Standardized uptake value  
Methodology 
AUC Area under the curve 
ROC Receiver operating characteristic  
SD Standard deviation 
SVM Support vector machine 
LOO Leave-one-out 
pSVM Proximal support vector machine 
CI Confidence interval 
Treatment  
APR Abdominoperineal resection  
CRM Circumferential margin  
CRT Chemoradiotherapy 
Gy Gray 
IGRT Image-guided radiotherapy  
LAR Low anterior resection  
MRF Mesorectal fascia 
TEM Transanal endoscopic microsurgery 
TME Total mesorectal excision 
APR Abdominoperineal resection  
Miscellaneous 
CDSS Clinical decision support system 
EORTC European organisation for research and treatment of cancer  
FFCD Fédération francophone de cancérologie digestive  
THUNDER Theragnostic utilities for neoplastic diseases of the rectum 
WHO World health organization 
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Summary 
The epidemiology and the treatment of rectal cancer were briefly discussed in chapter 
1. Preferably, the response to treatment and the consequence for a patients’ prognosis 
is assessed as early as possible in order to be able to adapt treatment accordingly. This 
concept of individualized medicine requires the development of specific computational 
tools to predict outcome after treatment because over the last few years the amount 
of available medical information has expanded rapidly. The opportunities for the 
physician to make a detailed assessment of risk and benefits associated with a specific 
combination of tumor, patient and treatment characteristics are expected to be 
greatly increased with the use of these tools. Eventually, these tools will be 
implemented within the infrastructure of hospitals and used in daily care. This thesis 
provided a first step towards these clinical decision support systems (CDSS) for rectal 
cancer.    
 
All the studies presented in this thesis focused on locally advanced rectal cancer 
(LARC), which is often treated with long course chemoradiotherapy (CRT) followed by 
surgery (TME). For LARC, the options to individualize treatment are highlighted 
throughout the thesis. One option is to predict pathologic complete response (pCR) in 
order to identify patients that respond excellent to the CRT. These patients are 
possible candidates for a wait-and-see policy in the surgical setting. Patients who 
respond less well might benefit from an extra boost of radiotherapy to promote more 
pCR cases. The worst responding group can be selected for additional chemotherapy. 
On the other hand, prediction of long-term follow-up outcomes, generally assessed in 
a 5-year time frame after treatment, may assist in the planning of follow-up strategies.  
For example, a high estimated risk for a local recurrence (LR) motivates an 
intensification of the follow-up, i.e. making the time shorter between hospital visits. 
High estimated risks for distant metastases (DM) and events for overall survival (OS), 
on the other hand, promotes the administration of adjuvant chemotherapy.  
 
The main aim of this thesis was to study the predictive value of clinical factors, imaging 
and blood biomarkers for response to treatment and follow-up outcome related to 
recurrences and survival for patients with locally advanced rectal cancer.   
   
In chapter 2 a review about predicting outcomes in the field of radiation oncology is 
presented. An overview of clinical, treatment, imaging and molecular factors that are 
associated with outcomes in radiation oncology is provided. Furthermore, the 
methodology behind the development of statistical prediction models is discussed. 
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This development does not only involve finding the relevant factors that influence 
outcome but also the training of a statistical model that is able to make predictions for 
new patients. To train models accurately and to validate them independently, datasets 
of large populations of representative patients are required. Integration of these 
validated decision support systems in the clinic that are constantly updated using new 
data (“rapid learning”) requires harmonization of data infrastructures and the 
willingness to accept these systems in healthcare organizations, so that data and 
knowledge are being shared in a standardized, instant and global manner. 
 
Tumor response prediction using PETCT-imaging and blood biomarkers 
 
Prediction of pathological complete response (15-30% of the patients) after CRT using 
clinical factors and sequential positron emission tomography (PET) combined with 
computed tomography (CT) imaging was described in chapter 3. This study involved 
large datasets from four different European centers. For the patients with imaging, a 
PETCT scan was made one week before and another scan around 8 weeks after 
treatment. It was found that the addition of the post-treatment PETCT scan 
information to the clinical data and the first PETCT scan resulted in a significant 
increase in prediction performance with acceptable levels of accuracy with area under 
the ROC curve (AUC) of around 0.85. The dominant tumor dimension and the maximal 
uptake of radioactive isotopes in the tumor as well as its relative difference between 
PET scans were found to be the best predictors for pCR. 
 
The time point at which the actual prediction of pCR is calculated is favored at an 
earlier stage to be able to adapt treatment. For this reason a large prospective study 
with PETCT imaging before and during CRT was presented in chapter 4. Tumor 
dimensions and change in PET activity within the tumor, together with clinical stage of 
the tumor, were found to be predictive for pCR. The model was externally validated 
and performed well (100% accuracy for the training set and 67% in validation).  
 
We are convinced that a holistic approach of combining multiple sources for data 
greatly improves the accuracy of prediction models for response to treatment. Blood 
biomarkers and their relationship with tumor response were studied in chapter 5 in a 
prospective study of 276 patients. Pre-treatment carcinoembryonic antigen (CEA) level 
is a significant predictor for pCR after CRT for LARC. For good response, i.e. yielded 
pathological tumor stage of 0-2 and no nodal involvement (ypT0-2N0), CEA and IL-8 
levels were both predictive. These blood biomarkers also had an added value to the 
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model with pre-treatment clinical- and PETCT-data. These results suggest that blood 
biomarkers have predictive potential for tailored therapy in rectal cancer. 
 
Predicting long-term follow-up outcome for decision support 
 
In chapter 6 a large study with 2795 patients from five European institutes aimed at 
the development of accurate prediction models for local recurrence, distant 
metastases and survival, based on only clinical data. The trained models were 
presented as nomograms, which can assign a new patient to one of the three 
proposed risk groups. This facilitates the selection of patients for clinical trials with 
different treatment approaches. External validation of the nomograms resulted in 
AUCs of 0.68 for LR, 0.73 for DM, and 0.70 for OS. Pathological staging was essential 
for accurate prediction of long-term outcome. 
 
The intermediate clinical outcomes pCR and 2-year disease free survival (2yDFS) were 
evaluated in chapter 7. Based on these intermediate endpoints which are both 
prognostic, different populations of rectal cancer patients were identified: highly 
responsive patients, responsive curable patients, and patients with early and late 
recurrence regardless of pCR status. pCR predictions may identify a minority of highly 
responsive patients for whom surgery can be tailored, organ preservation promoted, 
and quality of life or other patient-reported outcomes improved, whereas 2yDFS 
predictions identify less responsive patients who may benefit from more aggressive 
chemotherapy. Therefore, 2yDFS should also be considered as an intermediate 
endpoint in future trials, focusing on identifying and evaluating early predictors for pCR 
and 2yDFS in order to adapt treatment most efficiently. 
 
Finally, in chapter 8 the results presented of this thesis and areas of future research 
were discussed. The clinical impact of prediction models does not only depends on 
prediction accuracy, but also on the validation of these models in clinical trials and the 
dissemination of the acquired knowledge and developed tools. For the future, data 
enrichment using more advanced imaging techniques and analyses and adding 
biological markers from for example the genomic domain are expected to improve the 
quality of outcome predictions even more. If those improved models are integrated 
into a rapid learning healthcare system with suitable IT infrastructures and seamless 
interconnection between data systems, personalized treatment can and is expected to 
be fully embraced.   
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Samenvatting 
In hoofdstuk 1 wordt de epidemiologie en de behandeling van endeldarmkanker kort 
beschreven. Bij voorkeur wordt de respons op de behandeling en de consequenties op 
de prognose van een patiënt in een zo vroeg mogelijk stadium ingeschat, om de 
behandeling daarop aan te passen. Dit noemt men ook wel een geïndividualiseerde 
behandeling. Het kiezen van de optimale behandeling voor een patiënt is voor artsen 
echter steeds ingewikkelder geworden omdat de laatste jaren de hoeveelheid 
informatie betreffende de patiënt en specifieke kenmerken van de tumor is 
toegenomen. Ook zal het aantal behandelingsopties en combinaties van 
behandelingen alleen maar stijgen in de toekomst. Daarom is er een behoefte aan 
beslissingsmodellen die gebruik maken van de capaciteit van computers om al deze 
informatie te combineren en te koppelen aan behandelingsuitkomst. Het ontwikkelen 
van deze modellen is een eerste stap naar een Decision Support systeem, dat in de 
toekomst volledig geïntegreerd zal zijn in het ziekenhuis. In deze thesis zijn 
wetenschappelijk gefundeerde voorspellingsmodellen voor endeldarmkanker 
ontwikkeld. 
 
Alle studies in de thesis richten zich op lokaal gevorderd endeldarmkanker (locally 
advanced rectal cancer, LARC) dat meestal wordt behandeld met een langdurige 
chemoradiotherapie (CRT) gevolgd door een operatieve ingreep (TME). De opties om 
voor LARC de behandeling te individualiseren zijn beschreven in de thesis. Een optie is 
om pathologische complete respons (pCR) te voorspellen met als doel patiënten te 
selecteren die uitstekend reageren op de CRT. Deze patiënten zijn mogelijke 
kandidaten voor een beleid waarin een chirurgische ingreep vermeden kan worden 
(“wait-and-see”) en hebben dan ook geen extra behandeling nodig. Patiënten die 
echter minder goed reageren, zouden een extra dosis radiotherapie kunnen krijgen 
met als doel het aantal complete responders te vergroten. Als de respons echter 
afwezig lijkt te zijn, dan kunnen de betreffende patiënten een extra chemotherapie 
ondergaan. Daarnaast is het ook mogelijk om voorspellingen te doen over 
behandelingsuitkomsten gedurende het nazorg traject, waarbij een termijn van 5 jaar 
klinisch relevant is. Een hoog berekend risico op lokaal recidief (terugkeren van de 
tumor), bijvoorbeeld, pleit voor een intensievere nazorg. Hoge risico’s voor 
uitzaaiingen (metastasen) of overlijden van de patiënt pleiten voor het voorschrijven 
van adjuvante chemotherapie.  
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Het hoofddoel van deze thesis was het bestuderen van de waarde van klinische 
factoren, beeldvorming en bloed biomarkers voor het voorspellen van respons op de 
behandeling en nazorg gerelateerde uitkomsten als recidieven en overleving voor 
patiënten met lokaal gevorderde endeldarmkanker. 
 
In hoofdstuk 2 wordt een algemeen overzicht gegeven over de huidige stand van 
zaken met betrekking tot het voorspellen van uitkomsten in de radiotherapeutische 
oncologie. Daarbij worden klinische, behandeling gerelateerde, beeldvorming 
gerelateerde, en moleculaire factoren bediscussieerd waarvan bekend is dat ze 
geassocieerd zijn met de behandelingsuitkomst. Ook wordt de methodologie 
besproken die nodig is om statistische voorspellingsmodellen te ontwikkelen. Deze 
ontwikkelingen omvatten niet alleen het vinden van relevante factoren die klinische 
uitkomsten beïnvloeden, maar ook het trainen van een statistisch model dat in staat is 
om voor nieuwe patiënten een voorspelling te doen. Om deze modellen nauwkeurig te 
trainen en onafhankelijk te valideren zijn grote representatieve datasets nodig met 
medische informatie over patiënten en tumor karakteristieken. Het integreren van 
deze voorspellingsmodellen in de kliniek vraagt om een hoge mate van 
beschikbaarheid van nieuwe data. Hiervoor zijn de juiste infrastructuren en 
beleidsmanagement nodig. Eenmaal geïntegreerd, kan data en kennis op een 
gestandaardiseerde, snelle en wereldwijde wijze gedeeld worden.   
 
Tumor respons voorspellingen met PETCT beeldvorming en bloed biomarkers  
 
Het voorspellen van pathologische complete behandelingsrespons (in 15-30% van de 
patiënten) met behulp van herhaalde beeldvorming met PETCT 
(positronemissietomografie in combinatie met computertomografie) is beschreven in 
hoofdstuk 3. Deze studie bevat data uit vier verschillende Europese centra. Voor de 
patiënten die beeldvorming ondergingen werd 1 scan gemaakt in de week vóór de 
behandeling en 1 scan 8 weken na de behandeling. De gevonden resultaten laten zien 
dat de informatie uit de klinische gegevens en de PETCT scan van vóór de behandeling 
significant verbeteren wanneer PETCT informatie van na de behandeling wordt 
toegevoegd. Dit leidt tot een nauwkeurigheid van het model met acceptabele waarden 
voor de AUC van 0.85. De voorspellende factoren voor pCR zijn de tumor grootte, de 
maximale opname van de PET tracer (FDG) in de tumor en de relatieve afname van 
deze opname gemeten tussen de twee PETCT scans.  
 
Bij voorkeur is het tijdstip waarop de voorspelling voor pCR wordt gedaan zo vroeg 
mogelijk in het behandelingstraject om de mogelijkheid te behouden om de 
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behandeling aan te passen. Om deze reden is een grote prospectieve studie opgezet 
met PETCT beeldvorming vóór en tijdens CRT die is beschreven in hoofdstuk 4. De 
tumor grootte en de verandering van PET tracer opname in de tumor in combinatie 
met klinische classificatie waren in deze studie voorspellend voor pCR. Het model werd 
extern gevalideerd en presteerde goed (100% nauwkeurigheid voor de 
trainingsdataset en 67% voor externe validatie).  
 
We zijn overtuigd dat een holistische benadering met een combinatie van 
verschillende data bronnen de accuraatheid van voorspellingsmodellen sterk kan 
vergroten. Daarom zijn ook bloed biomarkers en de relatie met tumor respons 
onderzocht in hoofdstuk 5 in een prospectieve studie met 276 patiënten. Carcino-
embryonaal antigen (CEA) waarden vóór de behandeling hadden een significante 
associatie met pCR. Voor een goede response (tumor classificatie van 0-2 en geen 
betrokkenheid van lymfklieren, ypT0-2N0), waren de bloedwaarden van CEA en IL-8 
voorspellend. De bloed biomarkers hadden ook een toegevoegde voorspellende 
waarde in het model met klinische en PETCT factoren. Deze bevindingen wijzen erop 
dat bloed biomarkers belangrijke kandidaten zijn om therapie op maat voor 
endeldarmkanker te optimaliseren. 
  
Het voorspellen van uitkomsten tijdens de langdurige nazorg  
 
In hoofdstuk 6 is een grote studie beschreven met 2795 patiënten die behandeld zijn 
in vijf Europese instituten. Op basis van klinische data zijn nauwkeurige 
voorspellingsmodellen ontwikkeld voor lokaal recidieven, metastasen en overleving. 
De getrainde modellen zijn gepresenteerd als nomogrammen, die in staat zijn om voor 
één enkele patiënt een risico groep voor de betreffende uitkomst te berekenen. Zo een 
nomogram faciliteert ook de selectie van patiënten in klinische trials met verschillende 
behandelingsopties. Externe validatie van de nomogrammen resulteerde in AUCs van 
0.68 voor lokaal recidieven, 0.73 voor metastasen en 0.70 voor overleving. 
Pathologische tumor en lymfklier classificaties na behandeling hadden hierbij de 
grootste voorspellende waarde.  
 
De tussentijdse klinische uitkomsten pCR en ziekte vrije overleving binnen twee jaar 
(2yDFS) zijn geëvalueerd in hoofdstuk 7. Deze tussentijdse uitkomsten waren 
prognostisch in de data en op basis hiervan werden verschillende populaties 
endeldarmkanker patiënten geïdentificeerd: uitstekend reagerende patiënten, goed 
reagerende behandelbare patiënten en patiënten met vroeg of laat een recidief, 
ongeacht de status van pCR. Voorspellingen voor pCR kunnen een minderheid van de 
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patiënten identificeren voor wie een operatie op maat kan worden gegeven, orgaan 
preservatie kan worden gepromoot en de kwaliteit van leven kan worden verbeterd. 
Slecht reagerende patiënten kunnen beter met de voorspellingen voor 2yDFS 
geïdentificeerd worden en komen in aanmerking voor agressievere chemotherapie. 
Mede daarom, zou overwogen kunnen worden om 2yDFS als tussentijds eindpunt te 
evalueren in toekomstige klinische trials met als doel om vroege predictoren voor pCR 
en 2yDFS te vinden en behandelingsaanpassingen efficiënter maken. 
 
Ten slotte worden in hoofdstuk 8 de resultaten uit de gehele thesis besproken en met 
elkaar in verband gebracht. De klinische impact van voorspellingsmodellen hangt niet 
alleen af van de nauwkeurigheid van voorspellingen maar ook van een betrouwbare 
validatie in klinische trials en van de verspreiding van de opgedane kennis en 
modellen. Voor de toekomst wordt verwacht dat voorspellingsmodellen zullen 
verbeteren door het toevoegen van extra relevante data afkomstig van geavanceerde 
beeldvormingstechnieken en -analyses maar ook het toevoegen van moleculaire 
biomarkers uit bijvoorbeeld het genomica domein. Deze verbeterde modellen kunnen 
uiteindelijk pas volledig omarmd worden als ze geïntegreerd gaan worden in de snel 
lerende zorg systemen die de juiste IT infrastructuur hebben en zorgen voor een 
naadloze verbinding tussen de data systemen. 
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